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A B S T R A C T
Background
Many patients with cancer experience moderate to severe pain that requires treatment with strong opioids, of which oxycodone and
morphine are examples. Strong opioids are, however, not effective for pain in all patients, nor are they well-tolerated by all patients.
The aim of this review was to assess whether oxycodone is associated with better pain relief and tolerability than other analgesic options
for patients with cancer pain.
Objectives
To assess the effectiveness and tolerability of oxycodone for pain in adults with cancer.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE and MEDLINE
In-Process (Ovid), EMBASE (Ovid), Science Citation Index, Conference Proceedings Citation Index - Science (ISI Web of Science),
BIOSIS (ISI), PsycINFO (Ovid) and PubMed to March 2014. We also searched Clinicaltrials.gov, metaRegister of Controlled Trials
(mRCT), EU Clinical Trials Register and World Health Organization International Clinical Trials Registry Platform (ICTRP). We
checked the bibliographic references of relevant identified studies and contacted the authors of the included studies to find additional
trials not identified by the electronic searches. No language, date or publication status restrictions were applied to the search.
Selection criteria
We included randomised controlled trials (parallel-group or cross-over) comparing oxycodone (any formulation or route of adminis-
tration) with placebo or an active drug (including oxycodone) for cancer background pain in adults.
Data collection and analysis
Two authors independently extracted study data (study design, participant details, interventions and outcomes) and independently
assessed the quality of the included studies according to standard Cochrane methodology. Where possible, we meta-analysed the pain
intensity data using the generic inverse variance method, otherwise these data were summarised narratively along with the adverse event
and patient preference data. The overall quality of the evidence for each outcome was assessed according to the GRADE approach.
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Main results
We included 17 studies which enrolled/randomised 1390 patients with 1110 of these analysed for efficacy and 1170 for safety. The
studies examined a number of different drug comparisons. Four studies compared controlled release (CR) oxycodone to immediate
release (IR) oxycodone and pooled analysis of three of these studies showed that the effects of CR and IR oxycodone on pain intensity after
treatment were similar (standardised mean difference (SMD) 0.1, 95% confidence interval (CI) -0.06 to 0.26; low quality evidence).
This was in line with the finding that none of the included studies reported differences in pain intensity between the treatment groups.
Three of the four studies also found similar results for treatment acceptability and adverse events in the IR and CR groups; but one
study reported that, compared to IR oxycodone, CR oxycodone was associated with significantly fewer adverse events.
Six studies compared CR oxycodone to CR morphine and pooled analysis of five of these studies indicated that pain intensity did not
differ significantly between the treatments (SMD 0.14, 95% CI -0.04 to 0.32; low quality evidence). There were no marked differences
in adverse event rates, treatment acceptability or quality of life ratings.
The remaining seven studies either compared oxycodone in various formulations or compared oxycodone to different alternative
opioids. None of them found any clear superiority or inferiority of oxycodone for cancer pain, neither as an analgesic agent nor in
terms of adverse event rates and treatment acceptability.
The quality of this evidence base was limited by the risk of bias of the studies and by small sample sizes for many outcomes. Random
sequence generation and allocation concealment were under-reported, and the results were substantially compromised by attrition with
data missing from more than 20% of the enrolled/randomised patients for efficacy and from more than 15% for safety.
Authors’ conclusions
Overall, the data included within this review suggest that oxycodone offers similar levels of pain relief and adverse events to other
strong opioids including morphine, which is commonly considered the gold standard strong opioid. Our conclusions are consistent
with other recent reviews and suggest that while the reliability of the evidence base is low, given the absence of important differences
within this analysis it seems unlikely that larger head to head studies of oxycodone versus morphine will be justified. This means that
for clinical purposes oxycodone or morphine can be used as first line oral opioids for relief of cancer pain.
P L A I N L A N G U A G E S U M M A R Y
Oxycodone for cancer-related pain
Many patients with cancer experience moderate to severe pain that requires treatment with strong painkillers that are classified as
opioids. Oxycodone and morphine are examples of such strong painkillers that are used for the relief of cancer pain. Strong painkillers
are, however, not effective for pain in all patients nor are they well-tolerated by all patients. The aim of this review is to assess whether
oxycodone is associated with better pain relief and tolerability than other strong painkillers for patients with cancer pain. We found 17
relevant studies that compared different types of oxycodone to each other or to other strong painkillers. Generally, the studies showed
that oxycodone is an equally effective strong painkiller whether taken every 6 or every 12 hours. All the strong painkillers examined in
the studies are also associated with a number of unwanted effects, such as vomiting, constipation and drowsiness. Overall, we found
that the current evidence base is comprised of studies that contain small numbers of patients of which there is a significant (20%)
dropout rate. However, given the absence of important differences within this analysis, it seems unlikely that larger head to head studies
of oxycodone versus morphine are justified.
B A C K G R O U N D
Description of the condition
Pain from cancer can be caused by direct invasion of a tumour into
soft tissue or bone and is often a presenting symptom at the time of
diagnosis of cancer. A European survey published in 2009 found
that of 5000 cancer patients (including 617 community-based
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National Health Service (NHS) patients in the United Kingdom
(UK)) 72% experienced pain (77% of UK patients) which was of
moderate to severe intensity in 90% of this group (Breivik 2009).
This is consistent with a recent systematic review that demon-
strated cancer pain prevalence of up to 75% in advanced disease,
and that almost one in two patients are undertreated (Deandrea
2008). Pain in cancer patients may also be caused by cancer treat-
ments and by co-morbid conditions. In this review, we define can-
cer pain as pain arising as a direct consequence of the cancer, and
not from other aetiologies.
Description of the intervention
Oxycodone is a strong opioid analgesic indicated for the treatment
of moderate to severe chronic pain, including cancer pain. It is
available orally as immediate release solution and tablets (for 4-
hourly dosing) and as sustained (controlled) release tablets (for
12-hourly dosing). It is also available as a parenteral injection.
In some countries, oxycodone is available as a compound with
acetaminophen (paracetamol) or ibuprofen.
How the intervention might work
Oxycodone works primarily as an agonist of mu-opioid receptors
in the spinal cord and brain. It has some activity at kappa-opi-
oid receptors (which are also involved in nociception or analgesia)
though the importance of this mechanism in the overall analgesic
effect of oxycodone is unclear. Despite animal studies suggesting
differences in pharmacodynamics, these have not been demon-
strated in clinical studies to date. Therefore, the sharedmechanism
of action to other strong opioids (that is agonist activity at mu-
opioid receptors) means that clinical benefits and adverse effects
are likely to be similar. However, important differences exist in the
pharmacokinetics of strong opioids (for example morphine un-
dergoes second phase elimination via glucuronidation, while oxy-
codone undergoes extensive first phase metabolism via CYP2D6
and CYP3A4 pathways) so clinical equivalence cannot be inferred
(Gudin 2012; Leppert 2010).
Why it is important to do this review
The World Health Organization published the Method for Can-
cer Pain Relief (WHO analgesic ladder) in 1986 (WHO 1986)
which advocates a stepwise approach to analgesia for cancer pain
and revolutionised the use of oral opioids. It recommended that
morphine be used first line for moderate to severe cancer pain.
Observational studies have suggested that this approach results in
pain control for 73% of patients (Bennett 2008) with a mean re-
duction in pain intensity of 65% (Ventafridda 1987).
Many patients with cancer experience moderate to severe pain
that requires treatment with strong analgesics. Oxycodone and
morphine are examples of strong opioids that are used for the
relief of cancer pain. Strong opioids are, however, not effective
for pain in all patients, nor are they well-tolerated by all patients.
Recent guidance by the European Association for Palliative Care
on the use of opioids in cancer pain suggests that oxycodone could
be used as first line treatment of moderate to severe cancer pain
as an alternative to morphine (Caraceni 2012). The aim of this
review is to assess whether oxycodone is associated with better pain
relief and tolerability than other analgesic options for patients with
cancer pain. The protocol for this review was updated from Reid
2010.
O B J E C T I V E S
To assess the effectiveness and tolerability of oxycodone for pain
in adults with cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), with parallel-group or cross-
over design, comparing oxycodone (any formulation and any route
of administration) with placebo or an active drug (including oxy-
codone) for cancer background pain. We did not examine studies
on breakthrough pain.
Types of participants
Adults (aged ≥ 18 years) with cancer pain.
Types of interventions
Oxycodone (any dose, formulation and route of administration)
versus oxycodone (any dose, formulation and route of administra-
tion)
Oxycodone (any dose, formulation and route of administration)
versus other active drug (any dose, formulation and route of ad-
ministration)
Oxycodone (any dose, formulation and route of administration)
versus placebo
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Types of outcome measures
Primary outcomes
Pain intensity and pain relief.
Both of these outcomes had to be patient-reported and could be
reported in any transparent manner (for example by using numer-
ical or verbal rating scales). We did not consider these outcomes
when reported by physicians, nurses or carers. If possible, we aimed
to distinguish between nociceptive and neuropathic pain, but the
data were not presented in a manner that made this possible.
Secondary outcomes
Side effects or adverse events (e.g., constipation, nausea, vomiting,
drowsiness, confusion, respiratory depression), quality of life and
patient preference.
We considered all of these outcomes as they were reported in the
included studies.
Search methods for identification of studies
Wedidnot apply language, date or publication status (published in
full, published as abstract, unpublished) restrictions to the search.
Electronic searches
We identified relevant trials by searching the following databases:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (Issue 1 of 12, 2014);
2. MEDLINE and MEDLINE In-Process (Ovid) (1946 to 3
March 2014);
3. EMBASE (Ovid) (1947 to March 2014);
4. Science Citation Index (Web of Science) (1899 to 3 March
2014);
5. Conference Proceedings Citation Index - Science (Web of
Science) (1990 to 3 March 2014);
6. BIOSIS (Web of Science) (1926 to 3 March 2014);
7. PsycINFO (Ovid) (1806 to February week 4 2014);
8. PubMed (to 3 March 2014).
We applied to this search the Cochrane highly sensitive search
strategy for identifying randomised control trials (Lefebvre 2011).
The search strategies used can be found in Appendix 1.
Searching other resources
We checked the bibliographic references of relevant identi-
fied studies in order to find additional trials not identified
by the electronic searches. We also searched Clinicaltrials.gov
(13 March 2014), metaRegister of Controlled Trials (mRCT) (3
March 2014), EU Clinical Trials Register (3 March 2014) and
World Health Organization International Clinical Trials Registry
Platform (ICTRP) (3 March 2014) as complementary sources for
related studies, and we contacted authors of the included studies
to ask if they knew of any other relevant studies.
Data collection and analysis
Selection of studies
Two of the review authors (MSH, NB) assessed the titles and ab-
stracts of all the studies identified by the search for potential inclu-
sion. We independently considered the full records of all poten-
tially relevant studies for inclusion by applying the selection crite-
ria outlined in the Criteria for considering studies for this review
section. We resolved any disagreements by discussion. We did not
restrict the inclusion criteria by date, language or publication sta-
tus (published in full, published as abstract, unpublished).
Data extraction and management
Using a standardised data extraction form, two authors (MSH,
JSH) extracted data pertaining to study design, participant details
(including age, cancer characteristics, previous analgesic medica-
tion and setting), interventions (including details about titration)
and outcomes. We resolved any disagreements by discussion. If
there were studies for which only a subgroup of the participants
met the inclusion criteria for the current review, we would only ex-
tract data on this subgroup provided randomisation had not been
broken, however, no such studies were identified for inclusion.
Assessment of risk of bias in included studies
Two of the authors (MSH, JSH) independently assessed the
methodological quality of each of the included studies by us-
ing the ’risk of bias’ assessment method outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
For each study we assessed the risk of bias for the following do-
mains: selection bias (study level; 2 items; random sequence gener-
ation, allocation concealment), performance bias (outcome level;
2 items; blinding of patients, blinding of treating personnel), de-
tection bias (outcome level; 1 item; blinding of outcome assess-
ment), attrition bias (outcome level; 1 item; incomplete outcome
data) and reporting bias (study level; 1 item; selective reporting).
We also included an item that assessed the adequacy of titration
(with judgements made based on any available relevant informa-
tion, including design features, inclusion criteria, and interim pain
assessments) and another item that captured whether data were
available for both time periods in cross-over trials. Each of the
’risk of bias’ items required a ’low risk’, ’high risk’ or ’unclear risk’
response. We also documented the reasons for each response in
accordance with Higgins 2011, and resolved any disagreements
on the ’risk of bias’ ratings through discussion.
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The GRADE approach was used to assess the overall quality of
the evidence for each outcome, with downgrading of the evidence
from ’high quality’ by one level for serious (or by two for very
serious) study limitations (risk of bias), indirectness of evidence,
serious inconsistency, imprecision of effect estimates or potential
publication bias (Lagendam 2013). We included the following
outcomes in the summary of findings table (Table 1): pain inten-
sity, adverse events, treatment acceptability and quality of life.
Measures of treatment effect
For pain intensity we extracted the means and standard deviations
and we used these to estimate the standardised mean difference
(SMD) between the treatments along with the 95% confidence
interval (CI), as the outcome was not measured on the same scale
across studies. For adverse events we extracted event rates with
the aim of calculating risk ratios, however inspection of the data
indicated that this was not feasible.
Unit of analysis issues
The patient was the unit of analysis, but in a number of cases the
data reported in the included cross-over trials could not otherwise
be incorporated into the analyses (see Dealing with missing data),
so we included them as if the design had been parallel-group.
Higgins 2011 (in chapter 16) points out that this approach, while
giving rise to unit of analysis error, is nevertheless conservative as
it results in an under-weighting of the data. We had planned to
perform sensitivity analyses assessing the impact of this strategy
if we included cross-over trial data in this manner, but we were
unable to perform such analyses due to the lownumber of included
studies in the meta-analyses.
Dealing with missing data
In cases where data were missing, we contacted the authors to re-
quest the missing data. This strategy did not result in any addi-
tional data. We planned to limit imputation of missing data to the
imputation of missing standard deviations, if enough information
was available from the studies to calculate the standard deviation
according to the methods outlined by Higgins 2011. This was
not the case, so no data were imputed. We recorded the dropout/
missing data rates in the ’risk of bias’ tables under the items on
attrition bias and in the ’Participants’ section of the Characteristics
of included studies, and we addressed the potential effect of the
missing data on the results in the ’Discussion’ section of the re-
view. It was not possible to assess the impact of missing data in
sensitivity analyses due to the low study number. In all cases we
aimed to perform intention-to-treat analyses.
Assessment of heterogeneity
We assessed heterogeneity by using the I2 statistic. We considered
I2 values above 50% to represent substantial heterogeneity in line
with Higgins 2011 and we planned to assess potential sources of
heterogeneity through subgroup analyses as outlined in Subgroup
analysis and investigation of heterogeneity.
Assessment of reporting biases
In addition to implementing the comprehensive search strategy
outlined in the sectionSearchmethods for identification of studies,
the risk of outcome reporting bias was illustrated in the ’Risk of
bias’ summary figures that we constructed for each study and each
type of assessed bias.
Data synthesis
We entered the data extracted from the included studies into Re-
view Manager (RevMan 2014), which was used for data synthe-
sis. We analysed pain intensity using the generic inverse variance
method in accordance with Higgins 2011. As I2 was not above
50% we used a fixed-effect model. However, given the limitations
of this analysis strategy as outlined in the Unit of analysis issues
section, we also considered the results of the individual studies.
We planned to meta-analyse the adverse events data by using the
Mantel-Haenszel method, however, due to the generally low num-
ber of studies and the variability in the reporting of the adverse
events as well as in study design within each comparison it was not
feasible to meta-analyse the adverse events data. Adverse events
were instead summarised narratively and in tables.
Subgroup analysis and investigation of heterogeneity
Different aspects of the trials are likely to contribute heterogeneity
to the proposed main analyses. If there were sufficient data, we
therefore planned to perform subgroup analyses based on doses,
titration, formulations (for example immediate-release, sustained-
release), routes of administration (for example oral, rectal), length
of the trials and populations (for example adults, opioid-naive pa-
tients). However, as there were not sufficient data, we were unable
to perform any subgroup analyses.
Sensitivity analysis
If sufficient data were available, we planned to examine the ro-
bustness of the meta-analyses by conducting sensitivity analyses
using different components of the ’risk of bias’ assessment, partic-
ularly those relating to whether allocation concealment and blind-
ing were adequate. We also planned to conduct further sensitivity
analyses to examine the impact of missing data on the results if a
large proportion of the studies were at an ’unknown’ or ’high risk’
of attrition bias and, finally, we planned to use sensitivity analyses
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to examine whether publication status and trial size influenced the
results. Unfortunately, we were unable to perform any sensitivity
analyses due to the low number of studies within each comparison.
R E S U L T S
Description of studies
Results of the search
The search identified 854 unique records of which 757 were ex-
cluded based on the title/abstract and 97 were retrieved for full-
text evaluation. Of the 97 records, 17 studies published in 22 ar-
ticles were included, while 56 were excluded because they were:
not conducted in the target population examining the target com-
parisons as measured by the target outcomes of this review (not
following the PICO of this review) (N = 37), not RCTs (N = 9),
narrative reviews (N = 5) or duplicates (N = 5). See also Figure
1. In addition to the 17 included studies, 13 ongoing studies and
6 potentially relevant studies were identified by the search. One
of the ongoing studies was published in full after the search but
before publication of this review. This study was therefore also
included. We await further information, including study comple-
tion and publication, of the six potentially relevant studies before
we can ascertain their relevance to the current review and clas-
sify them accordingly. See Characteristics of ongoing studies and
Characteristics of studies awaiting classification, respectively.
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Figure 1. Study flow diagram.
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Included studies
The 17 included studies enrolled/randomised a total of 1390 pa-
tients (651 males, 621 females; for the remaining 118 patients
gender was not specified) with 1110 of these analysed for effi-
cacy and 1170 for safety. The reported mean/median ages of the
patient populations in the studies ranged from 45 years to 68.8
years. Ten of the studies were cross-over trials (Beaver 1978; Beaver
1978a; Bruera 1998;Gabrail 2004;Hagen 1997;Heiskanen 1997;
Kalso 1990; Lauretti 2003; Leow 1995; Stambaugh 2001) and
seven were parallel-group trials (Imanaka 2013; Kaplan 1998;
Mercadante 2010;Mucci-LoRusso 1998; Parris 1998; Riley 2014;
Salzman 1999), with eight of the studies conducted in the
USA (Beaver 1978; Beaver 1978a; Gabrail 2004; Kaplan 1998;
Mucci-LoRusso 1998; Parris 1998; Salzman 1999; Stambaugh
2001), two in Canada (Bruera 1998; Hagen 1997), two in Finland
(Heiskanen 1997; Kalso 1990) and one each in Italy (Mercadante
2010), Australia (Leow 1995), Brazil (Lauretti 2003), the UK
(Riley 2014) and Japan/Korea (Imanaka 2013). The length of the
trials ranged from single dose treatment to one year, and the stud-
ies reported the following comparisons:
• controlled-release (CR) oxycodone versus immediate-release
(IR) oxycodone (Kaplan 1998; Parris 1998; Salzman 1999;
Stambaugh 2001);
• CR oxycodone versus CR morphine (Bruera 1998;
Heiskanen 1997; Lauretti 2003; Mercadante 2010;
Mucci-LoRusso 1998; Riley 2014);
• CR oxycodone versus CR hydromorphone (Hagen 1997);
• CR oxycodone versus extended-release (ER) oxymorphone
(Gabrail 2004);
• CR oxycodone versus ER tapentadol (Imanaka 2013);
• intravenous (IV) oxycodone versus rectal oxycodone (Leow
1995);
• IV oxycodone followed by IR oxycodone versus IV
morphine followed by IR morphine (Kalso 1990);
• intramuscular (IM) oxycodone versus oral oxycodone
(Beaver 1978);
• IM oxycodone versus IM morphine versus IM codeine
(Beaver 1978a).
See alsoCharacteristics of included studies for further details about
the studies.
Excluded studies
A number of the studies identified in the search compared oxy-
codone in combination with another drug (for example naxolone
or acetaminophen) against oxycodone alone or placebo. Such stud-
ies were not included as they would not answer our primary ques-
tion, which concerned the effectiveness of oxycodone for cancer
pain. See also Characteristics of excluded studies.
Risk of bias in included studies
The risk of bias for the included studies is described in this section.
See also Figure 2 and Figure 3 for summaries of the risk of bias
judgements made for the included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
In all but three studies, not enough information was reported to
assess whether the methods employed to generate the randomi-
sation sequence and to ensure allocation concealment were ade-
quate. Two of these studies were considered to be at low risk of
bias for both items (Heiskanen 1997; Imanaka 2013), while the
third study was considered at low risk of bias for randomisation
sequence but at unclear risk of bias for allocation concealment
(Riley 2014). Only four studies reported enough information for
us to make a judgement that the treatment groups were compara-
ble at baseline (Imanaka 2013; Kaplan 1998; Riley 2014; Salzman
1999). In the remaining studies, it was unclear whether the patient
selectionmethods employed had resulted in comparable, balanced
groups at the start of the study.
Blinding
The problem of under-reporting was also an issue when assigning
risk of bias estimates to the items assessing performance and de-
tection bias, that is, blinding. In no instance was it directly and
unequivocally reported who was blinded, so we had to infer, on
the basis of supplementary information, whether we were reason-
ably certain that blinding had been adequately executed for a given
individual (that is patient, treating personnel and/or the outcome
assessors, where not the patients themselves). On this basis, the
risk of performance bias was considered to be low for the pri-
mary outcome of pain in 11 of the studies (Beaver 1978; Beaver
1978a; Bruera 1998; Hagen 1997; Heiskanen 1997; Imanaka
2013; Kaplan 1998; Lauretti 2003; Mucci-LoRusso 1998; Parris
1998; Stambaugh 2001), unclear in two studies (Gabrail 2004;
Kalso 1990) and high in four of the studies that were all de-
scribed as open-label (Leow 1995; Mercadante 2010; Riley 2014;
Salzman 1999). For adverse events, the risk of performance bias
was low in nine studies (Beaver 1978; Beaver 1978a; Bruera
1998; Hagen 1997; Imanaka 2013; Kaplan 1998; Lauretti 2003;
Mucci-LoRusso 1998; Stambaugh 2001), unclear in four studies
(Gabrail 2004; Heiskanen 1997; Kalso 1990; Parris 1998) and
high in the same four open-label studies as was the case for pain
(Leow 1995; Mercadante 2010; Riley 2014; Salzman 1999). The
pattern of judgements was identical for detection bias, for both
outcomes. This was the case for the primary outcome of pain be-
cause, according to our criteria, this outcome had to be patient
reported. It was therefore at risk of detection bias to the same ex-
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tent that it was at risk of performance bias since both depend on
patient blinding. As is also evident from the bias judgements (see
Characteristics of included studies), when a study was described
as double-blind but did not describe who was blinded, additional
information in the studies generally led us to the conclusion that
at least the patients seemed to be blinded, although we did not
feel able to gauge with sufficient confidence who else might have
been blinded. Given that it was not always clear who assessed the
adverse events, this accounts for the similar judgements for per-
formance and detection bias for this outcome.
Incomplete outcome data
Overall the data from only 79.9% of the total number of en-
rolled/randomised patients were analysed for pain and 84.2% for
adverse events, which indicates that attrition bias was a substan-
tial problem in this data set, with only four studies considered at
low risk (Kalso 1990; Kaplan 1998; Leow 1995; Parris 1998) and
10 studies considered at high risk (Bruera 1998; Gabrail 2004;
Hagen 1997; Heiskanen 1997; Imanaka 2013; Mercadante 2010;
Mucci-LoRusso 1998; Riley 2014; Salzman 1999; Stambaugh
2001), while three studieswere at unclear risk (Beaver1978; Beaver
1978a; Lauretti 2003) for the primary outcome of pain. For ad-
verse events, the risk of attrition bias was slightly less with seven
studies considered at low risk (Kalso 1990; Kaplan 1998; Imanaka
2013; Leow 1995; Mucci-LoRusso 1998; Parris 1998; Salzman
1999) and six studies considered at high risk (Bruera 1998; Hagen
1997;Heiskanen 1997;Mercadante 2010;Riley 2014; Stambaugh
2001), while four studies were at unclear risk (Beaver 1978; Beaver
1978a; Gabrail 2004; Lauretti 2003).
Selective reporting
Twelve of the included studies were not considered to be at risk
of selective reporting bias, whereas four of the studies either did
not report adverse events or did not report them in a manner so
they could be scrutinised for (and potentially included in) an evi-
dence synthesis (Beaver 1978; Beaver 1978a; Bruera 1998; Lauretti
2003); these studies were therefore judged at high risk. One study
only reported four adverse events in a transparent manner and
was therefore considered at unclear risk of reporting bias (Hagen
1997).
Other potential sources of bias
The patients appeared to be adequately titrated in the major-
ity of the studies (Bruera 1998; Gabrail 2004; Hagen 1997;
Heiskanen 1997; Imanaka 2013; Kalso 1990; Lauretti 2003;
Mucci-LoRusso 1998; Parris 1998; Riley 2014; Stambaugh 2001),
although this was unclear in four studies (Beaver 1978; Beaver
1978a; Leow 1995; Mercadante 2010) and not the case in one
study (Kaplan 1998). One study examined titration as its main
objective (Salzman 1999). For all 10 cross-over trials, data were
available for all cross-over phases.Only three studies undertook in-
tention-to-treat (ITT) analyses for both efficacy and safety (Leow
1995; Parris 1998; Stambaugh 2001), with a further three studies
performing these analyses for safety only (Kalso 1990; Salzman
1999) or for efficacy only (Riley 2014). The remaining studies did
not perform ITT for any of the outcomes. The vast majority of the
included studies had received commercial funding or had authors
who were employees of the drug manufacturers, or both (Beaver
1978; Beaver 1978a;Gabrail 2004;Hagen 1997;Heiskanen 1997;
Imanaka 2013; Kaplan 1998; Leow 1995; Mucci-LoRusso 1998;
Parris 1998; Salzman 1999; Stambaugh 2001). Only two stud-
ies were considered free from the potential influence of commer-
cial funding (Kalso 1990; Riley 2014) with a further three studies
having unclear status (Bruera 1998; Lauretti 2003; Mercadante
2010). All the included studies were considered at low risk of any
other biases (for example carry-over effects in the cross-over trials)
with the exception of two studies which were judged to be at ’un-
clear risk of other bias’ due to the manner in which the trials were
reported (Beaver 1978; Beaver 1978a).
Effects of interventions
Analysis 1.1 shows the pain intensity scores for each of the listed
treatment groups, subgrouped according to overall treatment com-
parisons. We felt that presenting the pain intensity data this way
for the studies where it was possible gave a comprehensive overview
of the pain intensity data for the majority of the included studies,
although the actual analyses should be treated with some caution
as outlined in the Unit of analysis issues section.
Controlled-release (CR) oxycodone versus immediate-release
(IR) oxycodone
Pooled analysis showed that there was no statistically significant
difference in pain intensity after treatment with either CR or IR
oxycodone (SMD0.1, 95%CI -0.06 to 0.26) (Analysis 1.1), which
was also in line with the finding that none of the included studies
reported that the pain intensity differed between the treatment
groups. Salzman 1999 could not be included in the pooled analysis
due to the design of the study, so is instead summarised narratively
below.
Kaplan 1998 reported in a parallel-group study lasting six days
that compared to IR oxycodone, CR oxycodone was associated
with significantly fewer adverse events overall and adverse events
related to the digestive system, and that significantly fewer patients
in theCRoxycodone group reported headache compared to the IR
oxycodone patients (see also Table 2). Kaplan found no difference
in treatment acceptability between the study groups (mean at study
end 3.2, SE = 0.1, in both groups).
In a parallel-group trial lasting five days, Parris 1998 reported that
all the adverse events observed during the study resolved and the
study found no significant differences in incidence rates of adverse
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events (see also Table 2) or acceptability of treatment between the
study groups.
Stambaugh 2001 conducted a cross-over study with a duration of
three to seven days per phase, and stated that: “The study showed
similar incidences and numbers of reports of individual adverse
events considered related to the IR and CR drug” (page 505), but
did not report any formal statistical comparisons of the adverse
event rates between the study groups (see also Table 2). In this
study 30/30 and 29/30 patients rated IR and CR oxycodone,
respectively, as of ’fair’, ’good’ or ’excellent’ acceptability during
the last 24 hours of the treatment phases, with 24/30 and 22/30
patients rating the drugs ’good’ or ’excellent’, respectively.
Salzman 1999 examined in a parallel-group trial lasting up to
21 days whether CR oxycodone could be used as readily as IR
oxycodone for titration to stable pain control and found that 22/24
and 19/24 patients in the CR and IR groups, respectively, achieved
stable pain control within a mean time of 1.6 days (SE = 0.4) and
1.7 days (SE = 0.6), respectively, with no significant differences in
the incidence of adverse events between the groups (see also Table
2).
CR oxycodone versus CR morphine
Pooled analysis including Bruera 1998, Heiskanen 1997,
Mercadante 2010, Mucci-LoRusso 1998 and Riley 2014 showed
that the pain intensity scores after treatment with CR oxycodone
and CRmorphine did not differ significantly (SMD0.14, 95%CI
-0.04 to 0.32) (Analysis 1.1). Lauretti 2003 could not be included
in the pooled analysis due to the design of the study and the results
of this study are therefore summarised narratively below.
In a cross-over trial with each phase lasting 7 days, Bruera 1998
reported that 8/23 patients preferred CR oxycodone treatment
while 11/23 patients preferred treatmentwithCRmorphine (non-
significant difference) and that: “There were no statistically sig-
nificant differences by treatment in mean severity for any of the
elicited adverse events or in the frequency of reporting of unelicited
events” (page 3225), but only data on the sedation and nausea
visual analogue scale (VAS) ratings were presented (see also Table
3).
Heiskanen 1997 conducted a cross-over trial lasting three to six
days per phase and found that vomiting was significantly more
common during morphine treatment while constipation was sig-
nificantly more common during oxycodone treatment; and re-
ported no other significant differences in adverse event rates be-
tween the drugs (see also Table 3). However, the mean daily ac-
ceptability of treatment ratings were significantly higher for mor-
phine (3.49/5; SE = 0.12) than for oxycodone (3.19/5; SE = 0.11).
In a parallel-group trial lasting four weeks (with an extension of
another four weeks), Mercadante 2010 found no significant dif-
ferences in the reported adverse events between the groups.
Mucci-LoRusso 1998 conducted a parallel-group trial lasting up
to 12 days and found that 40/48 and 42/52 patients achieved sta-
ble pain control after receiving CR oxycodone and CR morphine,
respectively, within a median of 2 days for both groups (ranges
were 1 to 10 and 1 to 9 days, respectively). Mucci-LoRusso 1998
also found that 74% and 77% of the CR oxycodone and CRmor-
phine patients, respectively, rated the acceptability of treatment as
good to excellent (non-significant) and that themean acceptability
ratings at the study end did not differ significantly between the
CR oxycodone (mean 4, SE = 0.1) and CR morphine (mean 3.9,
SE = 0.1) patients. The authors also reported that: “Overall, the
adverse experience profiles of CR oxycodone and CR morphine
were similar” (page 244; see also Table 3) and that there were no
clinically significant changes in quality of life for either treatment
group, although no formal analyses were shown for the former and
no results or analyses were shown for the latter outcome.
Lauretti 2003 conducted a two-phase (each lasting 14 days) cross-
over study to examine IR morphine consumption (which was the
main outcome) during treatment with CR oxycodone and CR
morphine, keeping the ratio of CR oxycodone and CR morphine
constant (1:1.8). IR morphine was used as rescue medication and
the patients were allowed to take as much as necessary to keep VAS
pain below 4. The patients consumed 38% more IR morphine
during treatment with CR morphine than with CR oxycodone.
Lauretti also found that CR and IR morphine were associated
with more nausea and vomiting (see also Table 3) and a similar
acceptance to the study drugs compared to the combination of CR
oxycodone and IR morphine. Lauretti 2003 concluded that the
results indicated that CR oxycodone combined with IR morphine
was associated with superior analgesia and lower, or similar, rates
of adverse events than a combination of CR and IR morphine.
In anopen-label, parallel-group trial of 1-year duration,Riley 2014
compared CR oxycodone (N = 100) to CR morphine (N = 98)
and found that 67% and 62% of the patients achieved a response
to first line oxycodone and morphine, respectively, and that this
was not a significant difference. Moreover, in the patients who
achieved a response to their assigned first line treatment none
of the five pain indices studied (that is ’worst pain’, ’least pain’,
’average pain’, ’pain right now’, and ’percentage relief ’) differed
significantly between the treatment groups. The authors also found
no significant differences in adverse event reaction scores between
oxycodone and morphine, either in first line responders or non-
responders. The adverse event rates are listed in Table 3.
CR oxycodone versus CR hydromorphone
In a cross-over trial lasting seven days per phase, Hagen 1997
found no difference in pain intensity between treatment with CR
oxycodone and CRhydromorphone (see also Analysis 1.1).Hagen
1997 also reported that no differences in the frequency of ad-
verse events were observed between the treatment groups with the
exception of drowsiness, which occurred more during treatment
with oxycodone (see also Table 4); 25.8% of the patients had no
treatment preference with approximately half of the remaining pa-
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tients preferring oxycodone (35.5%) while the other half preferred
hydromorphone (38.7%).
CR oxycodone versus extended-release (ER) oxymorphone
Gabrail 2004, in a cross-over trial with each phase lasting 7 to
10 days, found clinically indistinguishable mean 24-hour average
daily pain intensity ratings and also reported that no differences
were observed in quality of life (general activity, mood, walking
ability, normal work, relationships with others, sleep and enjoy-
ment of life) between the drugs, and that 78.3% of patients rated
oxycodone as ’excellent’, ’very good’ or ’good’ with 86.4% of the
patients giving oxymorphone such ratings. The adverse event rates
were also reported to be similar between the drug comparisons, al-
though no formal statistical analyses were presented (see also Table
4), and no patients withdrew due to abnormal laboratory values,
insufficient analgesia or loss to follow-up.
CR oxycodone versus ER tapentadol
Imanaka 2013, in a parallel-group trial of 4 weeks duration, found
equal analgesia between the study groups (see also Analysis 1.1)
with 82/139 oxycodone patients and 80/126 tapentadol patients
reporting ≥ 30% improvement in pain intensity during the last
3 days of treatment, and 59/139 oxycodone patients and 63/126
tapentadol patients reporting ≥ 50% improvement in pain in-
tensity during the last 3 days of treatment. Inspection of Table
4 suggests that the adverse events rates were comparable between
the treatment groups, but the authors did not present any formal
statistical analyses of this apparent equality.
Intravenous (IV) oxycodone versus rectal oxycodone
Leow 1995 conducted a single-dose cross-over study in 12 pa-
tients, with each phase lasting 24 hours, and found that while IV
oxycodone was associated with faster onset of pain relief relative
to rectal oxycodone, rectal oxycodone was associated with a longer
duration of pain relief compared to IV oxycodone. Leow 1995
reported no significant differences in the side effect profiles for the
two study arms (see also Table 4).
IV oxycodone followed by IR oxycodone versus IV morphine
followed by IR morphine
In a cross-over study comparing IV oxycodone titration (2 days)
followed by IR oxycodone titration (2 days) with IV morphine
titration (2 days) followed by IR morphine titration (2 days) in
19 analysed patients Kalso 1990 found that the patients achieved
equal analgesia with both drugs, but around 30% more IV oxy-
codone was needed compared to IV morphine and around 25%
less IR oxycodone was needed than IR morphine to achieve this.
Kalso 1990 also found that nausea was significantly more com-
mon with oral morphine treatment compared to the other three
treatment modalities (see also Table 4). Ten patients expressed no
treatment preference while five patients preferred oxycodone while
another five patients preferred treatment with morphine.
Intramuscular (IM) oxycodone versus oral oxycodone
In a single-dose, cross-over study Beaver 1978 compared 5 and 15
mg IM oxycodone to 10 and 30 mg oral oxycodone in 17 patients
of whom 13 completed at least one cross-over round of the study
medications. Beaver 1978 reported that oral oxycodone was 0.57
(95% CI 0.22 to 1.84) times as potent as IM oxycodone for pain
relief and 0.78 (95% CI 0.3 to 8.82) times as potent for change in
pain intensity. The side effects for both oral and IM oxycodone,
although infrequent, were related to dose, but otherwise no further
details on the observed side effects were provided.
IM oxycodone versus IM morphine versus IM codeine
In another single-dose, cross-over study Beaver 1978a compared
7.5 mg, 15 mg and 30 mg IM oxycodone to 8 mg, 16 mg and 32
mg IMmorphine in 34 patients of whom28 completed at least one
round of the study drugs. In this study, IM oxycodone was found
to be 0.74 (95% CI 0.36 to 1.2) times as potent as IM morphine
for pain relief and 0.68 (95% CI 0.32 to 1.07) times as potent as
IM morphine for change in pain intensity. In a further study of
similar design Beaver 1978a compared 7.5 mg, 15 mg and 30 mg
IM oxycodone to 90mg and 180 mg IM codeine and to 16mg IM
morphine in 30 patients of whom 26 completed at least one cross-
over round of the study medications. Beaver 1978a reported that
IM oxycodone was 10.72 (95% CI not reported) times as potent
as IM codeine for pain relief and 8.44 (95% CI 2.13 to 44.69)
times as potent as IM codeine for change in pain intensity. The
authors noted that in both studies side effects typical of narcotic
analgesics were observed, although not in sufficient numbers to
allow meaningful analysis, and they reported no further details on
adverse events.
D I S C U S S I O N
Summary of main results
We included 17 studies which enrolled/randomised a total of 1390
patients, with 1110 of these analysed for efficacy and 1170 for
safety. The studies examined a number of different drug compar-
isons. Four studies compared controlled-release (CR) oxycodone
to immediate-release (IR) oxycodone, and pooled analysis of three
of these studies showed that there was no difference in pain inten-
sity after treatment with either CR or IR oxycodone (SMD 0.1,
95% CI -0.06 to 0.26), which is also in line with the finding that
13Oxycodone for cancer-related pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
none of the included studies reported that the pain intensity dif-
fered between the treatment groups. Three of the four studies also
found no difference in treatment acceptability or adverse events
between the comparisons, but one study did report that compared
to IR oxycodone, CR oxycodone was associated with significantly
fewer adverse events. We noted that IR oxycodone was given every
six hours rather than every four hours in these studies. This might
have biased the efficacy data in favour of CR oxycodone, however,
the adverse effect data suggest that giving IR oxycodone every four
hours (more frequently) would have resulted in greater adverse
effects, which would have mitigated advantages in efficacy.
Six studies compared CR oxycodone to CR morphine and pooled
analysis of five of these six studies indicated that pain intensity
did not differ significantly between the treatments (SMD 0.14,
95% CI -0.04 to 0.32) with no marked differences in terms of ad-
verse event rates, treatment acceptability or quality of life ratings
between the treatments. These findings, however, contrast some-
what with those reported in Lauretti 2003, which was different
in design to the other four studies and examined IR morphine
consumption during treatment with CR oxycodone and CRmor-
phine while keeping the ratio of CR oxycodone and CRmorphine
constant. Lauretti 2003 found that the patients consumed 38%
more IRmorphine during treatment with CRmorphine thanwith
CR oxycodone, and that CR and IRmorphine was associated with
more nausea and vomiting and a similar acceptance to the study
drugs compared to the combination of CR oxycodone and IR
morphine, and therefore concluded that CR oxycodone combined
with IR morphine is associated with superior analgesia and lower
or similar rates of adverse events than a combination of CR and
IR morphine.
The remaining seven studies all compared either oxycodone in
different formulations or oxycodone to different alternative opi-
oids and none of them found any clear superiority or inferiority
of oxycodone for cancer pain, neither as an analgesic agent nor
in terms of adverse event rates or treatment acceptability. See also
Table 1 for a summary of the findings.
Overall completeness and applicability of
evidence
Although the findings of this review are applicable to the popula-
tion and comparisons defined for this review, that is patients who
need treatment with strong opioids for cancer pain, they should
be taken in the context that this review found 17 studies that
were eligible for inclusion and these studies reported on nine dif-
ferent comparisons involving oxycodone and included only 1390
patients. Moreover, for some of the outcomes (patient satisfaction
and quality of life) extremely few data were available. To some-
what mitigate this shortfall, we reported treatment acceptability as
a proxy. However, that does not change the fact that the evidence
base for the effectiveness and tolerability of oxycodone (relative
or absolute) for pain in adults with cancer is very limited and it
did not allow us to examine the effectiveness and tolerability of
oxycodone in detail through patient or treatment subgroup anal-
yses, or the robustness of the findings in sensitivity analyses. The
current evidence base would therefore benefit from more well-de-
signed, large randomised controlled trials.
Quality of the evidence
The quality of the evidence for all the outcomes was low or very
low. This is due to imprecision (low patient numbers) in some
cases and very serious study limitations in all cases. In general, the
assessment of the quality of the included studies was limited by
a great extent of under-reporting in the studies, especially for the
patient selection items (random sequence generation and alloca-
tion concealment), while blinding appeared to be reasonably well
undertaken overall, both in terms of treatment performance and
outcome assessment. However, as is not unusual for pain research,
the results were substantially compromised by attrition, with data
missing frommore than 20% of the enrolled/randomised patients
for efficacy, and from more than 15% for safety. These are sub-
stantial proportions and, while it did not appear to be selective
attrition, the results must be interpreted with caution.
Potential biases in the review process
Weundertook the review according to themethods specified in our
protocol, which were all in line with the recommendations of The
Cochrane Collaboration as outlined in theCochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), and included
a thorough search strategy designed to maximise the chances of
identifying all relevant studies. Contacting authors resulted in no
additional studies being identified, that is the review therefore only
contains data from published studies, some of which have not re-
ported all the outcome data despite having apparently collected
these data. The review may therefore be at some risk of publica-
tion bias, although publication bias is usually associated with pos-
itive results, and the majority of the included studies did not find
significant differences between their treatment groups in terms of
efficacy and safety. Moreover, the meta-analyses we undertook in-
cluded data from cross-over studies that were analysed as if they
were parallel-group studies. As outlined in Unit of analysis issues,
such practice results in unit of analysis error although, in turn,
this leads to an under-weighting rather than over-weighting of the
data. In future updates of this review we hope to be able to include
enough new studies in the meta-analyses to be able to examine the
effect of including cross-over trials in this manner through sensi-
tivity analyses.
14Oxycodone for cancer-related pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Agreements and disagreements with other
studies or reviews
King 2011 conducted a systematic review without meta-analy-
sis that also included observational studies and concluded that,
“There is no evidence from the included trials of a significant
difference in analgesia or adverse effects between oxycodone and
morphine or hydromorphone” (page 454). Caraceni 2011 reached
a similar conclusion in their systematic review without meta-anal-
ysis. Bekkering 2011 and Reid 2006 both included meta-analyses
in their systematic reviews and they also concluded that the effec-
tiveness of oxycodone and morphine did not significantly differ.
although the inclusion criteria employed by Bekkering 2011 dif-
fered from ours, with Bekkering 2011 excluding cross-over trials
and including trials of chronic non-malignant pain, whereas the
publication of Reid 2006 before the trial of Mercadante 2010 pre-
cluded its inclusion. That said, the conclusions of all these reviews
are all in agreement with those that we have reached in this review
dealing with the same comparisons as the aforementioned reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with cancer pain: we found low quality evidence
that oxycodone offers similar levels of pain relief and side effects
as morphine for patients with cancer.
2. For clinicians: we found low quality evidence that oxycodone
offers similar levels of cancer pain relief and adverse events to other
strong opioids including morphine, which is commonly consid-
ered the gold standard strong opioid.
3. For policymakers: the findings of this review are consistent with
current international guidance on using oxycodone or morphine
as first line opioids for patients with cancer-related pain.
4. For funders: we did not undertake cost-effectiveness analysis.
Implications for research
1. General: we found that the current evidence base is comprised
of studies that contain small numbers of patients in which there is
a significant (20%) dropout rate. For example, the direct compar-
ison meta-analysis between oxycodone and morphine is based on
fewer than 300 cancer patients in each treatment group; this is a
very small evidence base. However, given the absence of important
differences within this analysis, it seems unlikely that larger head
to head studies of oxycodone versus morphine will be justified.
2. Design: there were no implications for the design of future
clinical studies.
3. Measurement (endpoints): for future cancer pain studies, de-
veloping a single outcome that combines good pain control (no
more than mild on a verbal rating scale) with acceptable side ef-
fects (perhaps no more than mild severity on any adverse event)
would enable a clearer comparison between any analgesics used in
this context.
A C K N OW L E D G E M E N T S
This article presents an extension to a systematic review under-
taken as part of the 2011 National Institute for Health and Clin-
ical Excellence (NICE) guideline on “Opioids in palliative care”
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Centre for Cancer (NCC-C). The NCC-C receives funding from
NICE.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beaver 1978
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: USA
Participants Patients: 17 patients entered, ”13 patients completed at least one round“ (see Interven-
tions” below) and were analysed for efficacy (“The 4 patients who failed to complete a
single round did so for reasons extraneous to the drugs under study”); 5 males/8 females,
mean (range) age = 51 (23 to 68) years. “One of these patients appeared twice in the
study, and 5 completed a second round, yielding 19 cross-over comparisons.”
Inclusion criteria: “The subjects were patients with a variety of malignant tumours on the
wards of James Ewing Hospital. Each patient was first examined to ascertain the nature
and location of his or her pain, the extent of disease, prior experience with narcotics and
analgesic drugs and ability to communicate meaningful information about pain. At this
time, the patient was also told how the studies were to be conducted and that, while
all test medications might appear the same, they would actually include a number of
different drugs, some probably more effective than others in relieving pain. Many of the
patients had had some prior experience with oral or parenteral narcotics, and several had
a history of sufficient recent narcotic use to warrant the assumption that they possessed
some tolerance to narcotics. Patients were placed on a routine analgesic other than those
included in the study during nonstudy hours, and, insofar as was possible, concomitant
administration of psychoactive drugs was avoided.”
Exclusion criteria: See ’Inclusion criteria’. No other information provided.
Interventions Oxycodone arm
- Drug: Oxycodone + oral placebo
- Dose/dosing: 5 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration.
- Rescue medication: Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
Comparison arm 1
- Drug: Oxycodone + oral placebo
- Dose or dosing: 15 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
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Beaver 1978 (Continued)
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
Comparison arm 2
- Drug: Oxycodone + intramuscular placebo
- Dose or dosing: 10 mg
- Formulation: Immediate-release?
- Route of administration: Oral
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
Comparison arm 3
- Drug: Oxycodone + intramuscular placebo
- Dose or dosing: 30 mg
- Formulation: Immediate-release?
- Route of administration: Oral
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
- For cross-over trials, cross-over schedule: “Treatments were assigned to patients ac-
cording to a series of randomly chosen Latin squares, and each study medication was
administered on a separate day. Each patient received a low and a high dose of both the
“standard” and the “test drug,” chosen at equilog intervals. Unless a patient completed
all doses of the crossover comparison or “round,” his data were excluded from the relative
potency analysis. After completing the first round, some patients were able to repeat the
course, allowing for comparison of replicate rounds within the same individual.”
Outcomes - Pain intensity: Assessed by patient “hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hr had elapsed since administration of the study medication)
”; using a 4-point categorical scale from 0 (= none) (1 = slight, 2 = moderate) to 3 (=
severe)
- Pain relief: Assessed by patient hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hr had elapsed since administration of the study medication);
using a 5-point categorical scale from 0 (= none) (1 = slight, 2 = moderate, 3 = lots) to
4 (= complete)
“Patients who were remedicated before 6 hr elapsed after administration of a study
medication were assigned scores of zero (0) for change in pain intensity and pain relief
for the remaining observation points of the 6-hr observation period.”
- Side effects: “The observer also recorded apparent and volunteered side-effects, but
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Beaver 1978 (Continued)
leading questions were avoided.”
Notes - Study free of commercial funding? No: “This work was supported by grants awarded
by the Committee on Problems of Drug Dependence, National Academy of Sciences,
National Research Council, from funds contributed by a group of interested pharma-
ceutical manufacturers, and by National Cancer Institute Grant CA-08748.”
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? No: “Unless a patient completed all doses of the crossover
comparison or “round,” his data were excluded from the relative potency analysis”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatments were assigned to patients ac-
cording to a series of randomly chosen
Latin squares”. No further information re-
ported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Neither the patient nor the observer was
aware of the identity of the medications,
which were physically indistinguishable
and identified only by a numerical code on
individual dosage envelopes. To maintain
double-blind conditions, both capsules and
an injection, one of which was a dummy,
were administered each time a patient was
given a study medication.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient reported. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Patient reported. See cell above
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data from 13/17 patients reported. “One
of these patients appeared twice in the
study, and 5 completed a second round,
yielding 19 crossover comparisons.”
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Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data from 13/17 patients reported. “One
of these patients appeared twice in the
study, and 5 completed a second round,
yielding 19 crossover comparisons.”
Selective reporting (reporting bias) High risk No side effects or adverse events reported in
detail: “The side-effects are both intramus-
cular and oral oxycodone were dose-related
and qualitatively similar to those noted in
the codeine study.” (which were also not
reported in any detail at all: “While a dose-
response regression was generally evident,
side-effects did not occur with sufficient
frequency to allow meaningful analysis.”)
Other bias Unclear risk It is unclear if this study is subject to a high
risk of other biases
Were the patients adequately titrated? Unclear risk Not enough information provided
For cross-over trials: Are data available for
both time periods?
Low risk Yes,data are available from all the cross-over
periods
Beaver 1978a
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: USA
Participants ”The patient population and method of evaluating analgesic efficacy were similar to
those employed in the oral/parenteral analgesic relative potency assays of codeine and
oxycodone described in the previous paper“ Beaver 1978
This paper contains 2 studies:
’Intramuscular morphine and oxycodone’ and ’intramuscular codeine, oxycodone and
morphine’
’Intramuscular morphine and oxycodone’
Patients: 34 patients entered, ”28 patients completed at least one round“ (see Interven-
tions” below) and were analysed for efficacy (“All of the patients who failed to complete
a single round did so for reasons extraneous to the drugs under study”); 14 males/14
females, mean (range) age = 46 (23 to 68) years. “Of the 28 patients participating in the
study, 4 appeared twice in a single series, and 2 appeared in each of two series. Twenty-
four patients completed a second round, yielding a total of 58 crossover comparisons.”
’Intramuscular codeine, oxycodone and morphine’
Patients: 30 patients entered, “26 completed at least one round” (see Interventions“
below) and were analysed for efficacy (”The 4 who failed to complete a single round did
so for reasons extraneous to the drugs under study“); 14 males/12 females, mean (range)
age = 45 (23 to 80) years. ”Series I was carried out in 11 patients, one of whom appeared
twice in the series and 10 of whom completed a second round, yielding 22 cross-over
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comparisons of 90 and 180 mg of codeine, 7.5 and 15 mg of oxycodone and 16 mg
of morphine. Series II consisted of 27 cross-over comparisons in 16 patients of 90 and
180 mg codeine, 15 and 30 mg of oxycodone, and 16 mg of morphine. One patient
appeared in both Series I and Series II.“
Inclusion criteria: See above
Exclusion criteria: See above
Interventions ’Intramuscular morphine and oxycodone’:
”This assay consisted of three series, each comparing two doses of morphine sulfate (the
standard) with two doses of oxycodone hydrochloride (the test drug) by intramuscular
injection.“ ”The distribution of patients and doses in the various series is presented in
table 1. In general, the more obviously tolerant patients were given series II treatments,
which consisted of double the dosage in series I.“
Oxycodone arm
- Drug: Oxycodone hydrochloride
- Dose or dosing: Series I: 7.5 mg and 15 mg; Series II and III: 15 mg and 30 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See “Rescue medication” and “Inclusion criteria”
Comparison arm
- Drug: Morphine sulfate
- Dose or dosing: Series I and III: 8 mg and 16 mg; Series II: 16 mg and 32 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: “Assessed by patient ”hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)“. No further information reported
- Other medication: See ”Rescue medication“ and ”Inclusion criteria“
’Intramuscular codeine, oxycodone and morphine’:
”This assay consisted of two series, each comparing 90 and 180 mg codeine phosphate
(the standard) with two doses of oxycodone hydrochloride (the test drug) and a single
16 mg dose of morphine sulfate.“
Oxycodone arm
- Drug: Oxycodone hydrochloride
- Dose or dosing: Series I: 7.5 mg and 15 mg; Series II: 15 mg and 30 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
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Beaver 1978a (Continued)
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See “Rescue medication” and “Inclusion criteria”
Comparison arm 1
- Drug: Morphine sulfate
- Dose or dosing: Series I and II: 16 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: “Assessed by patient ”hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)“. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
Comparison arm 2
- Drug: Codeine phosphate
- Dose/dosing: Series I and II: 90 mg and 180 mg
- Formulation: Intramuscular
- Route of administration: Intramuscular
- Length of treatment: Appears to be single dose
- Titration schedule: No titration
- Rescue medication: ”Assessed by patient “hourly for 6 hours after administration of
the study medication or until pain returned to the premedication level and a routine
analgesic was administered (if at least 3 hr had elapsed since administration of the study
medication)”. No further information reported
- Other medication: See ’Rescue medication’ and ’Inclusion criteria’
- For cross-over trials, cross-over schedule: “Treatments were assigned to patients ac-
cording to a series of randomly chosen Latin squares, and each study medication was
administered on a separate day. Each patient received a low and a high dose of both the
“standard” and the “test drug,” chosen at equilog intervals. Unless a patient completed all
doses of the cross-over comparison or “round,” his data were excluded from the relative
potency analysis. After completing the first round, some patients were able to repeat the
course, allowing for comparison of replicate rounds within the same individual.”
Outcomes - Pain intensity: Assessed by patient “hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hr had elapsed since administration of the study medication)
”; using a 4-point categorical scale from 0 (= none) (1 = slight, 2 = moderate) to 3 (=
severe)
- Pain relief: Assessed by patient hourly for 6 hours after administration of the study
medication or until pain returned to the premedication level and a routine analgesic was
administered (if at least 3 hr had elapsed since administration of the study medication);
using a 5-point categorical scale from 0 (= none) (1 = slight, 2 = moderate, 3 = lots) to
4 (= complete)
“Patients who were remedicated before 6 hr elapsed after administration of a study
medication were assigned scores of zero (0) for change in pain intensity and pain relief
for the remaining observation points of the 6-hr observation period.”
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- Side effects: “The observer also recorded apparent and volunteered side-effects, but
leading questions were avoided.”
Notes - Study free of commercial funding? No: “This work was supported in part by grants
awarded by the Committee on Problems of Drug Dependence, National Academy of
Sciences, National Research Council, from funds contributed by a group of interested
pharmaceutical manufacturers, and by National Cancer Institute Grant CA-08748.”
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? No: “Unless a patient completed all doses of the crossover
comparison or “round,” his data were excluded from the relative potency analysis”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatments were assigned to patients ac-
cording to a series of randomly chosen
Latin squares”. No further information re-
ported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Neither the patient nor the observer was
aware of the identity of the medications,
which were physically indistinguishable
and identified only by a numerical code on
individual dosage envelopes. To maintain
double-blind conditions, both capsules and
an injection, one of which was a dummy,
were administered each time a patient was
given a study medication.” From Beaver
1978
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient reported. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk Patient reported. See cell above
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data included from 28/34 and 26/30 pa-
tients in the two studies, respectively
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Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data included from 28/34 and 26/30 pa-
tients in the two studies, respectively
Selective reporting (reporting bias) High risk No side effects or adverse events reported
in detail: Study 1: “While side-effects ob-
served after both morphine and oxycodone
were typical of the narcotic analgesics, they
did not occur with sufficient frequency to
allow ameaningful comparison of the side-
effect liability of the two drugs. Notewor-
thy was the virtual absence of side-effects
in patients in series II, an observation con-
sistent with these patients’ substantial tol-
erance to narcotics.” Study 2: “Side-effects
were qualitatively similar to those noted in
the oxycodone-morphine comparison, but
they did not occurwith sufficient frequency
to allow a meaningful comparison among
treatments.”
Other bias Unclear risk It is unclear if this study is subject to a high
risk of other biases
Were the patients adequately titrated? Unclear risk Not enough information provided
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available from all the cross-
over periods
Bruera 1998
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Canada
Participants Patients: 32 patients entered, 23 patients analysed for efficacy and VAS variables (5
patients dropped out during the CR morphine phase: 3 in phase 1, 2 in phase 2; 1
due to lack of pain control and adverse event, 1 due to protocol violation, 3 due to
adverse events; 4 patients dropped out during the CR oxycodone phase: 2 in phase 1, 2
in phase 2; 1 due to lack of pain control, 2 due to adverse events, 1 was lost to follow-up)
; 13 females, 10 males; age not reported; cancer type: lung (7), breast (7), prostate (1)
, other (8): cancer stage not reported; type of pain not reported; setting: palliative care
programme; previous analgesic medication: IR morphine (8), CR morphine (10), IR
oxycodone ± acetaminophen (11), CR hydromorphone (1), CR codeine (1), IR codeine
+ acetaminophen (1); duration of opioid use: 6.6 (± 10) months; duration of chronic
pain: 8 (± 13) months
Inclusion criteria: “The study included 32 patients from the Palliative Care Program at
the Cross Cancer Institute and Grey Nuns Hospital in Edmonton, Canada. All patients
were≥ 18 years of age, gave written informed consent, had pain due to cancer, and were
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receiving treatment with an oral opioid analgesic at study entry. Life expectancy for all
patients was estimated by the treating physician to be at least 4 months.”
Exclusion criteria: Use of active anticancer therapy, with the exception of hormones,
within 2 weeks of study entry; physical or mental inability to answer questions and
comply with the treatment protocol; history of intolerance of oxycodone or any related
compound; impaired renal or hepatic function; significantly impaired ventilatory func-
tion (clinically present dyspnea at rest); current use of an investigational drug; pregnancy
or lactation; unwillingness or inability to co-operate or give written, informed consent;
and inability to take oral medications
Interventions Oxycodone arm
- Drug: Oxycodone + placebo morphine
- Dose and dosing: Mean dose = 46.5 (± 57) mg every 12 hours
- Formulation: Controlled-release (CR)
- Route of administration: Oral
- Length of treatment: 7 days
- Titration schedule: “≥ 3 day prestudy history of stable analgesia (defined as a daily
rescue opioid consumption ≤ 20% of the scheduled daily opioid dose)”
- Rescue medication: Immediate-release oxycodone hydrocloride, at doses of ca 10% of
daily scheduled opioid dose. Mean daily number of doses = 2.3 (± 2.3)
- Other medication: No other analgesic agents. All other pre-study medications were
maintained with no changes allowed later than 72 hours before randomisation
Comparison arm
- Drug: Morphine + placebo oxycodone
- Dose and dosing: Mean dose = 72.6 (± 102) mg every 12 hours
- Formulation: Controlled-release (CR)
- Route of administration: Oral
- Length of treatment: 7 days
- Titration schedule: “≥ 3 day prestudy history of stable analgesia (defined as a daily
rescue opioid consumption ≤ 20% of the scheduled daily opioid dose)”
- Rescue medication: Immediate-release (IR) morphine, at doses of ca 10% of daily
scheduled opioid dose. Mean daily number of doses = 1.7 (± 2.1)
- Other medication: No other analgesic agents, all other pre-study medications were
maintained with no changes allowed later than 72 hours before randomisation
“Patients who had been receiving narcotic analgesics other thanmorphine or single-entity
oxycodone before the start of the study were transferred to an equianalgesic oral dose of
controlled-release oxycodone or controlled-release morphine at the start of phase 1. The
initial dose of controlled-release oxycodone was determined busing a 1:1.5 conversion
ratio between controlled-release oxycodone and controlled-release morphine”
- For cross-over trials, cross-over schedule: On day 8 patients were crossed over to receive
the alternative drug and placebo at a dose equivalent to that received at the start of phase
1. During both study phases, blind-labelled dose adjustments were permitted if patients
required more than 3 rescue analgesic doses over 24 hours
Outcomes - Pain intensity: Assessed by patient 4 times per day before dosing and at the end of each
phase; 100 mm VAS (0 = no pain to 100 = worst possible pain) and 5-point categorical
scale (0 = no pain to 4 = worst possible pain)
- Overall effectiveness of the study medication: Assessed by patient on days 8 and 15;
verbal rating scale (0 = not effective to 3 = highly effective)
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- Nausea and sedation: Days 8 and 15; 100 mm VAS (0 = no nausea or sedation to 100
extreme nausea or sedation)
- Adverse events: Recorded by patients; checklist (nausea, vomiting, constipation, dry
mouth, drowsiness, dizziness, difficulty concentrating, fatigue, poor sleep, vivid dreams,
hallucinations, headache, agitation, twitching, itching, sweating; rated from 0 (= none)
to 4 (intolerable)) and non-directed adverse events questionnaire
- Treatment preference: Assessed by patients and investigators at the end of study
Notes - Study free of commercial funding? Unclear. No information provided
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? No for efficacy or VAS variables where the analyses restricted
to the 23/32 patients who completed both study phases. Satefy variables were analysed
for all enrolled patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised. No further in-
formation provided
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Blinding was maintained by the double-
dummy technique using matching place-
bos of controlled release oxycodone and
controlled-release morphine. The immedi-
ate-release oxycodone and morphine for-
mulations were also blinded.”
Trial labelled as ’double-blind’
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk “Blinding was maintained by the double-
dummy technique using matching place-
bos of controlled release oxycodone and
controlled-release morphine. The immedi-
ate-release oxycodone and morphine for-
mulations were also blinded.”
Trial labelled as ’double-blind’
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above. Outcome was patient-re-
ported
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above. Outcome was patient-re-
ported
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Incomplete outcome data (attrition bias)
Pain
High risk 23/32 patients analysed
Incomplete outcome data (attrition bias)
Adverse events
High risk The only safety data analyses that are re-
ported analysed 23/32 patients
Selective reporting (reporting bias) High risk The majority of the adverse events are not
reported beyond the sentence “There were
no statistically significant differences by
treatment in mean severity for any of the
elicited adverse events or in frequency of
reporting of unelicited events.”
Other bias Low risk The authors report that “There was no ev-
idence of period or sequence (carry-over)
effect.” No other biases were identified
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes. Data only analysed if available from
both time periods
Gabrail 2004
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: USA
Participants Patients: 58 patients screened, 47 patients titrated, 45 patients randomised, and 44
patients received ≥ 1 dose of study medication and had ≥ 1 pain intensity evaluation
after treatment and were therefore analysed for safety (1/45 never received any double-
blind study medication and was excluded from all analyses). A total of 37/45 randomised
patients completed the first double-blindphase and≥ 5days of the secondphase andwere
analysed for efficacy (2/45 patients had insufficient visits or assessments to be included
in the efficacy population); 5/45 randomised patients discontinued the drug during the
double-blind treatment periods: 2 patients withdrew due to adverse events unrelated to
the study drug, 2 patients withdrew consent and 1 patient due to protocol violation. No
patients discontinued the study due to insufficient analgesia or loss to follow-up
A total of 21 safety and 18 efficacy patients received extended-release oxymorphone
followed by controlled-release oxycodone and 23 safety and 19 efficacy patients received
controlled-release oxycodone followed by extended-release oxymorphone
A total of 21 men and 23 women, mean age (range) = 59.3 (26 to 81) years; 80%
had severe untreated pain and 20% had moderate untreated pain. Previous anticancer
therapy included surgery (68%), chemotherapy (82%), radiotherapy (50%), and/or
immunotherapy (2.3%)
Inclusion criteria: Men and women aged ≥ 18 years with moderate to severe pain sec-
ondary to cancer who required long-term outpatient treatment with an opioid analgesic.
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Patients hospitalised for reasons unrelated to cancer were also eligible
Exclusion criteria: Allergy or sensitivity to morphine, extended-release oxymorphone,
controlled-release oxycodone or their components, requirement for a concurrent opioid
analgesic other than the study medication, contraindication to opioid therapy, preg-
nancy, lactation, plan for pregnancy, uncontrolled emesis, inability to take adequate oral
food and hydration, levels of hepatic enzymes (gamma-glutamyl transpeptidase, alanine
aminotransferase, and aspartate animotransferase) ≥ 3 times the upper limit of the nor-
mal range, receipt of radiotherapy or therapeutic radionuclides within the previous 2
weeks preceding study enrolment
Interventions Oxycodone arm
- Drug: Oxycodone
- Dose and dosing: Mean daily dose = 91.9 mg (any dose adjustments were made during
the first 3 days of the double-blind phase; dosage remained fixed thereafter)
- Formulation: Controlled-release (CR)
- Route of administration: Oral
- Length of treatment: 7 to 10 days, take medication at 8 am and 8 pm
- Titration schedule: “During the open-label titration/stabilization phase, patients re-
ceived either oxymorphone immediate-release (IR) or oxycodone CR to determine a
stable dosage, defined as a fixed dosage that provided adequate analgesia for at least 2
consecutive days, required no more than 2 doses of rescue medication/day, and produced
tolerable AEs.”
- Rescue medication: Tablets of 15 mg oral morphine sulfate (IR) every 4 to 6 hours as
needed. Patients requiring > 2 doses/day after the first 3 days of double-blind treatment
were discontinued. Mean daily dose (range) = 12.6 (0 to 75) mg
- Other medication: Not reported
Comparison arm
- Drug: Oxymorphone
- Dose and dosing: Mean daily dose = 45.9 mg (any dose adjustments were made during
the first 3 days of the double-blind phase; dosage remained fixed thereafter)
- Formulation: Extended-release, take medication at 8 am and 8 pm
- Route of administration: Oral
- Length of treatment: 7 to 10 days
- Titration schedule: “During the open-label titration/stabilization phase, patients re-
ceived either oxymorphone immediate-release (IR) or oxycodone CR to determine a
stable dosage, defined as a fixed dosage that provided adequate analgesia for at least 2
consecutive days, required no more than 2 doses of rescue medication/day, and produced
tolerable AEs.”
- Rescue medication: Tablets of 15 mg oral morphine sulfate (IR) every 4 to 6 hours as
needed. Patients requiring > 2 doses/day after the first 3 days of double-blind treatment
were discontinued. Mean daily dose (range) = 16.6 (0 to 90) mg
- Other medication: Not reported
- For cross-over trials, cross-over schedule: “Following the first double-blind treatment
period, patients crossed over to the alternative double-blind treatment (oxymorphone
ER or oxycodone CR) for an additional 7-10 days.”
Outcomes - Pain intensity: Assessed by daily diary recording by the patients of all study drugs taken
(including supplemental pain medication) and their 24-hour pain intensity, using an
11-point numerical scale (0 = no pain to 10 = worst possible pain) and the Brief Pain
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Inventory
- Quality of life: Assessed by the Brief Pain Inventory to assess the interference of pain
with 7 domains of quality of life (general activity, mood, walking ability, normal work,
relations with other people, sleep, and enjoyment of life). Appears to be rated by the
patients during the study visits that marked the end of each double-blind treatment
phase
- Global assessment of current pain medication, rated by patients and physicians in-
dependently following each double-blind phase. Physicians were asked “Please rate the
subject’s current pain medication used for treating their cancer pain”
- Karnofsky performance status: assessed by physicians at each visit
- Safety analysis: Assessed by physical examination, vital signs, clinical laboratory tests
(serum chemistry profile, complete blood count, urinanalysis), electrocardiograms and
themonitoring of adverse events (whichwere rated by the investigators asmild,moderate,
severe intensity, and as unlikely, possibly, probably related to study medication)
Notes - Study free of commercial funding? No, the study was funded by Endo Pharmaceuticals
Inc., Chadds Ford, PA and Penwest Pharmaceuticals Co., Danbury, CT
- Groups comparable at baseline? The authors report that there were no significant
differences in the demographic or baseline characteristics of the treatment groups, but
do not report these characteristics split by treatment group
- ITT analyses undertaken? No for efficacy and safety where the analyses were restricted
to 37 and 41 to 43 of 45 randomised patients, respectively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised. No further in-
formation provided
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as “double-blind”.
No further information reported, so it is
unclear who was blinded and whether it
was adequately executed
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
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Incomplete outcome data (attrition bias)
Pain
High risk 37/45 randomised patients were analysed
for efficacy
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk 41 to 43 of 45 randomised patients were
analysed for efficacy
Selective reporting (reporting bias) Low risk The main expected outcomes are reported
Other bias Low risk The authors report that “There were no se-
quence effects observed during the study;
comparable pain scores and other effi-
cacy measures were obtained irrespective of
the order in which patients received the
study medication.” No other potential bi-
ases were identified
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 40/45 patients
Hagen 1997
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Canada
Participants Patients: 44 patients enrolled, 31 patients completed the study. Reasons for withdrawal
included adverse events (N = 8), inadequate pain control (N = 3), intercurrent illness (N
= 1) and voluntary withdrawal (N = 1). “Failure to complete both phases of the study
did not appear to be related to toxicity of one of the study drugs over another.” The
analysis of all efficacy outcome variables, including VAS and categorical pain intensity,
sedation, VAS and nausea VAS were restricted to patients completing both study phases.
Spontaneously reported safety variables were analysed for all enrolled patients
13 men/18 women, mean age (SE) = 56 (3) years. Primary tumour: Breast (N = 7),
colorectal (N = 5), lung (N = 1), urological/prostate (N = 5), CNS (N = 4), unknown
primary (N = 2), other (N = 7). Type of pain: Bone (61%, soft tissue (29%), visceral
(23%), neuropathic (45%). Pain described as “lancinating” (16%): steady pain (61%),
incident pain with or without steady pain (52%)
Inclusion criteria: Patients with chronic cancer pain and stable analgesic requirements
Exclusion criteria: Knownhypersensitivity to opioid analgesics, intolerance of oxycodone
or hydromorphone, presence of a medical or surgical condition likely to interfere with
drug absorption in the gastrointestinal tract, concurrent use of other opioid analgesics
during the study period, presence of intractable nausea and vomiting, and patients who
had undergone or were expected to undergo therapeutic procedures likely to influence
their pain during the study period
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- Dose and dosing: Mean daily initial dose = 120 ± 22 mg, mean final dose = 124 ± 22
mg (blind-label dose changes were permitted, and in case of a dose change, the rescue
analgesic dose was modified accordingly)
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 7 days, 12-hourly
- Titration schedule: “Patients with 3 days of stable analgesic requirements on a prestudy
opioid were randomized to controlled-release oxycodone or controlled-release hydro-
morphone. Stable analgesia was defined as 2 or fewer rescue doses of opioid analgesic
per 24-hour period, calculated over 3 or more days.”
- Rescue medication: Incident and nonincident breakthrough pain was treated with
immediate-release oxycodone at a dosage of approximately 10% of the daily scheduled
dose. Mean daily frequency of rescue use (SD) = 1.4 ± 0.3 mg
-Othermedication: No other opioids were permitted. Nonopioid analgesics, such as cor-
ticosteriods, antidepressants, anticonvulsants, bisphosphonates and psychostimulants,




- Dose/dosing: Mean daily initial dose = 24 ± 4 mg, mean final dose = 30 ± 6 mg (blind-
label dose changes were permitted, and in case of a dose change, the rescue analgesic
dose was modified accordingly)
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 7 days, 12-hourly
- Titration schedule: “Patients with 3 days of stable analgesic requirements on a prestudy
opioid were randomized to controlled-release oxycodone or controlled-release hydro-
morphone. Stable analgesia was defined as 2 or fewer rescue doses of opioid analgesic
per 24-hour period, calculated over 3 or more days.”
- Rescue medication: Incident and nonincident breakthrough pain was treated with im-
mediate-release hydromorphone at a dosage of approximately 10% of the daily scheduled
dose. Mean daily frequency of rescue use (SD) = 1.6 ± 0.3 mg
-Othermedication: No other opioids were permitted. Nonopioid analgesics, such as cor-
ticosteroids, antidepressants, anticonvulsants, bisphosphonates and psychostimulants,
that had been part of the patient’s therapy were continued at the same dose level through-
out the study
- For cross-over trials, cross-over schedule: “At the end of Phase I, patients were crossed
over to the alternative treatment in Phase II without an intervening washout period.”
Outcomes - Pain intensity: Assessed by patients 4 times daily (8.00, 12.000, 16.00, and 20.00) on
a 100 mm visual analogue scale (going from no pain to excruciating pain) and on a 5-
point categorical scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = excruciating)
- Nausea and sedation: Assessed by patients 4 times daily (8.00, 12.000, 16.00, and 20.
00) on a 100 mm visual analogue scale (going from no nausea or sedation to severe
nausea or extreme sedation)
- Spontaneuosly reported, investigator-observed and elicited adverse events were recorded
at the end of each phase
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- Patient and investigator treatment preferences were recorded at the end of both phases
Notes - Study free of commercial funding? No information reported, but the second author
(Najib Babul) is an employee of Purdue Frederick, which is the manufacturer of the
controlled-release oxycodone study drug used in the study
- Groups comparable at baseline? No information provided about initial group allocation
- ITT analyses undertaken? No for efficacy where the analyses were restricted to 31/44
patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
Low risk “Blinding was maintained by the dou-
ble-dummy technique, which involved
matching placebos. In the active treat-
ment phases, patients received either active
controlled-release oxycodone and place-
bosmatching controlled-release hydromor-
phone or active controlled-release hydro-
morphone and placebos matching con-
trolled-release oxycodone.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk The analyses were restricted to 31/44 pa-
tients
Incomplete outcome data (attrition bias)
Adverse events
High risk The analyses were restricted to 31/44 pa-
tients, or not reported in a manner that al-
lowed them to be included in any meta-
analysis
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Selective reporting (reporting bias) Unclear risk The adverse event reporting is restricted to
4 adverse events in a manner that allows
them to be included in any meta-analysis
Other bias Low risk The authors reported that analysis of
treatment sequence revealed no significant
carry-over effects
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 31/44 patients
Heiskanen 1997
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Finland
Participants Patients: 45 patients enrolled, and 27/45 patients were evaluated for efficacy and safety.
Reasons for withdrawal included adverse events (all were nausea/vomiting; N = 7),
unstable pain control at the end of titration (N = 5), non-compliance (N = 3), sudden
deterioration unrelated to the study (N = 1), and a technical error (N = 1); 1 patient was
withdrawn due to suspected incomplete absorption of controlled-release oxycodone
16 men/11 women, mean age (range) = 60 (39-76) years. Primary tumour: Breast (N =
2), rectum (N = 5), lung (N = 4), prostate (N = 6), kidney (N = 1), pancreas (N = 4)
, unknown primary (N = 2), other (N = 3). Former analgesics: Morphine alone or in
combination with other analgesic (N = 20), oxycodone alone or in combination with
other analgesic (N = 5). 12 patients were randomised to titration with CR oxycodone
and 15 patients with CR morphine
Inclusion criteria: Patients with chronic cancer pain requiring opioid analgesics, who
were co-operative, and able to take oral medication and keep a simple diary
Exclusion criteria: Patients receiving radiation therapy or other cancer treatment that
could affect their pain
Interventions Oxycodone arm
- Drug: Oxycodone + morphine-matched placebo
- Dose and dosing: Mean daily initial dose = 123 mg at the end of titration
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 3 to 6 days, unclear how many doses per day
- Titration schedule: In opioid-naive patients the open-label titration phase (of 21-day
maximum duration) was started with a total daily dose of 40 mg oxycodone. Dose titra-
tion was continued until effective pain relief with acceptable adverse effects was achieved
for ≥ 48 hours. The controlled-release dose was titrated upwards if pain continued at
the moderate to severe level or if > 2 dose of escape analgesic were used in a 24-hour pe-
riod. The controlled-release dose was titrated downwards in case of unacceptable opioid
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adverse effects which were not manageable with appropriate treatment
- Rescue medication: Oxycodone hydrocloride solution in a dose of approximately 1/6
to 1/8 of the daily dose of controlled-release oxycodone; mean total amount per patient
during the last 3 days of the titration phase = 79 mg. Mean daily number of doses (SE)
during double-blind phase = 1.26 ± 0.22 mg
- Other medication: Non-steroidal anti-inflammatory analgesics, if used by the patient
before the study, were continued at the same dose
Comparison arm
- Drug: Morphine + oxycodone-matched placebo
- Dose and dosing: Mean daily initial dose = 180 mg at the end of titration
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 3 to 6 days, unclear how many doses per day
- Titration schedule: In opioid-naive patients the open-label titration phase (of 21-day
maximum duration) was started with a total daily dose of 40 mg oxycodone. Dose titra-
tion was continued until effective pain relief with acceptable adverse effects was achieved
for ≥ 48 hours. The controlled-release dose was titrated upwards if pain continued at
the moderate to severe level or if > 2 dose of escape analgesic were used in a 24-hour pe-
riod. The controlled-release dose was titrated downwards in case of unacceptable opioid
adverse effects which were not manageable with appropriate treatment
- Rescue medication: Morphine hydrochloride solution in a dose of approximately 1/6
to 1/8 of the daily dose of controlled-release morphine; mean total amount per patient
during the last 3 days of the titration phase = 74 mg. Mean daily number of doses (SE)
during double-blind phase = 0.79 ± 0.18 mg
- Other medication: Non-steroidal anti-inflammatory analgesics, if used by the patient
before the study, were continued at the same dose
- For cross-over trials, cross-over schedule: After 3 to 6 days of dosing, the patient visited
the Pain Relief Unit for an end of phase visit. A similar 3 to 6 day period was then
completed in a cross-over fashion using the other opioid
Outcomes - Pain intensity: Assessed by patients 4 times daily (morning, noon, evening, and bedtime)
on a 4-point verbal rating scale (none, slight, moderate, severe)
- Acceptability of therapy: Assessed by patients twice daily, considering pain intensity
and adverse effects during the previous 12-hour period on a 5-point verbal rating scale
(very poor, poor, fair, good, excellent)
- Adverse experiences: Recorded by patient in diary along with each dose of scheduled
and escape study medication, concomitant medications, and intercurrent illnesses
- At each double-blind phase ends, a Modified Specific Drug Effect Questionnaire was
completed by the patients and a trained research nurse or investigator
Notes - Study free of commercial funding? No, the study was funded by Purdue Frederick,
which is the manufacturer of the controlled-release oxycodone study drug used in the
study, and the Academy of Finland
- Groups comparable at baseline? No information provided about initial group allocation
- ITT analyses undertaken? No, the analyses were restricted to 27/45 patients
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Computer generated randomisation for
the open-label titration phase and again for
the double-blind phase was performed by
the Purdue FrederickCompany and a list of
randomisation codes was kept by the hos-
pital pharmacist.”
Allocation concealment (selection bias) Low risk See cell above. No further details reported.
Probably adequate
Blinding of participants and personnel
(performance bias)
Pain
Low risk A double-blind placebo controlled design
was used. It is unclear whowas blinded, but
it appears that at least the patients were
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient-reported. See also cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk The analyses were restricted to 27/45 pa-
tients
Incomplete outcome data (attrition bias)
Adverse events
High risk The analyses were restricted to 27/45 pa-
tients
Selective reporting (reporting bias) Low risk All expected main outcomes appear to be
reported
Other bias Low risk It is unclear whether there were any carry-
over effects, but there probably were none
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 27/45 patients
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Methods Design: Randomised, double-blind, parallel-group multicentre non-inferiority trial
Year: 25 August 2010 to 16 August 2012
Country: Japan, Korea
Participants Patients: 343 patients enrolled, and 340/343 patients received ≥ 1 dose of study drug
(N = 172 oxycodone, and N = 168 tapentadol); 236/343 patients completed treatment
(N = 123 oxycodone, and N = 113 tapentadol), and 231/343 patients completed the
study (N = 121 oxycodone, and N = 110 tapentadol). Reasons for withdrawal included
adverse events (N = 14 oxycodone, and N = 12 tapentadol), progressive disease (N = 15
oxycodone, and N = 11 tapentadol), withdrawal of consent (N = 8 oxycodone, and N
= 8 tapentadol), physician decision (N = 1 oxycodone, and N = 8 tapentadol), protocol
violation (N = 5 oxycodone, and N = 5 tapentadol), lack of efficacy (N = 1 oxycodone,
and N = 4 tapentadol), non-compliance (N = 4 oxycodone, and N = 1 tapentadol),
death (N = 1 oxycodone, and N = 0 tapentadol), other (N = 0 oxycodone, and N = 6
tapentadol)
Oxycodone: N = 172, 100 men and 72 women, mean age (SD) = 64.9 (11.41) years,
110 Japanese and 62 Korean. Primary tumour: gastrointestinal: N = 65; respiratory
or mediastinal: N = 46; > 92% patients had metastatic cancer. Former analgesics: not
reported
Tapendatol: N = 168, 90 men and 78 women, mean age (SD) = 65.5 (11.21) years,
111 Japanese and 57 Korean. Primary tumour: gastrointestinal: N = 70; respiratory
or mediastinal: N = 53; > 92% patients had metastatic cancer. Former analgesics: not
reported
Inclusion criteria: Patients aged ≥ 20 years with a diagnosis of any type of cancer,
experiencing chronicmalignant tumour-related pain, with an average pain intensity score
over the past 24 hours ≥ 4 on an 11-point numerical rating scale (NRS) (0 = ‘no pain’
to 10 = ‘pain as bad as you can imagine’) on the day of randomisation, who “had not
taken opioid analgesics (except for codeine phosphate (≤ 60mg/day), or dihydrocodeine
phosphate (≤ 30 mg/day) as antitussives) within 28 days before screening. Patients must
have been dissatisfied with the pain relief achieved on their current analgesic treatment
for cancer pain and must have had pain requiring treatment with an opioid analgesic
(based on the investigator’s assessment).”
Exclusion criteria: “an uncontrolled or clinically significant arrhythmia; a history of or
current disease that could result in increased intracranial pressure, disturbance of con-
sciousness, lethargy, or respiratory problems; any disease for which opioids are con-
traindicated; a history of surgery intended for the cure of the primary disease or for the
treatment of cancer pain within 28 days before screening or during the study; radiation
therapy within 7 days before screening; or a psychiatric disorder or concurrent symptoms
with accompanying pain that could interfere with efficacy and safety evaluations. Patients
were also excluded if they had any of the following laboratory values at screening: white
blood cell count ≤ 3000/mL, platelet count ≤ 10 x 104/uL, haemoglobin ≤ 9.5 g/dL,
corrected total serum calcium level > 12.5 mg/dL, alanine aminotransferase or aspartate
aminotransferase ≥ 3 times the upper limit of normal, total bilirubin ≥ 1.5 times the
upper limit of normal, or creatinine ≥ 2 mg/dL. The following medications were pro-
hibited: opioid analgesics (including codeine phosphate and dihydrocodeine phosphate
as antitussives), except morphine IR 5 mg as rescue medication); opioid antagonists
(e.g., naloxone, levallorphan), except for the treatment of respiratory depression; anti-
parkinsonian drugs; neuroleptics (including antipsychotics, except for prochlorperazine)
; monoamine oxidase inhibitors; serotonin norepinephrine reuptake inhibitors; nora-
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drenergic and specific serotonergic antidepressants; radiotherapy; nerve block; stimula-
tion analgesia; other investigational drugs. The following drugs were prohibited on an as-
needed basis as newly started treatment (but could be continued at the same and regimen
if started before study entry): Selective serotonin reuptake inhibitors; tricyclic or tetra-
cyclic antidepressants; anti-anxiety agents (e.g., benzodiazepines); hypnotics (e.g., benzo-
diazepines, non-benzodiazepine hypnotics, barbiturates); anticonvulsants; central mus-
cle relaxants; bisphosphonates; corticosteroids; anti-arrhythmics; non-opioid analgesics
(nonsteroidal anti-inflammatory drugs (e.g., cyclo-oxygenase II inhibitors)); pyrazolone
antipyretic agents (e.g., sulpyrine) and analine antipyretic agents (e.g., acetaminophen)
; neurotropin; pregabalin. The following were permitted as needed during the study:
topical corticosteroids; lidocaine (as a local anesthetic); acetaminophen (≤ 1.5 g/day
(Japan) or≤ 4 g/day (Korea) for fever reduction); supportive therapy for chemotherapy;
stable doses of very short-acting, non-benzodiazepine hypnotic drugs (for insomnia);
medications for nausea, vomiting, and constipation; and rescue medication (as described
below). Chemotherapy could be continued at the same dose or chemotherapy doses
could be reduced, discontinued, or restarted (if deemed necessary by the investigator);
however, if a patient’s chemotherapy was considered by the investigator to be interfering
with efficacy or safety evaluations of the study drug, that patient was excluded from the
study.”
Interventions Oxycodone arm
- Drug: Oxycodone HCI
- Dose/dosing: 5 to 40 mg bid. The median of the mean total daily dose = 13.8 mg. The
median modal (or most frequently used) total daily dose = 10 mg
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: “4 week double-blind treatment period (including titration and
maintenance periods), and a 1 week post-treatment period.” Median duration of treat-
ment = 28 days
- Titration schedule: “Study treatment was initiated with twice daily doses of oxycodone
HCl CR 5 mg. During the titration period, doses of study treatment could be increased
if necessary to achieve adequate pain control to a maximum of oxycodone HCl CR 40
mg bid after a patient had received the same dose at least four consecutive times. Dose
escalations could begin on Day 3 of the titration period. Although not required for dose
escalation, the following criteria were evaluated in patients who needed a dose escalation
(based on the investigators assessment): 24 hour pain intensity score (11-point NRS) of
at least 4 on the previous evaluation and rescue medication used for breakthrough pain at
least three times per day. Doses could be decreased during the study as needed for safety
reasons to the minimum doses of oxycodone HCl CR (5 mg bid). Study drug doses were
titrated to each patient’s optimal dose, balancing efficacy and tolerability, until sufficient
analgesia was attained. Patients with a pain intensity score of no more than 3 who did
not take rescue medication more than twice a day while taking stable doses of study drug
(six consecutive identical doses) over a consecutive 3 day period were considered eligible
to formally enter the maintenance period; patients who did not meet these criteria were
permitted to continue in the double-blind treatment period while continuing to titrate
their dose. During the maintenance period, patients continued taking the optimal dose
of study drug determined during the titration period. Dose adjustments were permitted
during the maintenance period except during the last 3 days. Dose levels during the last
3 days of the maintenance period were to be kept stable.”
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- Rescue medication: “Oral morphine IR 5 mg was permitted throughout the study
(except during the screening period) as rescue medication for breakthrough pain, with
no limit on the number and timing of doses per day.” The mean (SD) of the average
number of morphine IR doses taken per day = 1.4 (0.43); mean (SD) of the average total
daily dose = 6.7 (2.15) mg morphine IR
- Other medication: See the inclusion and exclusion criteria in cell above
Comparison arm
- Drug: Tapentadol
- Dose and dosing: 25 to 200 mg bid. The median of the mean total daily dose = 64.5
mg. The median modal (or most frequently used) total daily dose = 50 mg
- Formulation: Extended-release
- Route of administration: Oral
- Length of treatment: “4 week double-blind treatment period (including titration and
maintenance periods), and a 1 week post-treatment period.” Median duration of treat-
ment = 28 days
- Titration schedule: “Study treatment was initiated with twice daily doses of tapentadol
ER 25 mg. During the titration period, doses of study treatment could be increased if
necessary to achieve adequate pain control to a maximum of tapentadol ER 200 mg bid
after a patient had received the same dose at least four consecutive times. Dose escalations
could begin on Day 3 of the titration period. Although not required for dose escalation,
the following criteria were evaluated in patients who needed a dose escalation (based on
the investigators assessment): 24 hour pain intensity score (11 point NRS) of at least 4 on
the previous evaluation and rescue medication used for breakthrough pain at least three
times per day. Doses could be decreased during the study as needed for safety reasons
to the minimum doses of tapentadol ER (25 mg bid). Study drug doses were titrated to
each patient’s optimal dose, balancing efficacy and tolerability, until sufficient analgesia
was attained. Patients with a pain intensity score of no more than 3 who did not take
rescue medication more than twice a day while taking stable doses of study drug (six
consecutive identical doses) over a consecutive 3 day period were considered eligible to
formally enter the maintenance period; patients who did not meet these criteria were
permitted to continue in the double-blind treatment period while continuing to titrate
their dose. During the maintenance period, patients continued taking the optimal dose
of study drug determined during the titration period. Dose adjustments were permitted
during the maintenance period except during the last 3 days. Dose levels during the last
3 days of the maintenance period were to be kept stable.”
- Rescue medication: “Oral morphine IR 5 mg was permitted throughout the study
(except during the screening period) as rescue medication for breakthrough pain, with
no limit on the number and timing of doses per day.” The mean (SD) of the average
number of morphine IR doses taken per day = 1.4 (0.46); mean (SD) of the average total
daily dose = 7 (2.3) mg morphine IR
- Other medication: See the inclusion and exclusion criteria in cell above
Outcomes - Pain intensity: Assessed by patients once daily (evening on an 11-point numerical rating
scale from0 (no pain) to 10 (= pain as bad as you can imagine). Primary efficacy endpoint
was the mean change in average pain intensity from baseline to the last 3 days of study
- Patient global impression of change: Questionnaire completed at weeks 1, 2, 3 of
double-blind treatment and at the end of study or early withdrawal. Patients rated their
overall condition on a scale from 1 (= very much improved) to 7 (= very much worse) by
completing the following statement “Since the start of this treatment, my cancer-related
pain overall is...”
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- Adverse events: Monitored and coded using the Medical Dictionary for Regulatory
Activities. EAch instance of disease progression was considered an adverse event and
included in the analysis of treatment-emergent adverse events
Notes - Study free of commercial funding? No, the study was funded by Janssen Research and
Development
- Groups comparable at baseline? The groups appear to be comparable at baseline
- ITT analyses undertaken? No, the analyses were per protocol (= “a subset of the full
analysis population that excluded any patient with a major protocol deviation from a
predefined list of deviations”)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patient assignments to study treatment
were based on a computer-generated ran-
domization schedule prepared by the spon-
sor prior to the study; randomization was
balanced using randomly permuted blocks
and stratified by study site. An Interac-
tive Voice Response System (IVRS) as-
signed each patient a unique treatment
code,which determined that patient’s treat-
ment assignment.”
Allocation concealment (selection bias) Low risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The blindwas not broken until all patients
completed the study and the database was
finalized, except in case of emergency.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk Per protocol analyses including 139/172
oxycodone patients and 126/168 tapenta-
dol patients
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Incomplete outcome data (attrition bias)
Adverse events
Low risk The safety population included all random-
ized patients who received at least one dose
of study drug, that is 340/343 randomised
patients (172 oxycodone patients and 168
tapentadol patients)
Selective reporting (reporting bias) Low risk All main expected outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Kalso 1990
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Finland
Participants Patients: 20 patients entered, 19 patients analysed (1 patient excluded as her morphine
dose had to be considerably reduced due to side effects); 11 females, 9 males; median age
(range): 56 (20-75) years; cancer type: pancreatic (3), breast (5), prostate (1), gastric (1),
rectal (2), other (8): cancer stage: metastatic; type of pain: visceral (6), nerve (7), bone (5)
, bone-fracture (1), bone-nerve (1), soft tissue (1); setting: Not reported, tertiary?; previ-
ous analgesic medication: Buprenorphine (7), oxycodone (1), dextropropoxyphene (1)
, aspirin + codeine (1), ibuprophene + buprenorphene (2), indomethacine + buprenor-
phene (1), dextropropoxyphene + buprenorphene (1), diclophenac + buprenorphine (1)
, indomethacine + codeine (2), naproxyn + dextropropoxyphene (1), noramidopyrin +
pitofenon (1), ketoprofen + dextropropoxyphene (1)
Inclusion criteria: “Twenty patients, 11 women and nine men, who had metastasised
cancer and severe pain and who required a change from weaker narcotic analgesic agents
(codeine, dextropropoxyphene, buprenorphine) to morphine, participated in the study.
”
Exclusion criteria: None reported
Interventions Oxycodone arm
- Drug: Oxycodone hydrocloride
- Dose and dosing: Previous opioid treatment was discontinued 12 to 24 hours before
commencing the study, and during this time 1 mg/kg meperidine was given intramuscu-
larly when requested. The patients titrated themselves free from pain in 48 hours using
a patient-controlled analgesia (PCA) device. The concentration of both morphine hy-
drochloride and oxycodone hydrocloride was 10 mg/ml.This treatment was continued
for another 48 hours with the use of the same drug, which was now taken orally. The
oral dose was calculated from the IV consumption during the previous 24 hours. The
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daily oral dose was calculated in ml by assuming that the bioavailability of morphine was
either 44% (first 10 patients, group 1) or 33% (last 10 patients, group 2) and that the
bioavailability of oxycodone hydrocloride was 66% (group 1) and 50% (group 2). To
overcome the differences in bioavailabilities of the two drugs, the concentrations of the
oral solutions were 2.7 mg/ml for oxycodone hydrocloride and 4 mg/ml for morphine.
The dosing interval was 4 hours and the dose was increased by 1ml at a time if the patient
was not pain free during the 4-hour period. If the patient was pain-free, but too sedated,
the dose was decreased by 1 ml. PCA device: The bolus dose was 3 mg, which was given
over a period of 60 seconds, followed by a tail dose of 2 mg over 1 hour. The lockout
time, during which the patient was unable to initiate another dose, was 15 minutes. If
the patient was not free from pain with this regimen, the tail dose was increased by 2 mg
at a time
- Formulation: Immediate-release (oral)
- Route of administration: IV (2 days) then oral (2 days)
- Length of treatment: 4 days
- Titration schedule: See ’Dose and dosing’ section above
- Rescue medication: See ’Dose and dosing’ above. No further information was reported
- Other medication: Any pre-existing treatment with non-steroidal anti-inflammatory
drings was continued
Comparison arm: Same as oxycodone arm, just replacing oxycodone with morphine
- For cross-over trials, cross-over schedule: “The same protocol was then repeated with
the other drug for another 96 hours”
Outcomes - Pain severity: Assessed by patient at study start and every 4 hours from 8 am to 8 pm;
VAS from 0 to 10
- Side effects:Determinedby questioning (have youhadnausea, constipation, drowsiness,
sedation symptoms, hallucinations, or any other symptoms you would connect with the
analgesic?) scored according to grade (moderate = 1, severe = 2); registered on the second
day of each study period
- Sleep quality, registered on the second day of each study period
- Patient preference or acceptability with reason
The last 24 hours of each of the four study stages were considered as the steady state and
the drug consumptions, and the ratings from the VAS during this period were used for
the statistical calculations
Notes - Study free of commercial funding? Yes. Supported by the Paolo (non-profit) Foundation,
Helsinki, Finland
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? No, the data from 1 patient in regard to morphine con-
sumption was excluded as her morphine dose had to be considerably reduced due to side
effects. Her data was included in the patient preference analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised. No further in-
formation provided
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Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Unclear risk The study is described as “double-blind”.
No further information reported, so it is
unclear who was blinded and whether it
was adequately executed
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Unclear risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above
Incomplete outcome data (attrition bias)
Pain
Low risk The data from 1/20 patients were excluded
Incomplete outcome data (attrition bias)
Adverse events
Low risk Think the data from 1/20 patients were ex-
cluded
Selective reporting (reporting bias) Low risk The main expected outcomes are reported
Other bias Low risk The authors report that “The order in
which the drugs were given (either as the
first or the second study drug) had no ef-
fect on the drug consumption.” No other
potential biases were identified
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 19/20 patients
Kaplan 1998
Methods Design: Randomised, double-blind, parallel-group trial
Year: Not reported
Country: USA
Participants Patients: 180 patients enrolled (108 before protocol amendment allowing dose titration
before randomisation and 72 after the amendment; 16 of the 72 patients discontinued
before randomisation due to lack of acceptable pain control (N = 6), intercurrent illness
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(N = 4), adverse event (N = 2), death (N = 1), withdrawal of consent (N = 1), other (N
= 2). 164 patients were randomised (controlled-release oxycodone : N = 81; immediate-
release oxycodone: N = 83); N = 156 were included in efficacy analyses (4 patients did
not receive the study medication, 3 patients did not complete the efficacy ratings and 1
patient may have received unblinded treatment). All 160 patients who received at least
one dose of study medication were included in the safety analyses (of adverse events).
74% of patients were white; mean (SE) age = 59 (1) years; 58% were male; most patients
were receiving oral morphine at study entry; cancer type: gastrointestinal (22%), lung
(21%), prostate (17%), breast (10%), gynaecological (10%): predominant pain sites
were bone and viscera, with an additional 15 patients (9 in controlled-release oxycodone
group and 6 in the immediate-release oxycodone group) reporting neuropathic pain
Inclusion criteria: “Male and female patients with cancer-related pain were enrolled at
17 centers. The study received institutional review board approval at each center and all
patients gave written informed consent. At the time of enrollment, patients were being
treated with a strong single-entity opioid or 10 or more tablets per day of a fixed-dose
opioid/nonopioid analgesic; were receiving a stable opioid dose; and had stable coexistent
disease. Under the original protocol, patients were excluded if they were receiving any
other analgesics (opioid or nonopioid) or if theywere to receive radiotherapy immediately
before enrollment or during the study period. After the study had begun, these exclusion
criteria were eliminated by an amendment to facilitate enrollment into the study, which
had been slow.”
Exclusion criteria: See above
Interventions Oxycodone arm
- Drug: Oxycodone
- Dose/dosing: Oxycodone tablets (10 mg) every 12 hours (8 am and 8 pm) and placebo
tablets every 2 pm and bedtime. Mean daily dose (range) = 114 (20 to 400) mg
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 6 days
- Titration schedule: The original study design did not allow dose titration or use of res-
cue medication for breakthrough/incident pain. Patients whose pain was not effectively
controlled at the initial oxycodone dose calculated from previous opioid use were discon-
tinued from the study. However, an interim analysis conducted to determine whether
dose adjustments were required showed that drop-out rates were too high for relevant
conclusions. This suggested that the initial conversion dose estimate was not adequate
for a subgroup of patients, and the protocol was amended to include open-label titration
with immediate-release oxycodone before the patients were randomised to double-blind
treatment, as well as the use of immediate-release oxycodone 5 mg tablets as rescue medi-
cation throughout the trial. Supplemental doses could be taken no more frequently than
every 4 hours at no more than approximately 1/6 of the daily dose of study medication.
No further information was reported
- Rescue medication: See ’Titration schedule’ above. Mean number of rescue medication
doses per day = 0.6
- Other medication: See ’Inclusion criteria’ above. No further information reported
Comparison arm
- Drug: Oxycodone
- Dose and dosing: Oxycodone tablets (5 mg) every 6 hours (8 pm, bedtime (≥ 3 hours
after 8 pm, but not after 2 am), 8 am and 2 pm). Mean daily dose (range) = 127 (40 to
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- Route of administration: Oral
- Length of treatment: 6 days
- Titration schedule: The original study design did not allow dose titration or use of res-
cue medication for breakthrough/incident pain. Patients whose pain was not effectively
controlled at the initial oxycodone dose calculated from previous opioid use were discon-
tinued from the study. However, an interim analysis conducted to determine whether
dose adjustments were required showed that drop-out rates were too high for relevant
conclusions. This suggested that the initial conversion dose estimate was not adequate
for a subgroup of patients, and the protocol was amended to include open-label titration
with immediate-release oxycodone before the patients were randomised to double-blind
treatment, as well as the use of immediate-release oxycodone 5 mg tablets as rescue medi-
cation throughout the trial. Supplemental doses could be taken no more frequently than
every 4 hours at no more than approximately 1/6 of the daily dose of study medication.
No further information was reported
- Rescue medication: See ’Titration schedule’ above. Mean number of rescue medication
doses per day = 1
- Other medication: See ’Inclusion criteria’ above. No further information reported
Outcomes - Pain intensity: Assessed by patient at study start and 4 times daily at 8 am, 2 pm, 8 pm
and bedtime; categorical verbal scale from 0 (= none, 1 = slight, 2 = moderate) to 3 (=
severe)
- Acceptability of treatment: Assessed by patient at study start and twice daily at 8am
and 8 pm; categorical verbal scale from 1 (= very poor; 2 = poor, 3 = fair, 4 = good) to 5
(= excellent)
- Adverse events: Those spontaneously reported by patients or observed by investigators
were recorded, and their severity and relationship to study drug (none, possible, probable,
definite) were assessed by each investigator
Notes - Study free of commercial funding? No, some or one of the authors (including the
corresponding author) are or is employee(s) of Purdue Pharma Ltd, the manufacturer of
the study drugs
- Groups comparable at baseline? The authors report “There were no significant differ-
ences in the primary pain site, prestudy opioid, or cancer diagnosis between the two
treatment groups”. No other information reported
- ITT analyses undertaken? No, 156 and 160/164 patients, respectively, were included
in the safety and efficacy analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors state that the patientswere ran-
domised, but give no further details
Allocation concealment (selection bias) Unclear risk The authors state that the patientswere ran-
domised, but give no further details
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Blinding of participants and personnel
(performance bias)
Pain
Low risk Double-blind placebo-controlled study. To
maintain the blind, all doses of the study
medication were encapsulated in green size
#00 lactose-filled capsules
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
Low risk A total of 156/164 patients were included
in the efficacy analyses
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 160/164 patients were included
in the safety analyses
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? High risk No before amendment, unclear after
amendment
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Lauretti 2003
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: Brazil
Participants Patients: 22/26 enrolled patients were evaluated (withdrawals due to death (unrelated to
the study, N = 1), uncontrollable nausea/vomiting (N = 1), and unstable pain control
requiring spinal drugs (N = 2)); mean/median (?) (SD/inter-quartile range?) age = 59
(19) years; 15 males/7 females; cancer type: oropharynx (N = 9), lung (N = 3), prostate
gland (N = 2), colon (N = 4), gastric (N = 2), ovary (N = 2); pain types were somatic
and visceral; adjuvant therapy: radiation (N = 1), chemotherapy (N = 6), radiation/
chemotherapy (N = 4), none (N = 11)
Inclusion criteria: “26 patients with chronic cancer pain of the visceral and somatic type.
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.... Before enrolling in this actual study, patients received 3-4mg/kg−1 tramadol, plus
nonsteroidal anti-inflammatory drugs: however they still complained of pain VAS ≥ 4
cm”
Exclusion criteria: None listed
Interventions Oxycodone arm
- Drug: Oxycodone
-Dose/dosing:The optimumdosagewas calculated on a daily basis, and the consumption
ratio of oxycodone to morphine was set at 1:1.8
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 14 days
- Titration schedule: The study started with an open-label, randomised titration phase
to achieve stable pain control for 7 days. Patients only used immediate-release morphine
and had free access to it to keep pain VAS < 4
- Rescue medication: At any point, patients were allowed to use immediate-release mor-
phine (10 mg tablets) as needed to keep pain VAS ≤ 4




-Dose/dosing:The optimumdosagewas calculated on a daily basis, and the consumption
ratio of oxycodone to morphine was set at 1:1.8
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 14 days
- Titration schedule: The study started with an open-label, randomised titration phase
to achieve stable pain control for 7 days. Patients only used immediate-release morphine
and had free access to it to keep pain VAS < 4
- Rescue medication: At any point, patients were allowed to use immediate-release mor-
phine (10 mg tablets) as needed to keep pain VAS ≤ 4
-Othermedication: As part of the protocol, all patients were taking oral 25mg amitripty-
line at bedtime
- For cross-over trials, cross-over schedule: “After stable pain relief was achieved [during
titration phase], this was followed by a double-blind, cross-over phase in two periods,
14 days each...... and no period of washout was was allowed for ethical reasons”
Outcomes - Pain intensity: Assessed by patients; 10 cm VAS from 0 (= no pain at all) to 10 (= worst
possible pain)
- Patient satisfaction: Assessed by patient
- Adverse events: Assessed by patient (possibly using a 10 cmVAS similar to pain intensity,
but data not reported that way)
- Number of rescue morphine tablets: Assessed by patient
It also appears that an investigator recorded these data on a weekly basis
Notes - Study free of commercial funding? No information reported
- Groups comparable at baseline? Unclear, no information reported
- ITT analyses undertaken? No, 22/26 patients were included in the analyses
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
Low risk The patients were blinded, but it is unclear
whether the investigator administering the
drugs was
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk The patients were blinded, but it is unclear
whether the investigator administering the
drugs was
Blinding of outcome assessment (detection
bias)
Pain
Low risk The patients and outcome assessor were
blinded
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk The patients and outcome assessor were
blinded
Incomplete outcome data (attrition bias)
Pain
Unclear risk Data from 22/26 patients included
Incomplete outcome data (attrition bias)
Adverse events
Unclear risk Data from 22/26 patients included
Selective reporting (reporting bias) High risk All obvious outcomes are reported, al-
though not in the most useful manner (e.
g., no collapsing across study phase weeks,
that is, mean final weekly dose of CR oxy-
codone and morphine are reported for 4
weeks, not 2 weeks)
Other bias Low risk It is unclear whether there were any carry-
over effects, but there probably were none
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available from both time peri-
ods, although not reported by arm (see two
cells above)
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Leow 1995
Methods Design: Randomised, open-label, single-dose, cross-over trial
Year: Not reported
Country: Australia
Participants Patients: 12 patients entered; 5 females, 7 males; mean age (SD): 68.8 (12.6) years;
cancer type: cervical (2), breast (1), prostate (1), bowel (1), anal (1), endometrial (1),
renal (1), lung/bronchial (2), skeletal or thoracic-vertedral metastases (2); all inpatients;
all receiving oral nutrition; none hypovolemic; all opioid-naive apart from 1 patient who
was receiving paracetamol + dextropropoxyphene. Two patients had compromised renal
function, and 5 patients had impaired liver function to varying degree
Inclusion criteria: Inpatients with moderate to severe cancer pain
Exclusion criteria: Known hypersensitivity to oxycodone or other opioid analgesics and/
or a history of drug dependence
Interventions Oxycodone arm
- Drug: Oxycodone hydrocloride
- Dose and dosing: Single dose of IV oxycodone hydrochloride in a concentration of 5
mg/ml, equivalent to 4.5 mg/ml oxycodone base. The mean (SD) IV oxycodone dose
administered was 0.11 (0.02) mg/kg (range 5.4 to 9 mg), which a previous study by the
authors had shown to produce satisfactory analgesia in patients with moderate to severe
cancer. Patients with impaired liver function received the lower doses of IV oxycodone.
The IV oxycodone dose was administered into a forearm vein. The rate of injection (0.
5 to 5 min) was titrated by the anaesthetist
- Formulation: IV
- Route of administration: IV
- Length of treatment: 24 hours, 1 dose
- Titration schedule: See ’Dose and dosing’ section above
- Rescue medication: Oral paracetamol (up to 1 g every 4 hours) or Di-Gesic (up to
2 tablets every 4 hours) were available as rescue medication on patient request. Nine
patients asked for supplementary analgesics after 4 hours post-dosing




- Dose and dosing: Single dose of 30 mg oxycodone base in a rectal suppository
- Formulation: Suppository
- Route of administration: Rectal
- Length of treatment: 24 hours, 1 dose
- Titration schedule: See ’Dose and dosing’ section above
- Rescue medication: Oral paracetamol (up to 1 g every 4 hours) or digesic (up to 2 tablets
every 4 hours) were available as rescuemedication on patient request. Nine patients asked
for supplementary analgesics after 6 to 8 hours post-dosing
- Other medication: “Medications that had been taken routinely by patients before the
study, were permitted.”
- For cross-over trials, cross-over schedule: “Patients were randomly assigned to begin
treatment with either a single dose of.... The second treatment was administered 24 h
after the first dose.”
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Outcomes - Pain intensity: Assessed by patient at study start at 0.5, 1, 2, 4, 8, 12 and 24 hours
post-dosing; 10 cm VAS with delimiters ’no pain’ and ’worst pain imaginable’
- Side effects: Assessed by questioning the patient at study start at 0.5, 1, 2, 4, 8, 12 and
24 hours post-dosing; Patients were asked to report any side effects, but were specifically
asked whether they experienced nausea, vomiting, pruritus, lightheadedness, or drowsi-
ness, using a 4-point verbal rating scale going from 0 to 3 (none = 0, mild = 1, moderate
= 3, severe = 3)
Notes - Study free of commercial funding? No. Supported by the Boots Company (Australia;
manufacturer of the rectal suppository study drug), Pty Ltd, theUniversity ofQueensland
Cancer Research Fund, and the Queensland Cancer Fund
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? It appears so. It is not possible to confirm it based on the
presented date, but no information to the contrary is reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to begin
treatment with...” No further information
reported
Allocation concealment (selection bias) Unclear risk “Patients were randomly assigned to begin
treatment with...” No further information
reported
Blinding of participants and personnel
(performance bias)
Pain
High risk The study was open-label
Blinding of participants and personnel
(performance bias)
Adverse events
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Pain
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Adverse events
High risk The study was open-label
Incomplete outcome data (attrition bias)
Pain
Low risk All data appear to be included. It is not pos-
sible to confirm it based on the presented
data, but no information to the contrary is
reported
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Incomplete outcome data (attrition bias)
Adverse events
Low risk All data appear to be included. It is not pos-
sible to confirm it based on the presented
data, but no information to the contrary is
reported
Selective reporting (reporting bias) Low risk All expected outcomes seem to be reported
Other bias Low risk “An absence of carryover effects (P > 0.05)
betweenTreatments 1 and 2was confirmed
using the Grizzle analysis for cross-over de-
signs”
Were the patients adequately titrated? Unclear risk Not enough information reported
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available from both time peri-
ods
Mercadante 2010
Methods Design: Randomised, parallel group trial
Year: Not reported
Country: Italy
Participants Patients: 60 patients randomised; 46/60 patients completed baseline evaluation (21
patients in group oxycodone and 25 patients in group morphine, 14/60 patients did not
complete baseline evaluation as they were lost to follow up); 27 females, 19 males; mean
age (SD): 63.2 (9.48) years. 19 oxycodone and 20 morphine patients completed 4 weeks
of study participation and 7 and 10 patients, respectively, completed 8 weeks of study
participation
Inclusion criteria: Patients with pancreatic cancer with local disease, presenting abdom-
inal pain with an intensity ≥ 4/10 numerical rating scale from 0 to 10, and no longer
responsive no nonopioid analgesics
Exclusion criteria: Distant and bone metastases, or prevalent somatic pain due to evident
peritoneal involvement, changes in chemotherapy regimen, hepatic or renal failure, cog-




- Dose and dosing: Starting dose of 20 mg/day, according to an approximate morphine:
oxycodone ratio of 1.5:1. For patients requiring an increase in the dose for increasing
pain (> 4/10 or > 3 breakthrough pain medications per day) during the study period,
opioid doses were increased according to the clinical needs. Mean dose (SD) at week 1:
23.8 (8) mg/day; mean dose (SD) at week 2: 25.5 (8) mg/day; mean dose (SD) at week
3: 27.9 (9) mg/day; Mean dose (SD) at week 4: 33.1 (14) mg/day; mean dose (SD) at
week 8: 45.7 (24) mg/day
- Formulation: Sustained-release
- Route of administration: Oral
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- Length of treatment: 4 weeks (with a study extension up to 8 weeks)
- Titration schedule: “Patients were recruited and followed during admission to the
palliative care unit, as outpatients and at home. Physicians provided frequent call contacts
to adjust the opioid dose at any time”. See also ’Dose and dosing’ section above. No
further information provided
- Rescue medication: Oral morphine in doses of 1/6 of the daily dose was provided
(starting at 5 mg initially)




- Dose and dosing: Starting dose of 30 mg/day, according to an approximate morphine:
oxycodone ratio of 1.5:1. For patients requiring an increase in the dose for increasing
pain (> 4/10 or > 3 breakthrough pain medications per day) during the study period,
opioid doses were increased according to the clinical needs. Mean dose (SD) at week 1:
35 (9) mg/day; mean dose (SD) at week 2: 36.2 (14) mg/day; mean dose (SD) at week
3: 41 (19) mg/day; mean dose (SD) at week 4: 42.6 (21) mg/day; mean dose (SD) at
week 8: 60 (46) mg/day
- Formulation: Sustained-release
- Route of administration: Oral
- Length of treatment: 4 week (with a study extension up to 8 weeks)
- Titration schedule: “Patients were recruited and followed during admission to the
palliative care unit, as outpatients and at home. Physicians provided frequent call contacts
to adjust the opioid dose at any time”. See also ’Dose and dosing’ section above. No
further information provided
- Rescue medication: Oral morphine in doses of 1/6 of the daily dose was provided
(starting at 5 mg initially)
- Other medication: “Adjuvants and symptomatic drugs were prescribed as indicated by
the clinical situation.”
Outcomes - Pain intensity (average in the last 24 hours): Assessed by patient, using a numerical
rating scale from 0 to 10
- Opioid-related symptoms (including nausea and vomiting, drowsiness and confusion)
: Assessed by patient, using a categorical scale from 0 (= absent, 1 = slight, 2 = moderate)
to 3 (= severe)
- Constipation: Assessed by patient, using a categorical scale from 0 (= 1 passage, 1 to 2
days; 1 = 1 passage, 3 to 4 days; 2 = 1 passage, 4 days) to 3 (= only by enema)
Notes - Study free of commercial funding? Unclear. No details reported
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? No, it does not appear so. From baseline to study end at 4
weeks 11/30 oxycodone patients and 10/30 morphine patients dropped out of the study
and only the data from patients who completed the study phases are reported/analysed
by week (0, 1, 2, 3, 4, and 8)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “Patients were randomized by a computer
system in 2 groups.” No further informa-
tion reported
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
High risk Unblinded study
Blinding of participants and personnel
(performance bias)
Adverse events
High risk Unblinded study
Blinding of outcome assessment (detection
bias)
Pain
High risk Unblinded study
Blinding of outcome assessment (detection
bias)
Adverse events
High risk Unblinded study
Incomplete outcome data (attrition bias)
Pain
High risk From baseline to study end at 4 weeks
11/30 oxycodone patients and 10/30 mor-
phine patients dropped out of the study and
only the data from patients who completed
the study phases are reported/analysed by
week (0, 1, 2, 3, 4, and 8)
Incomplete outcome data (attrition bias)
Adverse events
High risk From baseline to study end at 4 weeks
11/30 oxycodone patients and 10/30 mor-
phine patients dropped out of the study and
only the data from patients who completed
the study phases are reported/analysed by
week (0, 1, 2, 3, 4, and 8)
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? Unclear risk Not enough information reported
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
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Methods Design: Randomised, parallel group trial
Year: Not reported
Country: USA
Participants Patients: 101 patients randomised; 100/101 patients received≥ one dose of study med-
ication; N = 48 in oxycodone group and 52 in the morphine group, 55% patients were
male, mean (range) age = 59 (30 to 83) years; bone and viscera were most common
pain sites; nerve pain was the primary pain type in 10/48 oxycodone and 9/52 mor-
phine patients; most common pre-study pain medication was fixed-dose oxycodone-
acetaminophen combination (22 patients in each group), followed by single-entity mor-
phine (13 oxycodone and 17 morphine patients). Most patients were receiving > 1 pain
medication pre-study and all but 3 patients (all in the oxycodone group) were receiv-
ing opioids prior to enrolment, the mean (range) oral oxycodone equivalent of the pre-
study dose = 64 (14 to 280) mg in the oxycodone group and 70 (14-235) mg in the
morphine group. 7 oxycodone and 9 morphine patients discontinued the study before
achieving stable pain control due to adverse experiences (2 oxycodone and 6 morphine
patients), intercurrent illness (3 oxycodone patients), ineffective treatment (1 oxycodone
and 1 morphine patients), patient request (1 oxycodone and 1 morphine patients), and
protocol violation (1 morphine patient). An additional 4 patients dropped out of the
study after achieving stable pain control due to adverse experience (1 oxycodone patient)
, protocol violation (1 oxycodone patient), intercurrent illness (1 morphine patient) and
worsening of pre-existing condition (1 morphine patient)
Inclusion criteria: Patients who required around-the-clock treatment with opioid anal-
gesics for chronic cancer-related pain with the equivalent of 30 to 340 mg of oral oxy-
codone daily. Patients whose pain was not controlled by maximum recommended doses
of nonopioid analgesics were also eligible if they would require ≥ 30 mg
Exclusion criteria: “a history of sensitivity to oxycodone or morphine, any contra-indi-
cation for opioid therapy (such as paralytic ileus or severe pulmonary disease) or severely
compromised organ function that could obscure efficacy or or adversely affect safety. Pa-
tients whose pain control was so fragile they could not switch opioids were also excluded.
”
Interventions Oxycodone arm
- Drug: Oxycodone hydrochloride
- Dose and dosing: Multiples of 20 mg tablets, every 12 hours (8 am and 8 pm). Starting
dose was calculated from the patients’ pre-study daily opioid dose and could be adjusted
based on the investigator’s judgement. The dose was titrated until stable pain control was
achieved. Pain control was considered stable when, over a 48-hour period, the every 12
h dose was unchanged, ≤ 2 supplemental analgesic doses were taken per day, the dosing
regimen for any non-opioids or adjuvants was unchanged, and the patient reported that
pain control was acceptable and any side effects were tolerable. Patients who could not
be stabilised within 10 days were discontinued. Mean final daily doses of every 12 h
(range): 101 (40 to 360) mg
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: Up to 12 days
- Titration schedule: See ’Dose and dosing’ section above
- Rescue medication: Immediate-release oxycodone in multiples of two 5 mg tablets.
Each supplemental medication dose was 1/4 to 1/3 of every 12 h scheduled dose. Patients
were instructed to take a supplemental dose as needed for breakthrough pain, but not
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more frequently than once every 2 to 4 hours or 1 hour before activity associated with
incident pain. Median dose use on the next to last study day (during stable pain control)
= 1 (range 0 to 4) and median dose use on last study day (during stable pain control) =
1 (range 0 to 3)
- Other medication: “Non-opioid analgesics and adjuvant medications were allowed
during the study provided they had been given on a regular basis (not as needed) before
the study.”
Comparison arm
- Drug: Morphine sulfate
- Dose and dosing: Multiples of 30 mg tablets, every 12 hours (8 am and 8 pm). Starting
dose was calculated from the patients’ pre-study daily opioid dose and could be adjusted
based on the investigator’s judgement. The dose was titrated until stable pain control
was achieved. Pain control was considered stable when, over a 48-hour period, the q12h
dose was unchanged, ≤ 2 supplemental analgesic doses were taken per day, the dosing
regimen for any non-opioids or adjuvants was unchanged, and the patient reported that
pain control was acceptable and any side effects were tolerable. Patients who could not
be stabilised within 10 days were discontinued. Mean final daily doses every 12 h (range)
: 140 (60 to 300) mg
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: Up to 12 days
- Titration schedule: See ’Dose and dosing’ section above
- Rescue medication: Immediate-release morphine in multiples of 15 mg tablets. Each
supplemental medication dose was 1/4 to 1/3 of every 12 h scheduled dose. Patients
were instructed to take a supplemental dose as needed for breakthrough pain, but not
more frequently than once every 2 to 4 hours or 1 hour before activity associated with
incident pain. Median dose use on the next to last study day (during stable pain control)
= 1 (range 0 to 3) and median dose use on last study day (during stable pain control) =
1 (range 0 to 3)
- Other medication: “Non-opioid analgesics and adjuvant medications were allowed
during the study provided they had been given on a regular basis (not as needed) before
the study.”
Outcomes - Pain intensity (average since previous evaluation): Assessed by patient at baseline and
before every q12h dose, using a categorical scale from0 (= none) (1 = slight, 2 =moderate)
to 3 (= severe). Also assessed after≥ 48 hours of stable pain control using the categorical
scale and a 100 mm VAS scale from 0 (= no pain) to 100 (worst possible pain)
- Adverse experiences and drug effects: Assessed by patient in a daily diary, and after ≥
48 hours of stable pain control by using the Specific Drug Effect Questionnaire 100 mm
VAS scale (?) from 0 (= not at all) to 100 (an awful lot); also assessed by observers after
≥ 48 hours of stable pain control by using the Specific Drug Effect Questionnaire 100
mm VAS scale (?) from 0 (= not at all) to 100 (extremely)
- Drowsiness and nausea: Assessed by patient after ≥ 48 hours of stable pain control (?)
, using a categorical scale from 0 (= none, 1 = slight, 2 = moderate) to 3 (= severe) and a
100-mm VAS scale from 0 (= none) to 100 (worst possible)
- Acceptability of therapy: Assessed by patient at baseline and study end, using a cate-
gorical scale from 1 (= very poor, 2 = poor, 3 = fair, 4 = good) to 5 (= excellent)
- Quality of life: Assessed by patient at baseline and study end, using the Functional
Assessment of Cancer Therapy-General (FACT-G), a 28-item questionnaire consisting
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of 5 subscales measuring different aspects of quality of life: Physical, social/family, rela-
tionship with physician, emotional and functional
Notes - Study free of commercial funding? No. The authors were either “financially compen-
sated for their efforts” or employees of the study drug manufacturer
-Groups comparable at baseline?Unclear. No patient details reported by initial treatment
allocation
- ITT analyses undertaken? No, 100/101 patients were analysed for safety; 79/101 pa-
tients who achieved stable pain control and had simultaneous pharmacokinetic-pharma-
codynamicassessments were analysed for efficacy (39 oxycodone, 40 morphine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block randomization was used to ensure
that all centers had a comparable number
of patients in each treatment group.” No
further information reported
Allocation concealment (selection bias) Unclear risk No further information reported than that
in the cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The double-dummy technique was used
to blind the study medications.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk “The double-dummy technique was used
to blind the study medications.”
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient recorded. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk A total of 79/101 patients
who achieved stable pain control and had
simultaneous pharmacokinetic-pharmaco-
dynamic assessments were analysed for ef-
ficacy
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 100/101 patients were analysed
for safety
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
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Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? Low risk The patients were adequately titrated
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Parris 1998
Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: USA
Participants Patients: 111 patients randomised; 103/111 patients received≥ one dose of study med-
ication; N = 52 in controlled-release group and 51 in the immediate-release group, 50%
patients were female, average (mean?) (range) age = 57 (31 to 80) years; bone (45%)
and viscera (28%) were most common pain sites; most common cancer diagnoses were
breast, gastrointestinal, lung, and gynaecological. 66/111 patients completed the 5-day
study period (33 in each group). Pre-study analgesics: Oxycodone and acetaminophen
(71%), most lower-dose patients received a total daily pre-study oxycodone dosage of
30 to 45 mg with 2.0 to 2.9 g of acetaminophen; higher-dose patients received a daily
oxycodone dosage of 50 to 60mgwith 3.2 to 3.9 g of acetaminophen; other prior opioids
included codeine and acetaminophen (17%), hydrocodone and acetaminophen (10%)
, propoxyphene napsylate and acetaminophen (2%), and transdermal fentanyl (1%)
(protocol violation). A total of 19 controlled-release and 18 immediate-release patients
discontinued the study due to adverse events (4 controlled-release and 7 immediate-
release patients), unrelated illness (1 in each group), ineffective treatment (10 controlled-
release and 4 immediate-release patients), protocol violation (4 controlled-release and 5
immediate-release patients), and other (1 immediate-release patient)
Inclusion criteria: ”The study included adult patients recruited from 15 centers in the
United States who were receiving 6 to 12 tablets or capsules per day of fixed-combination
analgesics for cancer-related pain. Patients were of either gender and had stable coexistent
disease.“
Exclusion criteria: ”Patients were excluded if their pain was not already acceptably con-
trolled; if they had surgery or radiotherapy within 10 days of prior to study or anticipated
these procedures during study; of they had compromised function of a major organ sys-
tem; or of they were receiving nonopioid analgesics (before the protocol was amended)
. Of course, concomitant nonanalgesic therapies were allowed during the study. To en-
courage participation and to lower the discontinuation rate, the protocol was modified
during the study to include patients undergoing or recently given radiotherapy and those
receiving stable doses of nonopioid analgesics or analgesic adjuvants. In addition,. pa-
tients receiving ten to more tablets or capsules of fixed-combination analgesics were no
longer permitted to enter the study, but could be enrolled in a companion study intended
for patients with greater opioid requirements.“
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- Dose and dosing: 30 mg, every 12 hours, thus total daily dosage = 60 mg. Mean daily
dosage = 60 mg (see ’Titration schedule’ below)
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: Patients needing titration of analgesic or supplemental medication
were required to discontinue from the study
- Rescue medication: See ’Titration schedule’
- Other medication: ”See ’Titration schedule’. “Of course, concomitant nonanalgesic
therapies were allowed during the study”
Comparison arm
- Drug: Oxycodone
- Dose and dosing: 15 mg, 4 times daily, thus total daily dosage = 60 mg. Mean daily
dosage = 60 mg (see ’Titration schedule’ below)
- Formulation: Immediate-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: Patients needing titration of analgesic or supplemental medication
were required to discontinue from the study
- Rescue medication: See ’Titration schedule’
- Other medication: See ’Titration schedule’. “Of course, concomitant nonanalgesic
therapies were allowed during the study”
Outcomes - Pain intensity: Assessed by patient at baseline and 4 times daily, that is, morning
(overnight pain rating), midday (morning pain rating), evening (afternoon pain rating),
and bedtime (evening pain rating), using a categorical scale from 0 (= none) (1 = slight,
2 = moderate) to 3 (= severe)
- Acceptability of current therapy: Assessed by patient at baseline and 2 times daily, that
is, for both day and night, using a categorical scale from 1 (= very poor) (2 = poor, 3 =
fair, 4 = moderate) to 5 (= excellent)
- Adverse experiences: “Observers contacted patients by telephone daily throughout the
5-day study period and recorded information about adverse events and changes in the
patients’ condition.”
Notes - Study free of commercial funding? No. The study was sponsored by the drug manu-
facturers (The Purdue Frederick Company and Purdue Pharma L.P.) and some of the
authors were employees of the study drug manufacturer
- Groups comparable at baseline? No patient details reported by initial treatment allo-
cation
- ITT analyses undertaken? Yes, it seems so. 103/111 patients who took ≥ 1 study drug
dose constituted the ITT population (52 controlled-release, 51 immediate-release), 8/
111 patients were excluded for administrative reasons, which are not further specified;
109/111 patients were analysed for safety
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported beyond that
“Thiswas a randomized, double-blind, par-
allel-group study”
Allocation concealment (selection bias) Unclear risk See cell above
Blinding of participants and personnel
(performance bias)
Pain
Low risk “This was a randomized, double-blind,
parallel-group study”.... “using a double-
dummy technique”. No further informa-
tion reported
Blinding of participants and personnel
(performance bias)
Adverse events
Unclear risk See cell above. We here assume that the
patients were blinded, but it is unclear
whether the personnel administering the
study medication or the personnel assess-
ing some of the outcomes, or both, were
also blinded
Blinding of outcome assessment (detection
bias)
Pain
Low risk This outcome was patient-assessed. See cell
above
Blinding of outcome assessment (detection
bias)
Adverse events
Unclear risk See cell above. We here assume that the
patients were blinded, but it is unclear
whether the personnel administering the
study medication and/or the personnel as-
sessing some of the outcomes were also
blinded
Incomplete outcome data (attrition bias)
Pain
Low risk A total of 103/111 patients who took ≥ 1
study drug dose constituted the ITT pop-
ulation (52 controlled-release, 51 immedi-
ate-release), 8/111 patients were excluded
for administrative reasons, which are not
further specified. The pain data appear to
include these 103 patients
Incomplete outcome data (attrition bias)
Adverse events
Low risk A total of 109/111 patients were analysed
for safety
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
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Were the patients adequately titrated? Low risk The patients were probably adequately
titrated because otherwise they were dis-
continued
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Riley 2014
Methods Design: Randomised, double-blind, parallel group trial (with cross-over to other arm for
non-responders to first line opioid)
Year: 2006 to 2011
Country: UK
Participants Patients: 200 patients randomised; 198/200 patients received≥ 1 dose of study medica-
tion; N = 100 in the oxycodone group and 98 in the morphine group; 198 were included
in the intention-to-treat analyses:
- Oxycodone: N = 100; 38 males and 62 females, mean (SD) age = 58.9 (13.2) years;
cancer diagnosis: breast (18), lower gastrointestinal (16), upper gastrointestinal (2), pan-
creas and hepatobiliary (4), sarcoma (8), lung (13), gynaecological (9), urinary tract (3)
, prostate (8), haematological (7), malignant melanoma (6), head and neck (3), other
(3); concomitant opioid medications before randomisation: As required morphine (40)
, as required oxycodone (3), codeine (45), tramadol (45), dihydrocodeine (5), dextro-
propoxyphene (1), buprenorphine (3). A total of 20/100 patients who received first line
oxycodone withdrew from the trial for drug (16) or trial (4) reasons
- Morphine: N = 100; 50 males and 50 females, mean (SD) age = 59.2 (11.6) years;
cancer diagnosis: breast (14), lower gastrointestinal (11), upper gastrointestinal (10),
pancreas and hepatobiliary (10), sarcoma (11), lung (5), gynaecological (7), urinary tract
(12), prostate (2), haematological (6), malignant melanoma (4), head and neck (2), other
(6); concomitant opioid medications before randomisation: As required morphine (51)
, as required oxycodone (1), codeine (47), tramadol (47), dihydrocodeine (3), dextro-
propoxyphene (0), buprenorphine (0). 13/98 patients who received first line oxycodone
withdrew from the trial for drug (10) or trial (3) reasons
Inclusion criteria: “Inpatients and outpatients were identified and recruited at a tertiary
referral cancer center by the specialist palliative care team. Patients were eligible if they
needed to begin a regular oral strong opioid for cancer-related pain and were strong
opioid naive, that is, had not taken a regular strong opioid within the previous month.
The use of an ”as required“ strong opioid was permitted (less than six doses in 24 hours)
. Patients were recruited before, or within 24 hours, of starting a regular strong opioid.”
Exclusion criteria: Renal impairment (serum creatinine ≥ 1.5 times the upper limit of
normal), requirement of parenteral opioids, previous poor response to either morphine
or oxycodone, and pregnancy
Interventions Oxycodone arm
- Drug: Oxycodone
- Dose and dosing: See ’Titration schedule’. No further information reported
- Formulation: Controlled-release
- Route of administration: Oral
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- Length of treatment: 1 year
- Titration schedule: “Patients were initially titrated on immediate-release preparations,
administered at four-hourly intervals with additional as required doses available for
breakthrough pain .... the starting dose was determined by the treating physician on
an individual patient basis and titrated accordingly.... until adequate pain control was
achieved or intolerable side effects were reported by the patient. At this stage, patients
were converted to the comparable modified-release preparations.
Nonresponders to the first opioid were switched to the alternative opioid. As this was
not a stable analgesic setting, the ratio of oral morphine:oxycodone (2:1).... Doses were
retitrated according to response.”
- Rescue medication: See ’Titration schedule’
- Other medication: “Adjuvant medications (laxatives, antiemetics, coanalgesics) were
either started or continued where indicated.”
Comparison arm
- Drug: Morphine
- Dose and dosing: See ’Titration schedule’. No further information reported
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 1 year
- Titration schedule: “Patients were initially titrated on immediate-release preparations,
administered at four-hourly intervals with additional as required doses available for
breakthrough pain .... the starting dose was determined by the treating physician on
an individual patient basis and titrated accordingly.... until adequate pain control was
achieved or intolerable side effects were reported by the patient. At this stage, patients
were converted to the comparable modified-release preparations.
Nonresponders to the first opioid were switched to the alternative opioid. As this was
not a stable analgesic setting, the ratio of oral morphine:oxycodone (2:1).... Doses were
retitrated according to response.”
- Rescue medication: See ’Titration schedule’
- Other medication: “Adjuvant medications (laxatives, antiemetics, coanalgesics) were
either started or continued where indicated.”
Outcomes - Pain intensity: Assessed by patient at baseline and daily during titration in addition to
the following times: (1) when the patient is clinically stabilised on first line opioid, (2)
if the patient does not respond to first-line opioid and requires switching to alternative
opioid, (3) when patient is clinically stabilised on second line opioid, (4) if the patient’s
analgesic requirement have increase by 200% of their initial stable opioid dose, and
(5) if the patient does not respond to second line opioid or fits the criteria to exit the
study, using an 11-point numerical rating scale (the Brief Pain Inventory) with five pain
modalities from 0 (= no pain) to 10 (= worst pain imaginable)
- Adverse experiences: Assessed by patient at baseline anddaily during titration in addition
to the following times: (1) when the patient is clinically stabilised on first line opioid, (2)
if the patient does not respond to first-line opioid and requires switching to alternative
opioid, (3) when patient is clinically stabilised on second line opioid, (4) if the patient’s
analgesic requirement have increase by 200% of their initial stable opioid dose, and
(5) if the patient does not respond to second line opioid or fits the criteria to exit the
study, using an 11-point numerical rating scale from 0 (= no symptom) to 10 (= worst
symptom severity imaginable) for nausea, vomiting, constipation, diarrhoea, drowsiness,
confusion or disorientation or hallucinations, bad dreams and other notable symptoms.
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During assessments patients were also asked to report any new adverse events
- Responding patients (primary outcome): Defined as patients who responded clinically
to morphine and oxycodone when used as the first line strong opioid in cancer-related
pain, that is, opioid non-response was classified as inadequate analgesia despite dose
escalation or intolerable side effects, or both, and adequacy of pain control and tolerability
of side effects were defined by patients’ subjective assessment, regardless of score
Notes - Study free of commercial funding? “This study was funded by the Palliative Care
Research Fund from the Royal Marsden Hospital, St. Joseph’s Hospice, the Asmarley
Trust, and an unrestricted educational grant from Napp Pharmaceuticals. None of the
funding bodies had any role in the design and conduct of the study, the collection,
management, analysis, or interpretation of the data, and the preparation, review, and
approval of the manuscript, or in the decision to submit for publication. The authors
report no conflicts of interest. The study also was supported by the National Institute for
Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton
and Harefield National Health Service Foundation Trust and Imperial College London.
”
- Groups comparable at baseline? Yes, the groups seem to be comparable at baseline
- ITT analyses undertaken? Yes for efficacy, but data only included for 153/198 patients
for safety
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to either mor-
phine or oxycodone in a 1:1 ratio via com-
puter-generated random permuted blocks.
”
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
High risk “This independent study was an open-label
one because of safety, logistical, and finan-
cial considerations.”
Blinding of participants and personnel
(performance bias)
Adverse events
High risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
High risk Patient-assessed. See cell above
Blinding of outcome assessment (detection
bias)
Adverse events
High risk See cell above
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Incomplete outcome data (attrition bias)
Pain
High risk Data only available for 80/100 patients in
the oxycodone group and 85/100 in the
morphine group for the meta-analyses
Incomplete outcome data (attrition bias)
Adverse events
High risk Adverse events reported for 153/198 pa-
tients
Selective reporting (reporting bias) Low risk All obvious outcomes are reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? Low risk Yes, the patients appear to be adequately
titrated
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Salzman 1999
Methods Design: Randomised, double-blind, parallel group trial
Year: Not reported
Country: USA
Participants Patients: 50 patients randomised; 48/50 patients received≥ 1 dose of study medication;
N = 24 in each group. 35/50 patients completed the titration period, 3 patients discon-
tinued the study due to adverse events, 8 due to ineffective treatment or intercurrent
illnesses, and 2 due to other reasons
Controlled-release group: 8 males and 16 females, mean (range) age = 60 (25 to 77)
years; patients taking pre-study opioids: Yes: N = 23, No: N = 1
Immediate-release group:13 males and 11 females, mean (range) age = 61 (39 to 91)
years; patients taking pre-study opioids: Yes: N = 22, No: N = 2
Inclusion criteria: Patients aged ≥ 18 years with stable cancer pain not adequately con-
trolled by prior analgesic therapy with or without opioids. Among patients who were
receiving nonopioid analgesic therapy, the dosing regimen was stabilised≥ 1 week before
the initiation of study medication and remained stable for the duration of the studies
Exclusion criteria: ”Patients excluded from the studies included individuals with an
allergy or contraindication to opioid therapy; patients with a history of substance abuse;
patients receiving an opioid analgesic that could not be discontinued; cancer patients
prescribed oral oxycodone at a total dose of more than 400 mg/day“
Interventions Oxycodone arm
- Drug: Oxycodone
- Dose and dosing: Starting dose for opioid-naive patients = 20 mg/day, and for non-
opioid-naive patients the starting dose was based on the prior 3 days of analgesic therapy;
every 12 hours at 8 am and 8 pm (± 1 hour each time). Mean final daily dose (SE) = 104
(20) mg
- Formulation: Controlled-release
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- Route of administration: Oral
- Length of treatment: Up to 21 days
- Titration schedule: ”The starting dose was titrated upward in each study to a limit of
400 mg/day..... Among those who required titration, the dose was increased until the
patients rated their level of pain at an intensity of no greater than “slight” (1.5) on the
CAT scale. The dose could be adjusted every 24 to 48 hours if necessary. Criteria for
stable pain control were said to be met if pain was stabilized at 1.5 or below for 48 hours
while patients were taking no more than two doses per day of supplemental analgesic.“
- Rescue medication: ”Supplemental analgesic was permitted as needed for control of
breakthrough or incident pain and was provided in doses of 5mg IR oxycodone (1 tablet)
for patients titrated to 20 to 40 mg/day and 10 mg IR oxycodone (2 X 5 mg tablets) for
patients titrated to 60 to 80 mg/day. For patients receiving doses greater than 80 mg/
day, the supplemental analgesic dose was approximately 1/6 of the patient’s total daily
oxycodone dose rounded to the nearest 5 mg. Rescue medication was taken no more
than once every 4 hours.“
- Other medication: ”All other opioid analgesics were prohibited. Besides nonopioid
analgesic medications (discussed above), othermedications necessary for patients’ welfare
were administered under the supervision of the investigator/physician“
Comparison arm
- Drug: Oxycodone
- Dose and dosing: Starting dose for opioid-naive patients = 20 mg/day, and for non-
opioid-naive patients the starting dose was based on the prior 3 days of analgesic therapy;
four times daily at 8 am, 2 pm, 8 pm and bedtime (± 1 hour each time). The bedtime
dose was to be taken ≥ 3 hours after the 8 pm dose. Mean final daily dose (SE) = 113
(24) mg
- Formulation: Immediate-release
- Route of administration: Oral
- Length of treatment: Up to 21 days
- Titration schedule: ”The starting dose was titrated upward in each study to a limit of
400 mg/day..... Among those who required titration, the dose was increased until the
patients rated their level of pain at an intensity of no greater than “slight” (1.5) on the
CAT scale. The dose could be adjusted every 24 to 48 hours if necessary. Criteria for
stable pain control were said to be met if pain was stabilized at 1.5 or below for 48 hours
while patients were taking no more than two doses per day of supplemental analgesic.“
- Rescue medication: ”Supplemental analgesic was permitted as needed for control of
breakthrough or incident pain and was provided in doses of 5mg IR oxycodone (1 tablet)
for patients titrated to 20 to 40 mg/day and 10 mg IR oxycodone (2 X 5 mg tablets) for
patients titrated to 60 to 80 mg/day. For patients receiving doses greater than 80 mg/
day, the supplemental analgesic dose was approximately 1/6 of the patient’s total daily
oxycodone dose rounded to the nearest 5 mg. Rescue medication was taken no more
than once every 4 hours.“
- Other medication: ”All other opioid analgesics were prohibited. Besides nonopioid
analgesic medications (discussed above), othermedications necessary for patients’ welfare
were administered under the supervision of the investigator/physician“
Outcomes - Pain intensity: Assessed by patient in daily diary, using a categorical scale from 0 (=
none) (1 = slight, 2 = moderate) to 3 (= severe). Also assessed at the clinic visit at the end
of the titration period
- Adverse events: Assessed by patient in daily diary, using a categorical scale from 0 (=
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none) (1 = slight, 2 = moderate) to 3 (= severe). Also assessed at the clinic visit at the end
of the titration period
- Time to stable pain control was recorded as zero for patients meeting the criteria for
success in the first 48 hours (i.e., no titration was needed).”
Notes - Study free of commercial funding? No. The study was sponsored by the drug manufac-
turer (Purdue Pharma L.P.) and some of the authors were employees of the study drug
manufacturer
- Groups comparable at baseline? The groups appear to be comparable at baseline
- ITT analyses undertaken? Yes, it seems so for adverse events where the data from 48/
50 patients are analysed, but only the data from 35/50 are analysed for pain intensity as
only 35/50 patients completed the titration phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
High risk The study was open-label
Blinding of participants and personnel
(performance bias)
Adverse events
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Pain
High risk The study was open-label
Blinding of outcome assessment (detection
bias)
Adverse events
High risk The study was open-label
Incomplete outcome data (attrition bias)
Pain
High risk Data reported for 35/50 patients
Incomplete outcome data (attrition bias)
Adverse events
Low risk Data reported for 48/50 patients
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
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Were the patients adequately titrated? Unclear risk Not applicable. This study was a titration
study
For cross-over trials: Are data available for
both time periods?
Unclear risk Not applicable
Stambaugh 2001
Methods Design: Randomised, double-blind, cross-over trial
Year: Not reported
Country: USA
Participants Patients: 40 patients entered; 30/40 patients completed both of the double-blind periods
with 100% compliance; 9 patients discontinued the study during the titration phase due
to adverse events (2), lack of efficacy (4), intercurrent illness (1), and ’other’ reasons (2)
, and 1 patient discontinued the study during the double-blind phase due to weakness
secondary to progressive disease
10 males and 20 females, mean (range) age = 60 (34 to 83) years; primary pain site was
bone (27), viscera (1), and other (2). All patients were receiving therapy that included
opioids pre-study
Inclusion criteria: Patients aged > 18 years with moderate or severe cancer-related pain
who did not require > 240 mg/day oral oxycodone equivalent for pain relief who were
able to take oral medication and and practiced a medically acceptable method of birth
control if female with childbearing potential
Exclusion criteria: Primary tumour or metastatic disease in the brain, received chemo-
therapy within 3 days of study entry, drug abuse, severe cognitive impairment, com-
promised hepatic or renal function, radiotherapy to the pain site, or hypersensitivity to
oxycodone
Interventions Oxycodone arm
- Drug: Oxycodone + placebo
- Dose and dosing: The total 24-hour oxycodone dose was equal to the stable daily dose
obtained at the end of the titration phase. Drug administration 4 times daily consisting
of oxycodone interspersed with placebo, resulting in q12h dosing of oxycodone. Mean
final daily dose is not reported
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: Up to 35 days, consisting of a titration period of 2-21 days,
followed by two double-blind cross-over periods each lasting 3 to 7 days
- Titration schedule: Open-label with immediate-release oxycodone, starting dose was
comparable to that calculated, based on the past 3 days of analgesia therapy. “The subjects
completed the titration phase at home while monitored on a daily basis by telephone
by the research monitor. Recommendations regarding changes in in medication were
used to minimize oxycodone use while providing adequate analgesia. More than 2 rescue
medication doses per 24-hour period or a moderate or severe global pain score indicated
inadequate pain control. Patients whose pain was inadequately controlled after 21 days
or who required more than 240 mg or less than 20 of oxycodone daily were discontinued
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from the study”
- Rescue medication: Immediate-release oxycodone in 5 mg tablets
- Othermedication: “Concurrent, stable therapy with acetaminophen, NSAIDs, or anal-
gesic adjuvants and coanalgesics were allowed. Opioids other than the study medication




- Dose and dosing: The total 24-hour oxycodone dose was equal to the stable daily dose
obtained at the end of the titration phase. Drug administration 4 times daily, qid dosing
of oxycodone. Mean final daily dose is not reported
- Formulation: Immediate-release
- Route of administration: Oral
- Length of treatment: Up to 35 days, consisting of a titration period of 2 to 21 days,
followed by two double-blind cross-over periods each lasting 3 to 7 days
- Titration schedule: Open-label with immediate-release oxycodone, starting dose was
comparable to that calculated, based on the past 3 days of analgesia therapy. “The subjects
completed the titration phase at home while monitored on a daily basis by telephone
by the research monitor. Recommendations regarding changes in in medication were
used to minimize oxycodone use while providing adequate analgesia. More than 2 rescue
medication doses per 24-hour period or a moderate or severe global pain score indicated
inadequate pain control. Patients whose pain was inadequately controlled after 21 days
or who required more than 240 mg or less than 20 of oxycodone daily were discontinued
from the study”. Stable pain control for 48 hours to 10 days was required before entry
into the double-blind phase
- Rescue medication: Immediate-release oxycodone in 5 mg tablets
- Othermedication: “Concurrent, stable therapy with acetaminophen, NSAIDs, or anal-
gesic adjuvants and coanalgesics were allowed. Opioids other than the study medication
were prohibited. All medically necessary but noninvestigational medications were per-
mitted.”
- For cross-over trials, cross-over schedule: “After successful completion of period 1,
patients were crossed over into the double-blind period 2 without a washout.” The
procedures for this period were identical to those in period 1
Outcomes - Pain intensity or pain relief: Assessed by patient in daily diary, using an 11-point scale
from 0 (= no pain or no relief ) to 10 (= severe pain or complete relief )
- Acceptability of treatment: Assessed by patient in daily diary, using a 5-point scale from
1 (= very poor) (2 = poor, 3 = fair, 4 = good) to 5 (= excellent)
- Adverse events: Spontaneuosly reported by patient in daily telephone contact
Notes - Study free of commercial funding? No. The study was sponsored by the drug manufac-
turer (Purdue Frederick Company) and one of the authors was employed by the study
drug manufacturer
- Groups comparable at baseline? No details reported about initial group allocation
- ITT analyses undertaken? Yes, although only data from 30/40 patients are analysed
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
Pain
Low risk “The double-blind periods were blinded by
using three tablets identical in appearance:
5mg IR oxycodone, 10mgCR oxycodone,
and placebo.”
Blinding of participants and personnel
(performance bias)
Adverse events
Low risk See cell above
Blinding of outcome assessment (detection
bias)
Pain
Low risk Patient reported outcome. See also cell
above
Blinding of outcome assessment (detection
bias)
Adverse events
Low risk See cell above
Incomplete outcome data (attrition bias)
Pain
High risk Data from 30/40 patients analysed
Incomplete outcome data (attrition bias)
Adverse events
High risk See cell above
Selective reporting (reporting bias) Low risk All obvious outcomes appear to be reported
Other bias Low risk The study does not appear to be subject to
high risk of other biases
Were the patients adequately titrated? Low risk The patients were probably adequately
titrated. Pain intensity dropped from6 (SD
= 2.2) at the beginning of titration to 2.7
at the completion of the titration phase
For cross-over trials: Are data available for
both time periods?
Low risk Yes, data are available for both study periods
for 30/40 patients
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Study Reason for exclusion
Ahmedzai 2012 Comparison not in PICO: Oxycodone-naloxone versus oxycodone
Chen 2009 Comparison not in PICO: Oxycodone-acetominophen versus morphine
Dunlop 2013 Comparison not in PICO: Oxycodone-naloxone versus oxycodone
Garassino 2010 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
Garassino 2011 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
Garassino 2013 Comparison not in PICO: Fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of
oxycodone and fixed-dose pregabalin
Leppert 2011 Comparison not in PICO: Oxycodone-naxolone versus oxycodone
Li 2008 Comparison not in PICO: Oxycodone-acetominophen versus oxycodone
Li 2010 Comparison not in PICO: Oxycodone + gabapentin versus oxycodone
Meng 2008 Published completely in Chinese. Translator confirmed that the study is not an RCT, but rather a retrospective
review of cancer patient charts
NCT01859715 Population not in PICO: “Patients with pain and/or nausea are enrolled in the Emergency Department (ED).
They are given either oxycodone, hydrocodone, or ondansetron at the discretion of the Emergency Department
(ED) provider or the triage nurse by triage protocol. Detailed prescription, over the counter, herbal, supplement,
and illicit drug ingestion histories are taken from the patient or their health care proxy. Serial visual analogue scales
are captured prior to study drug administration then between 30 and 90 minutes following drug administration.
” “Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision
or by triage nurse randomization.” Unclear whether it is a RCT
NCT01885182 Comparison not in PICO: Oxycodone-naxolone versus oxycodone
Pang 2009 Comparison not in PICO: fixed doses of oxycodone-acetominophen versus background doses of oxycodone-
acetominophen plus additional dose for breakout pain versus controlled-release oxycodone plus oxycodone-
acetominophen for breakout pain
Shi 2008 Comparison not in PICO: Oxycodone-acetominophen versus morphine
Sima 2010 Comparison not in PICO: Oxycodone + aceteminophen versus placebo
Sima 2010a Comparison not in PICO: Oxycodone + aceteminophen versus placebo
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Sima 2012 Comparison not in PICO: Oxycodone + paracetamol versus placebo
Stambaugh 1980 Comparison not in PICO: Oxycodone-acetominophen (tylox) versus oxycodone-aspirin (Percodan)
Stambaugh 1980a Comparison not in PICO: Oxycodone + aspirin + caffiene + phenaticin (Percodan) versus zomepirac versus
placebo
Stambaugh 1981 Comparison not in PICO: Oxycodone + aspirin + caffiene + phenaticin (Percodan) versus zomepirac versus
placebo
Stambaugh 1987 Comparison not in PICO: Xorphanol versus oxycodone-acetominophen versus placebo
Stambaugh 1990 Comparison not in PICO: Flurbiprofen versus oxycodone-acetominophen versus placebo
Wu 2009 Comparison not in PICO: Oxycodone-acetominophen versus tramadol
Xiong 2008 Comparison not in PICO: Oxycodone-acetominophen versus morphine
Zou 2009 Comparison not in PICO: Oxycodone + acetaminophen versus increased dose of existing opioid treatment
Characteristics of studies awaiting assessment [ordered by study ID]
2012-001578-26
Methods Randomised, parallel-group, open-label controlled trial: An International, Multicentre, Open Randomised Parallel
Group Trial Comparing a Two Step Approach for Cancer Pain Relief With the Standard Three Step Approach of the
WHO Analgesic Ladder in Patients With Cancer Pain Requiring Step 2 Analgesia
Participants Inclusion Criteria:
- 18 years of age and over.
- Patient has a cancer diagnosis (based on radiological, histological, cytological, or operative evidence). Those with
haematological malignancies are eligible
- Cancer related pain - which in the opinion of the clinician is caused by the presence of tumour or metastases
- Average pain score > 4, on a numerical rating scale from 0 to 10, requiring step 2 analgesia (weak opioid)
- Patient is able to comply with trial procedures
Exclusion criteria:
- Patients who have received radiotherapy in the previous 6 weeks or are planned to receive radiotherapy during the
trial period where in either case, it is expected to affect pain during the trial period
- Pain due to surgery in the preceding 4 weeks
- Life expectancy less than two months (based on clinical impression)
- Patients with psychotic disorders or cognitive impairment
- Patients who have received regular doses (scheduled doses - not as required dosing) of weak or strong opioids in the
preceding two weeks
- Patients using immediate-release opioids > 2 doses/24 hours, in the previous 24 hours
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Interventions Standard 3 Step approach (patients will be managed according to the standard 3 Step approach of theWHO analgesic
ladder (Step 1 - Step 2 - Step 3)) versus
2 Step approach (patients managed according to the WHO analgesic ladder bypassing Step 2, i.e., patients will move
from Step 1 of the WHO analgesic ladder to Step 3)
Drugs to be used: Oral morphine, oral oxycodone, oral tramadol, codeine
Outcomes Primary outcome measures:
- Time to achieving stable pain control, where stable pain control is defined as the first day of three consecutive days
with average pain score less than or equal to 3 using scores from the Patient Diary and patient assessments. (Time
frame: Up to 20 days)
Secondary outcome measures:
- Mean of daily average pain scores from the Patient Diary
- Mean of daily worst pain scores from the Patient Diary
- Percentage of days with average pain score ≥ 6 from the Patient Diary
- Percentage of days with worst pain score ≥ 6 from the Patient Diary
- Pain intensity, pain relief, and pain interference scores at day 10 and 20 from the Brief Pain Inventory
- Patient distress score at day 10 and 20 from the NCCN Distress Thermometer
Notes Location: UK, Norway, Australia, Italy, Germany, Uganda, Spain
Sponsors and collaborators: University of Edinburgh, NHS Lothian, Mundipharma (UK), St Olavs Hospital (Nor-
way)
Principal investigators: Marie Fallon, University of Edinburgh
Target enrolment: N = 450
Study dates: March 2012 to December 2014
Other study ID numbers: NCT01493635, 11/SS/0079
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Methods Poster Presentations
Session title: Chronic pain
Presentation date: Sunday, 15 March 2009
Evaluation of efficacy and safety of prolonged-release oxycodone at different dosages for the treatment of severe
chronic pain
Aurilio C, Sansone P, Pace MC, Passavanti MB, Romano SV, Pota V
Second University of Naples, Department of Anaesthesiological, Surgical and Emergency Sciences, Napoli, Italy
Background and aims: It’s important to arrange a correct and flexible therapy for the treatment of chronic malignant
and non-malignant pain especially in fragile patients. The aim of this study is to evaluate the efficacy and safety of
prolonged-release (PR) oxycodone 10 mg/morning and 20 mg/evening versus PR oxycodone 20 mg twice a day
Methods: After local ethical committee approval and written informed consent 40 patients (13 men and 27 women)
, affected by severe chronic pain (mean NRS 8) were randomised in two groups: OD group: 20 patients receiving
PR oxycodone 10 /morning and 20 /evening; OS Group: 20 patients who receiving PR oxycodone 20 mg every 12
hours. The observation period was 28 days with 5 visits, once a week (T0 to T5). NRS was the parameter of efficacy
while the incidence and intensity of nausea, vomiting, somnolence, stipsis and itching were the parameters of safety.
Any assumption of rescue medication (immediate-release oral morphine 10 mg) was registered
Results: Both the groups presented a 50% reduction of pain T1, and kept a very good analgesia for all the observation
period. In OD group there was a lower incidence of adverse events than in OS Group. In OS group there was a lower
assumption of rescue medication than in OD Group
Conclusion: Therapy using PR oxycodone at different dosages allows a pain reduction similar to therapy with PR
oxycodone at same dosage. Moreover with this therapeutic scheme it’s possible to reduce the incidence of adverse
events





Methods JapicCTI-090789: An open-label study of intravenous (i.v.) S-811717 (oxycodone hydrochloride solution for injec-
tion) in patients with cancer pain
JapicCTI-090790: An extension study of S-811717 (oxycodone hydrochloride solution for injection) in patients
with cancer pain
JapicCTI-090791: An open-label study of subcutaneous injection (s.c.) S-811717 (oxycodone hydrochloride solution
for injection) in patients with cancer pain
Participants Inpatients with pain associated with various cancers aged ≥ 20 years
Interventions S-811717
Outcomes - To evaluate the efficacy and safety of S-811717 in patients with pain caused by various cancers
- To determine the pharmacokinetics of S-811717 and its metabolites. No other information available
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Notes Location: Japan
Sponsors, collaborators, investigators: Shionogi & Co, Ltd., Research and Development
No other information available
NCT00378937
Methods An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic
Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach
Participants Disease characteristics:
- Diagnosis of cancer
- Requires regular step-2 analgesia for the management of cancer-related pain
Patient characteristics:
- Aged ≥ 18 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Must be able to take oral medicationMust be willing and able to complete a daily patient assessment booklet (PAB)
- No history of the following conditions: Depression, personality disorders that may lead to self-harm, admission to
the hospital for psychiatric reasons, any other psychological disorder that, in the opinion of the investigator, would
preclude study treatment
- Not at risk of additional CNS depressant effects due to study drugs
- No known history of alcohol or drug abuse or, in the opinion of the investigator, tendency towards drug abuse or
addiction
- No current abuse of alcohol or drugs
- No known sensitivity to oxycodone hydrochloride or other opioids
- No history of a specific or allergic reaction to study drugs
- No contraindications as a result of adverse drug reaction or drug interactions of oxycodone or other opioid drugs
- No other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation
Prior concurrent therapy:
- More than 30 days since prior and no concurrent chemotherapy or radiotherapy
- At least 2 weeks since prior regular (i.e., 4 times per day) step-2 analgesics
- More than 3 months since prior regular use of opioids, defined as having a regular prescription of an opioid
medication
- Not planning to undergo cancer-related surgery
- No other concurrent opioid-based medication other than oxycodone hydrochloride capsules as escape medication
(arm II)
- No concurrent participation in another clinical trial involving a new chemical entity
Interventions Arm 1: Patients receive an analgesic regimen, according to their level of pain, for up to 18 weeks
- Step 1: Patients in mild pain receive oral acetaminophen 4 times daily
- Step 2: Patients in mild-to-moderate pain receive oral codeine or oral dextropropoxyphene hydrochloride 4 times
daily and oral acetaminophen 4 times daily
- Step 3: Patients in moderate-to-severe pain receive oral morphine or oral oxycodone hydrochloride 6 times daily
(every 4 hours) with or without a non-opioid analgesic
Patients may also receive an adjuvant drug (i.e., for side effects or for primary indication other than pain management
that is analgesic in selected circumstances)
versus
Arm 2: Patients receive oral oxycodone hydrochloride twice daily for up to 18 weeks. Patients may receive a different
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opioid analgesic or analgesia or adjuvant medication as in arm I, if needed
Patients in both arms may also receive additional medication for breakthrough pain. Patients complete a patient-
assessment booklet (PAB) daily which includes a Box-Scale (BS)-11 rating for average pain; questions regarding
contact (e.g., telephone or visit) with healthcare professionals on that day; and information regarding the number of
times escape medication is used. Quality of life and levels of cancer pain are assessed using the short form of the Brief
Pain Inventory (BPI). After completion of study treatment, patients are followed at 4 weeks
Outcomes Primary Outcome Measures:
- Percentage of time in assessment periods 1 and 2 (i.e., first 4 weeks) with a BS-11 pain score of ≤ 4 (i.e., mild pain)
Secondary Outcome Measures:
- Percentage of time in assessment periods 3 and 4 with a BS-11 pain score of ≤ 4
- Mean BS-11 pain scores
- Time to reach stable pain control
- Mean escape medication use
- Quality of sleep
- Global assessment of pain relief with study drugs
- Mean pain intensity, pain interference, and pain relief scores as measured by the BPI
- Overall number of phone calls, home visits by a nurse, home visits by a doctor, and unscheduled visits to a healthcare
provider, related to pain control or analgesic medication during study treatment
Notes Location: US
Sponsors and collaborators: University Hospitals Bristol NHS Trust
Study chair: Geoff Hanks, University Hospitals Bristol NHS Trust
Target enrolment: N = 30
Study dates: ?
Other study ID numbers: CDR0000507650, CRUK-ON/2003/1772, EU-20640, EUDRACT-2004-004235-66,
NAPP-CRUK-ON/2003/1772
NCT00726830
Methods Randomised, parallel-group, open-label controlled trial: A Randomized Comparison of Oral Methadone as a “First-
Switch” Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-
Hematology Outpatients With Pain Management Problems: The “Simply Rotate” Study
Participants Disease characteristics:
- Receiving ongoing care in the outpatient medical oncology setting
- Self-reported pain (of any cause) for which long-acting strong opioids (morphine or oxycodone) have been prescribed
or administered oral morphine-equivalent daily dose (MEDD) of existing opioid regimen (long-acting or immediate-
release) 40 to 300 mg/day
-Worst pain score on a scale of 0 (no pain) to 10 (worst pain) of≥ 5 for≥ 1 week duration based on verbal self-report
or ≥ 1 persistently bothersome symptom attributed to an opioid side effect (e.g., fatigue, confusion, depressed level
of consciousness, memory loss, personality change, anorexia, constipation, dehydration, nausea, vomiting, weight
loss, pruritus, urticaria, impotence, reduced libido, and urinary retention or hesitancy), or both
Patient characteristics:
- Aged ≥ 18 years
- None of the following conditions that could predispose the patient to prolongedQT interval-associated tachycardia:
serum potassium < 3.0 mg/dL; cocaine abuse within the past 3 months; family history of sudden death; advanced
heart failure (ejection fraction < 40% or New York Heart Association (NYHA) class III or IV heart disease, or both
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- No known or suspected cognitive impairment that could interfere with adherence to the medication plan or self-
report of symptoms and side effects
- Not pregnant or nursing
- Fertile patients must use effective contraception
Prior concurrent therapy:
- See ’Disease characteristics’
- More than 4 weeks since prior radiotherapy or surgery for local control of cancer or pain palliation
- More than 60 days since prior use of the same long-acting opioid (i.e., the new long-acting opioid) that patient is
switching to on the study
- More than 12 weeks since prior methadone therapy
- More than 3 days since prior and no concurrent transdermal fentanyl, oxymorphone, or buprenorphine
- Concurrent systemic anticancer therapy or bisphosphonates allowed provided therapy was initiated ≥ 4 weeks ago
- Concurrent tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, or other
adjuvant analgesics or psychostimulants allowed provided therapy was initiated ≥ 2 weeks ago; dose expected to
remain stable until after the first week of opioid rotation on study
- No concurrent methadone maintenance therapy for opioid addiction
- No concurrent intrathecal infusion of analgesics
- No concurrent antiarrhythmic medications (e.g., amiodarone or quinidine)
Interventions Opioid rotation to oral methadone (participants are switched from their current opioid medication (oxycodone or
morphine) to methadone. Participants receive oral methadone 2 to 3 times daily for 4 weeks) versus
Opioid rotation to another long-acting strong opioid (participants currently receiving oxycodone are switched to sus-
tained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants
receive either oral SR morphine or oxycodone 2 to 3 times daily for 4 weeks)
Outcomes Primary outcome measures:
- Number of participants with at least a 3-point reduction in pain score on the M.D. Anderson Symptom Inventory
(MDASI) (time frame: 28 days)
- MDASI questionnaire completed on days 8, 15, and 22 after enrollment. The ’primary success’ is defined as a 3-
point reduction in pain score on the MDASI. Scores from baseline and from four weeks later compared using the
MDASI average pain intensity on a scale of 0 (no pain) to 10 (worst pain)
Secondary outcome measures:
- Number of participants with 30% reduction in total summary score for the Individual Composite Drug Toxicity
Score (CDTS) Items (time frame: 28 days) (Designated as safety issue)
Notes Location: US
Sponsors and collaborators: M.D. Anderson Cancer Institute, National Cancer Institute
Principal investigators: Michael J Fisch, MD, Anderson Cancer Center; James D Bearden, CCOP - Upstate Carolina
Target enrolment: N = ?
Study dates: March 2009 to October 2010
Other study ID numbers: 2007-0791, MDA-2007-0791, CDR0000598283
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Methods It is unclear whether this is a retrospective study or a randomised controlled trial. Authors e-mailed on 14 January
2014 for clarification
Design: ’Randomized’, parallel-group
Year: 2006 to 2008
Country: China
Participants Patients:
- Oxycodone (commercial name Tai Lening): N = 42, 42 analysed, M/F = unclear, median (range) age = 55 (28 to
83) years. Primary tumours were: lung cancer (12) , breast cancer (5), liver cancer (6), gastric cancer (4), nasopha-
ryngeal carcinoma (3), colorectal cancer (3), oesophageal cancer (3), lymphoma (2), osteosarcoma (2), chordoma (1)
, pancreatic cancer (1)
-Morphine sulfate controlled-release (MSContin): N = 45, 45 analysed, 27 males and 18 females; median (range) age
= 53 (30 to 76) years. Primary tumours were: Lung cancer (14), breast cancer (6), liver cancer (6); gastric cancer (6),
oesophageal cancer (3), pancreatic cancer (2), nasopharyngeal (2), colorectal cancer (2), non-Hodgkin’s lymphoma
(2), ovarian cancer (2)
Inclusion criteria: “87 patients who were diagnosed with malignant tumour based on histopathology and cytology,
with moderate to severe cancer pain and who did not respond to non-steroidal anti-inflammatory drugs and weak
opioid analgesics”
Exclusion criteria: Not reported
Interventions Oxycodone arm
- Drug: Oxycodone + 1 tablet (each containing oxycodone 5 mg, acetaminophen 325 mg),
- Dose and dosing: every 6 h (2 oxycodone tables has equal titration dose with oral morphine 30 to 40 mg)
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: Not clear but seems they have same dose increased as the contin group
- Rescue medication: During the treatment, if patients have short term unsatisfactory treatment efficacy or have
sudden intensified pain, then short-acting morphine injection was administrated. The patients were considered
treatment failure if the pain relief was not relieved until the observation period had ended or the limit dose was
reached
- Other medication: Unclear
Comparison arm
- Drug: Morphine sulfate (MS Contin)
- Dose and dosing: 20 mg/day as the first dose
- Formulation: Controlled-release
- Route of administration: Oral
- Length of treatment: 5 days
- Titration schedule: MS Contin group with 20 mg/day as the first dose, if the pain could be relieved, then continued
using the same dose as maintenance treatment. If the pain was not relieved after 24 hr, then increased the dose until
a satisfactory pain relief, or till reach the maximum dose (the maximum dose = 270 mg/day)
- Rescue medication: During the treatment, if patients have short-term unsatisfactory treatment efficacy or have
sudden intensified pain, then short-acting morphine injection was administrated. The patients were considered
treatment failure if the pain relief was not relieved until the observation period had ended or the limit dose was
reached
- Other medication: Unclear
For both groups, if the patients had intolerable adverse reactions when increasing the dose, the drugs could be
discontinued at any time, then the patients were observed 30 days and then evaluated the treatment efficacy
The patient was also considered as treatment failure if the treatment has to be stopped due to intolerable adverse
events
79Oxycodone for cancer-related pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Song 2009 (Continued)
Outcomes - Pain Intensity (PI) and pain relief: the WHO linear Visual Analog Scale VAS was used, the degree of pain was
graded using by dividing a line into 10 segments: 0 = no pain, 1 to 3 as mild, 4 to 7 as moderate, severe pain as 8 to
9, 10 = extreme pain
Complete remission (CR): completely no pain after treatment, with a pain score of 0 on a 0 to 10 VAS. Partial
remission (PR): pain reduced significantly, there was no sleep disturbance, have normal daily life, the pain reduced
4 or more grades in the segments.(YY’s note: they did not say scores lower than 4, they said reduced 4 or more, CR
can be translated as complete relief ). Mild remission (NC): certain degree of pain relief, but require enhanced pain
control, patients had sleep disturbances, VAS score reduced 1 to 3 grades in the 0 to 10 VAS line. (YY note, NC
normally means no changes). Treatment failure (PD): no pain relief compared to baseline. (YY note - PD normally
means progression of disease). The authors considered patients who were CR or PR as “treatment was effective”
- Adverse reactions. Patients were observed for all kinds of adverse reactions: constipation, nausea, vomiting, dizziness,
drowsiness, skin rash or itching, abdominal discomfort etc
Notes Study free of commercial funding? Unclear
Were the patients adequately titrated? Unclear, possibly?
Groups comparable at baseline? Unclear, probably if properly randomised
ITT analyses undertaken? Yes
Characteristics of ongoing studies [ordered by study ID]
2006-003151-21
Trial name or title Study to compare the tolerability of slow release oxycodone versus slow release morphine in the treatment of
severe cancer pain. The study is geared towards a clinical practice improvement
Methods Randomised, parallel-group, open controlled trial
Participants Inclusion criteria:
- Patients older than 18 years of age
- Patients with oncological referred pain within the 24 hours preceding the initial administration of treatment
with an intensity of greater than or equal to 5 measured by the numerical scale NRS of 11 levels 0 to 10
- Patients who did not take other analgesics or who only took NSAIDs and/or weak opioids either I or II on
the WHO scale
- Patients have given their written consent
- Patients in the study have been given at least one month to live
- Patients are required to follow the treatment regiment for at least 2 weeks under clinical observation
- Patients with KPS greater than or equal to 40
Exclusion criteria:
- Treatment with morphine, oxycodone, buprenorphine, fentanyl, or methadone in the 30 days leading up
to the study
- Patients whose medical history, based on the opinions of a physicians, is significant for intolerance to
morphine or oxycodone
- Patients whose doctors have suggested they should add ex novo another analgesic adjuvant steroids, anti-
convulsants, antidepressants
- Patients with severe renal impairment
- Patients with moderate to severe hepatic insufficiency. Patients with dyspnea or severe BPCO
- Patients who are not able to be treated taking oral medications as recommended by the WHO guidelines
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- Patients who have a history of ongoing psychiatric illness
- Patients with cognitive deficit that cannot consent to the treatment and will not comply with the treatment
protocol
- Patients with cerebral metastasis
- Patients who are either pregnant or breast feeding
Interventions Oxycodone (prolonged-release oral tablet)
versus
morphine (slow-release)
Outcomes The primary outcome variable is the dichotomous variable that indicates a worsening, in the first 14 days of
treatment, of at least one of the following adverse effects nausea, vomiting, hallucinations, mental confusion,
constipation, sedation, dry mouth, itching. The patient was defined to have deteriorated if, in respect to the
baseline evaluation, he registered a worsening of at least 2 points of a scale of 0 to 10 for at least one of the
symptoms considered and for at least one of the two weeks of treatment. For hallucinations the worsening is
indicated by the presence of at least one episode during the two weeks of treatment
Starting date Not reported
Contact information Location: Italy
Sponsors: Istituto Nazionale Per La Cura Tumori
Principal investigators: Not reported
Notes Target enrolment: N = 400
Study completion date: ? but of 1-year duration
Other study ID numbers: None reported
2008-002273-12
Trial name or title Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety
and pharmacogenetic factors
Methods Randomised, parallel-group, open controlled trial
Participants Inclusion criteria:
- age > 18 years
- oncologic, chronic, neurophatic or nociceptive peripheral pain
Exclusion criteria:
- abuse history
- opioid analgesic use history
- opioid allergies
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hydromorphone (prolonged-release oral tablet)
Outcomes Pain reduction at least 40% in VAS scale
Starting date Not reported
Contact information Location: Italy
Sponsors: Ospedale Policlinico S. Matteo
Principal investigators: Not reported
Notes Target enrolment: N = 320
Study completion date: ? but of 3-year duration
Other study ID numbers: None reported, but is it the same as NCT00916890 below?
2009-013118-28
Trial name or title Bukkaalinen fentanyyli syöpäpotilaiden toimenpidekivun hoidossa (“The buccal fentanyl in cancer pain
management measure”)
Methods Randomised, cross-over (open or blind?) controlled trial
Participants Inclusion criteria:
- Cancer metastatic to the bone
- beginning radiotherapy to bone metastases (?)
Exclusion criteria:
- Severe hepatic, renal or cardiac dysfunction
- uncontrolled or rapidly increasing pain
- dry mouth
- oral mucositis or stomatitis
- pregnancy or breastfeeding
- impaired cognitive performance
- increased intracranial pressure
- drug abuse or history of drug use within the previous 5 years, or of use of CYP3A4 inhibition drug(s?)
(translated from Finnish)
Interventions Fentanyl (buccal) versus
oxycodone (oral) (Oxynorm)
Outcomes Pain relief and speed of effect for fentanyl compared to oxycodone, radiation therapy-related acute, short-
term pain relief (translated from Finnish), side effects
Starting date Not reported
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Contact information Location: Finland
Sponsors: Tarja Heiskanen
Principal investigators: Not reported
Notes Target enrolment: N = ?
Study completion date: ?
Other study ID numbers: None reported
2010-020402-15
Trial name or title Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of oxycodone
after once daily administration of oxycodone HCl XL tablets in comparison to twice daily administration of
Oxygesic® tablets in patients with chronic pain
Methods Randomised, double-blind, cross-over controlled trial
Participants Inclusion criteria:
- Caucasian male and female patients ≥18 years of age with chronic cancer pain
- Patients with predominantly non-neuropathic pain
- Patients requiring continuous oral opioid therapy with at least 40 mg oxycodone per day (or equivalent)
- Adequate analgesia (mean ’current’ pain intensity per day ≤ 40 mm on VAS) prior to randomisation for at
least three consecutive days
- Stable analgesic requirements prior to randomisation for at least three days (stable maintenance dose of
oxycodone; requirement of at least 40 mg oxycodone per day; ≤ 2 doses of rescue medication per day),
tolerable AEs
- ECOG (Eastern Cooperative Oncology Group) performance status < 3
- Life expectancy of at least 3 months
- Female patients of childbearing potential agree to undergo pregnancy tests
- Willingness to undergo a pre-study physical examination and pre- and post-study laboratory investigations
- Ability to comprehend and willingness to sign informed consent
Exclusion criteria:
- Hypersensitivity to oxycodone or any of the excipients of the study drugs
- Patients requiring more than 120 mg oxycodone per day (or equivalent)
- Surgery within 1 month prior to study start and/or anticipated or scheduled surgical intervention during
the study
- Intravenous chemotherapy or radiotherapy, or both, for pain alleviation or neural blockade within 2 weeks
prior to study start or anticipated or scheduled during the course of the study, or combinations
- Known or suspected clinically significant respiratory depression, hypoxia, hypercapnia, or decrease in respi-
ratory reserve
- Knownor suspected severe obstructive pulmonary disease, acute or severe bronchial asthma, or cor pulmonale
- Known or suspected significant hepatic impairment (hepatic transaminases > 3 times the upper limit of
normal)
- Known or suspected severe renal impairment (CRCL <30 ml/min) or patients with renal failure who are on
any form of dialysis
- Known or suspected significant circulatory disturbance, hypotension, or circulatory shock
- Known or suspected clinically relevant endocrine disorder, such as myxoedema, not adequately treated
hypothyroidism or adrenocortical insufficiency (e.g. Addison’s disease)
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- Known or suspected paralytic ileus, significant impairment of bowel motility severe enough to potentially
result in ileus
- Known or suspected acute or chronic pancreatitis or biliary tract disease
- Any gastro-intestinal pathology or surgery or intractable vomiting likely to significantly influence drug
absorption
- Inability to swallow the study drugs whole (e.g., due to dysphagia)
- Known or suspected significant prostatic hypertrophy or urethral stricture severe enough to potentially result
in urinary retention
- Known or suspected CNS depression (signs and symptoms: decreased vital signs, impaired thinking and
perception, slurred speech, slowed reflexes, fatigue, decreased consciousness), coma, or convulsive disorder
- Known or suspected elevation of intracranial pressure
- Known or suspected acute alcoholism, delirium tremens, or toxic psychosis
- History of drug addiction or drug seeking behaviour
- Concomitant treatment with MAO inhibitors
- Pregnancy or breast-feeding. Women of childbearing potential unable or unwilling to practice adequate
contraceptivemeasures. Reliablemethods forwomen are orally administered hormonal contraceptives, surgical
intervention (e.g., tubal ligation), intrauterine device (IUD) and sexual abstinence
- Any other condition of the patient that in the opinion of the investigator may compromise evaluation of
the study treatment or may jeopardize patient’s compliance or adherence to protocol requirements
- Previous enrolment in this study or participation in any other drug investigational trial within the past 30
days (or five half-lives whichever is longer) prior to enrolment
- Persons suspected to be at risk of suicide
- Persons who are not suitable for inclusion in the study in the opinion of the investigator. Adults, elderly,
with chronic cancer pain
Interventions Oxycodone (once daily administration of oxycodone HCl XL tablets) versus
oxycodone (twice daily administration of Oxygesic® tablets)
Outcomes Primary outcome measures:
- Overall ’current’ pain intensity (PI) on 0 to 100 mm VAS (mean ’current’ PI of the last 5 days of each
treatment period). Pain intensity (PI) will be assessed five times daily, i.e., at 08:00 h, 11:00 h, 14:00 h, 17:00
h, and 20:00 h (allowed deviation ± 20 min) on a 0 to 100 mm VAS (’current’ pain). PI assessment at 08:00
h and 20:00 h will also comprise ratings of PI over the past 12 hours (’recalled’ pain during day- and night-
time). From the PI scores the mean ’current’ PI over all time points of the last 5 treatment days of period 1
and period 2 (= overall mean ’current’ PI) will be calculated for each patient as the primary efficacy endpoint
Secondary outcome measures:
- mean ’current’ pain intensity (PI) per day
- mean ’current’ PI per time point
- mean ’recalled’ PI over the past 12 hours at 08:00 h
- mean ’recalled’ PI over the past 12 hours at 20:00 h
- overall effectiveness on 4-point CAT by patient and investigator (assessed at the end of each treatment
period)
- daily dose of rescue medication for each of the last 5 days of period 1 and 2
- mean daily dose of rescue medication over the last 5 treatment days of period 1 and 2
- total amount of rescue medication over the last 5 treatment days of period 1 and 2
Starting date 3 September 2010
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Contact information Location: Germany, Hungary (?)
Sponsors: Dr Martina Maritz, Develco Pharma Schweiz AG, Hauptstrasse 61, Binningen, 4102 Switzerland:
E-mail: m.maritz@develco.ch, tel: +41 614255020, fax: +41 614255029
Principal investigators: Not reported
Notes Target enrolment: N = 126
Study completion date: 7 February 2012
Other study ID numbers: None reported
Elsayem 2010
Trial name or title Abstract (this is all the information in the record)
TPS324
Background:Methadone is an opioidwithmany unique pharmacologic properties and it ismuch less expensive
than other opioids commonly used in cancer painmanagement. It is a particularly attractive analgesic to use for
opioid switching,with the goal of improving analgesia and/or decreasing opioid-related side effects. Prospective
trials involving methadone for opioid switching are uncommon in publicly-funded, clinical cooperative
groups. This trial in progress will help determine the feasibility, safety, and efficacy of two approaches to
opioid switching. It will also provide useful information regarding the feasibility of opioid-related research
conducted by oncologists in the outpatient community setting
Methods: This NCI-funded, randomized, prospective, open-label trial intends to enroll 300 cancer patients in
the outpatient community setting. Eligible patients have inadequate pain control and/or intolerable opioid-
related side effects and are prescribed either sustained-release morphine or oxycodone, with an oral morphine
equivalent daily dose between 40mg and 300mg. Patients are randomly assigned to be rotated to either
oral methadone or oral sustained-release morphine or oxycodone, and the new opioid dose is determined
using study-specific equianalgesic tables. Patients receive immediate-release opioids for breakthrough pain
and supportive measures for side effects, and patients have their opioids titrated according to study protocol
Evaluation occurs at enrollment and thenweekly for a total of 4 weeks using validated tools that include:M.D.
Anderson Symptom Inventory (MDASI), Composite Drug Toxicity Score (CDTS), and Revised Edmonton
Staging System (rESS) for Cancer Pain. We hypothesize that 60% of patients rotated to methadone will
achieve a 30% reduction in pain and/or opioid-related side effects; whereas 40% of patients rotated to either
sustained-release morphine or oxycodone will achieve this response. We define primary success as a 3-point
reduction in pain score-measured by MDASI-from baseline to completion of the study
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Trial name or title DS-7113b phase III study A randomized double-blind comparison study with immediate release (IR) oxy-
codone in opioid-naive patients with cancer pain
Methods A multicentre, active controlled, randomised, double-blind, parallel-group study
Participants Inclusion criteria:
- Both genders, aged ≥ 20 years
- Patients receiving non-opioid analgesics for cancer pain, who have not been receiving opioid analgesics
- Patients whose VAS is ≥ 35 mm and judged necessary to be treated with strong opioid analgesics
- Patients with an ECOG Performance Status (PS) ≤ 3, etc
Exclusion criteria:
- Patients with symptom(s) or finding(s) falling under the contraindications or relative contraindications
stated in the package insert for oxycodone hydrochloride powder and morphine hydrochloride preparations,
etc
Interventions DS-7113b:
Each patient will be administered 4 doses a day orally for 5 days, versus
Oxycodone hydrochloride powder:
Each patient will be administered 4 doses a day orally for 5 days
Outcomes Primary outcome measures:
Change of VAS between pre-treatment and end of treatment
Secondary outcome measures:
Response rate at end of treatment (analgesia improvement rate), efficacy and safety
Starting date 1 October 2013
Contact information Location: Japan
Sponsors, collaborators, investigators: Daiichi Sankyo Company, Limited
Principal investigator: Not reported
Notes Target enrolment: Not reported
Study completion date: 31 March 2015
Other study ID numbers: None reported
NCT00916890
Trial name or title Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety
and Pharmacogenetic Factors Influence
Methods Randomised (parallel group), single-blind (outcome assessor) controlled trial
Participants Inclusion criteria:
- Adult oncologic patients (≥ 18 years old)
- Chronic peripheral neuropathic or nociceptive pain, or both
- Written informed consent
Exclusion criteria:
- Pediatric patients
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- Mental impaired patients
- Substance abuse disorder
- Opioid allergy
- History of opioids use or addiction
- Severe immunodeficiency, severe renal impairment, severe liver disease
- Cachectic state
- HIV positive patients
Interventions Morphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will
be randomly assigned to a patient) versus
oxycodone (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will
be randomly assigned to a patient) versus
fentanyl (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and
less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly
assigned to a patient) versus
buprenorphine (after a titration phase with fast-release oral morphine, once the optimal dosage (no side effects
and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will
be randomly assigned to a patient)
Outcomes Primary outcome measures:
- To identify the drug with the best clinical-pharmacological safety-efficacy profile among the four opi-
oids: oral extended-release morphine, oral extended-release oxycodone, transdermal fentanyl and transdermal
buprenorphine. (Time frame: 15 days after randomisation (Reduction of at least 40% of median daily pain,
on a NRS))
“We will define a treatment effective if it will produce a mean reduction of NRS values at least of 40% than
basal values. Among all effective treatments, we will identify the best as the one that will have a reduction of
NRS to a value of 4 or less in 90% of patients compared to the 70% of the others treatments. To evaluate
pharmacological safety the plasma concentrations of the drugs and their metabolites will be measured.We will
branch patients population in 3 groups to evaluate the correlation between clinical-pharmacological response
and genetics (responder,partially and not responder).”
Secondary outcome measures:
- Pharmacokinetic of opioids and of their metabolites during long-term administration; correlation between
specific genotypes and clinical response or the clinical/pharmacological susceptibility to side-effects on ad-
ministration of a specific opioid. (Time frame: 6 months (each patient will be followed for 6 month after
enrolment with clinical and pharmacological evaluations once a month and if inefficacy, tolerance or side
effects))
- Comparison of plasma levels of opioids and of their metabolites in ’responder’ patients (clinical effectiveness
without side effects), ’partial responder’ patients (clinical effectiveness without side effects but taking not
more than 2 rescue doses per day), and in ’non-responder’ patients (3 groups: clinical inefficacy, side effects,
tolerance or opioid induced hyperalgesia). Evaluation of the correlation between the polymorphisms studied
and clinical response; the frequency of allelic variants of interest will be compared in ’responder’, ’partial
responder’ and ’non-responder’
Starting date February 2009
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Contact information Location: Italy
Sponsors, collaborators, investigators: IRCCS Policlinico S. Matteo, University of Pavia, Italy
Principal investigator: Massimo Allegri, IRCCS Foundation Policlinico “San Matteo”, Pavia, Italy; e-mail:
m.allegri@smatteo.pv.it, Tel: 00390382502627
Notes Target enrolment: N = 320
Study completion date: December 2015
Other study ID numbers: PT-SM-1-Op-Cancer
NCT01165281
Trial name or title A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the
Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate
to Severe Chronic Malignant Tumor Related Cancer Pain
Methods Randomised (parallel-group), double-blind (patient, caregiver, investigator) controlled trial
Participants Inclusion criteria:
- Aged ≥ 20 years
- Documented clinical diagnosis of any type of cancer
- Diagnosis of chronic malignant tumour-related cancer pain with an average score for pain intensity in the
past 24 hours of ≥ 4 on the 11-point numerical rating scale (NRS) on the day of randomisation (Day -1)
- Have not received treatment with opioid analgesics within 28 days before screening (note: codeine phosphate
(≤ 60 mg/d) or dihydrocodeine phosphate (≤ 30 mg/d) for antitussive use are allowed)
- Dissatisfied with pain relief by the current treatment and for whom the investigator or designee judges that
treatment with opioid analgesics is required
Exclusion criteria:
- Have complicated with uncontrolled or clinically significant arrhythmia
- Have previous or concurrent presence of any disease which may develop increased intracranial pressure,
disturbance of consciousness, lethargy, or respiratory problems such as traumatic encephalopathywith cerebral
contusion, intracranial hematoma, disturbance of consciousness, brain tumour, cerebral infarction, transient
ischemic attack, epilepsy or convulsive diseases
- Have history of alcohol or drug abuse
- Have any disease for which opioids are contraindicated such as serious respiratory depression of serious
chronic obstructive pulmonary disease, bronchial asthma attack, cardiac failure secondary to chronic pul-
monary disease, paralytic ileus, status epileptics, tetanus, strychnine poisoning, acute alcohol poisoning, hy-
persensitivity to opium alkaloid, haemorrhagic colitis, or bacterial diarrhoea
Interventions R331333 ((referred to as JNS024 ER or CG5503) one 25 mg to 200 mg capsule twice daily for 4 weeks)
versus
Oxycodone CR (one 5 mg to 40 mg capsule twice daily for 4 weeks)
Outcomes Primary outcome measures:
- The average pain intensity score using an 11-point numerical rating scale (NRS) (time frame: change from
baseline to the last 3 days of study drug administration)
Secondary outcome measures:
- The Patient Global Impression of Change (PGIC) (time frame: at the end of the 4-week double-blind
treatment phase)
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- The duration of rescue medication (time frame: during the 4-week double-blind treatment phase)
- The concentration of JNS024 in blood samples from patients (time frame: protocol-specified time points
during Weeks 1, 2, and 4)
- The proportion of patients responding to treatment, including at least 30% and 50%, based on the per cent
change from baseline using an 11-point numerical rating score (NRS) (time frame: at Week 4 of the double-
blind treatment phase on an 11-point NRS)
- Adverse events and findings from clinical laboratory tests, physical examinations, vital signs measurements,
and ECG measurements reported (time frame: from time of screening (Days -7 to -1) to post-treatment
(Week 5) or time of early termination from study)
Starting date August 2012
Contact information Location: Japan, Republic of Korea
Sponsors, collaborators, investigators, study director: Janssen Research &Development, L.L.C. Clinical Trial
(no other contact information reported)
Notes Target enrolment: N = 343
Study completion date: August 2012
Other study ID numbers: CR017188, JNS024ER-KAJ-C02
NCT01205126
Trial name or title A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of
OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily
in Subjects With Cancer Pain
Methods Randomised (parallel group), double-blind (patient, caregiver, investigator) controlled trial
Participants Inclusion criteria:
- Aged 18 to 70 years
- Currently receiving strong oral or transdermal (through the skin) opioid analgesics with inadequate control
of moderate to severe cancer pain or currently receiving weak opioids for cancer pain and are eligible according
to the study protocol to receive treatment with a strong opioid analgesic
- Require or are expected to require between 40 mg and 184 mg of oral morphine or morphine equivalents
every 24 hours
- Are not expected to start a course of chemotherapy, radiotherapy, target cancer therapy, hormone therapy
or diphosphate 2 weeks prior to randomisation or during the study
- If receiving long-term treatment including hormone, target cancer therapy and diphosphate, the treatment
should keep stable as much as possible from 2 weeks before randomisation and up to the completion of the
study
- Have a life expectancy of 12 weeks or longer
Exclusion criteria:
- Have pure neuropathic pain, pain of unknown origin, or acute pain
- Have only pain on movement
- Are receiving or have received treatment with medical isotopes within the previous 2 weeks prior to ran-
domisation
- Have narrowing (irrespective of cause) of the gastrointestinal tract or have blind loops of the gastrointestinal
tract or gastrointestinal obstruction
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- Have any significant central nervous system (CNS) disorder or any disorder that predisposes the patient to
respiratory depression
- Have any condition wherein the risks of treatment with study drug may outweigh the potential benefits
Interventions Hydromorphone hydrochloride (HCl), all patients will take 2 capsules (caps) twice daily for up to 36 days
as follows: 1 cap containing 8 mg or 16 mg of hydromorphone HCL (H) + 1 cap of dummy placebo (DP)
followed 12 hr later by 2 caps containing DP or 2 caps containing 24 mg or 32 mg H followed 12 hr later by
2 caps DP versus
Oxycodone HCl CR, all patients will take 2 caps twice daily for up to 36 days as follows: 1 cap containing
10 mg, 20 mg or 40 mg oxycodone HCL CR (Oxy) + 1 cap of DP administered at 12 hour intervals or 1 cap
containing 10 mg Oxy + 1 cap containing 20 mg Oxy administered at 12 hour intervals
Outcomes Primary outcome measures:
- Patient assessment of pain at its worst in the last 24 hours, included as an item in the Brief Pain Inventory
(BPI) Short Form, where 0 = no pain and 10 = pain as bad as you can imagine. (Time frame: at endpoint (the
last recorded value obtained up to the end of the study (Day 29 ± 1 day))
Secondary outcome measures:
- Other assessments of pain severity and pain relief from the BPI (Short Form). (Time frame: from Day 1
(baseline or randomisation) to the last recorded value obtained up to the end of the study (Day 29 ± 1 day))
- Number of breakthrough pain medication doses taken (time frame: from Day 1 in the titration phase up
through the end of the study (Day 29 ± 1 day))
- Number of patients with treatment emergent adverse events, serious adverse events and adverse events
leading to discontinuation from the study (time frame: from Day 1 in the titration phase up through the end
of the study (Day 29 ± 1 day))
Starting date December 2009
Contact information Location: China
Sponsors, collaborators, investigators, study director: Johnson & Johnsopn Pharmaceutical Research & De-
velopment, L.L.C. Clinical Trial (no other contact information reported)
Notes Target enrolment: N = 258
Study completion date: February 2011
Other study ID numbers: CR017437, 42801PA|3009
NCT01675622
Trial name or title A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine
Tablets for the Treatment of Chinese Patients With Cancer Pain
Methods Randomised, parallel-group, double (triple?)-blind (patient, care-giver, investigator, outcome-assessor) con-
trolled trial
Participants Inclusion criteria:
- Patients of either sex aged 18 to 80 years inclusive, with cancers of all types
- Patients with moderate to severe cancer pain, whose pain intensity NRS ≥ 4
- Patients who can understand and are able to complete NRS and BPI assessment
- Patients who have given written informed consent to participate in the study
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Exclusion criteria:
- Patients who are pregnant, or lactating
- Patients who are unable to manage their pain effectively with opioids
- Patient who need ≥ 120mg morphine or equivalent for treatment of pain at time of study entry
- Patients who are receiving chemotherapy, or still under the responsive period of chemotherapy (patients who
are at the interval period of chemotherapy can be enrolled into study. That is to say, patients who completed
chemotherapy for more than 2 weeks can enrolled, or patients has completed chemotherapy for at least one
week could be enrolled at the discretion of the investigator)
- Patients who have received radiotherapy for bony metastasis, patients receiving radiotherapy within the 4-
week period before study entry (patient receiving radiotherapy for area other than pain area can be enrolled)
, or patients who were scheduled to receive radiotherapy for pain area during study period
- Patients are receiving or should receive anticonvulsive drugs or antidepressant drugs considered by investigator
for the treatment of neuropathy pain
- Patients are receiving or should receive any analgesic other than study medicine, including NSAIDs
- Patients with other unstable disease, or with dysfunction of important organ
- Patients with an ongoing infection, abscess or fever
- Patient with serious abnormal liver or renal function (ALT, AST, creatinine, urea nitrogen) which is higher
than 3 times upper limit
- Paralytic or mechanical ileus
- Persistent asthma, chronic obstructive diseases, and cor pulmonary
- Intracranial neoplasms, and intracranial hypertension with central respiratory depression risk
- Monoamine oxidase inhibitors (MAOIs) or same type drugs have been administered in last 2 weeks
- Patients who are currently taking active treatment for epilepsy or arrhythmias
- Patients with known sensitivity or record of specific or allergic reaction to oxycodone or morphine
- Patients excludedby the contra-indications, adverse drug reaction (ADRs) anddrug interactions of oxycodone
or morphine as detailed in the data sheet, summary of product characteristics or investigator’s brochure
- Patients with a history of drug or alcohol abuse
- Patients who participated in another clinical research study involving a new chemical entity within one
month prior to study entry
- Patients whose concomitant medication is likely to be changed within the study period, with the exception
of treatment for opioid side effects
- Patients who, in the opinion of the investigator, are unsuitable to participate in the study for any other
reason not mentioned in the inclusion and exclusion criteria
Interventions Oxycodone (5 mg, l0 mg and 20 mg capsules every 6 h, 5 to 8 days) versus
morphine (tablets 10 mg and 20 mg, oral every 4 to 6 hours)
Outcomes Primary outcome measures:
- NRS (Numerical Rating Scale) score (time frame: 5 to 8 days). To compare the average for decrease of NRS
score after double-blind treatment between the two treatment groups
- The average dose of study medicine used during double blind treatment period (time frame: 5 to 8 days).
To compare the average dose of study medicine used during double-blind treatment period between the two
treatment groups
Secondary outcome measures:
- BPI (Brief pain inventory) (time frame: 19 to 22 days). To compare BPI score at baseline, after completion
of double-blind treatment and open-label treatment to baseline between the two treatment groups
- Times and frequency of breakthrough pain and the total dose of rescue medicine for breakthrough pain
(time frame: 19 to 22 days). To compare the times and frequency of breakthrough pain and the total dose of
rescue medicine for breakthrough pain during double-blind phase between the two treatment groups
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- Patient assessments of satisfaction for pain management (time frame: 19 to 22 days). To compare patient
assessments of satisfaction for pain management between the two treatment groups at the end of double-
blind treatment and the open-label treatment period
- Average time for titration (time frame: 1 to 3 days). To compare the average time for titration between the
two treatment groups
Starting date December 2010
Contact information Location: China
Sponsors, collaborators: Mundipharma
Principal investigator: Shiying Yu, Wuhan Tong Ji Hospital
Notes Target enrolment: N = 240
Study completion date: July 2012
Other study ID numbers: OXYC10-CN-303
NCT01809106
Trial name or title RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids
(Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the
Moment of Starting 3rd Step of WHO Analgesic Ladder
Methods Randomised (parallel? cross-over?), open-label controlled trial
Participants Inclusion criteria:
- Patients with diagnostic (histological or cytological) evidence of locally advanced or metastatic solid tumour
- with average pain intensity ≥ 4, measured with NRS and related to the last 24 hours, due to the cancer,
requiring for the first time an analgesic treatment with third step WHO opioids
- life expectancy > one month
- ’strong’ opioid naïve
- eligible to take any of the medications under evaluation, by transdermal system (TDS) or by mouth
- age ≥ 18 years
Exclusion criteria:
- Patients recruited in other researches that conflict or may confound the conduction and results of the present
study
- lack of informed consent
- with presence of other diseases, including psychiatric ormental illness, severe senile or other formof dementia
that can interfere with participation and compliance with the study protocol or can contra-indicate the use
of the investigational drugs
- with presence of co-morbidities, which could create potentially dangerous drug interactions with opioids
(e.g., use of macrolide antibiotics or antifungal)
- any kind of contraindications to the use of opioid drugs
- with a known story, past or current, of drugs abuse or addiction
- use of drugs which present a combination of opioids and other molecule (such as NSAIDs, paracetamol,
naloxone)
- who cannot guarantee regular follow-up visits for logistic or geographic reasons
- need of starting third step treatment in an ’emergency clinical situation’ that does not allow the correct
procedures of randomisation
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- diagnosis of primary brain tumour or leukaemia
- diagnosis of chronic renal failure
- patients with antalgic radiotherapy or radio-metabolic therapy in progress or completed less than 14 days
before study
- patients starting a first line chemotherapy simultaneously to the beginning of the study
- other types of analgesic treatments, including local-regional anesthetic techniques or neurosurgical or ablative
methods
Interventions Morphine (60 mg/24 hours) versus
oxycodone (40 mg/24 hours) versus
buprenorphine (35 µg/hour) versus
fentanyl (25 µg/hour)
Outcomes Primary outcome measures:
- Proportion of non-responder (NR) patients (time frame: 28 days)
- Evaluation of the proportion of NR patients. NRs correspond to the subjects who do not report any analgesic
effects, with a pain intensity difference (PID) from visit 6 and visit 1≤ 0%, (using a 0 to 10 NRS). It includes
the situations of average pain intensity ’stable’ or ’worsened’ at day 28 compared with baseline values
Secondary outcome measures:
- Proportion of full responders (FR) (time frame: 28 days)
- Evaluation of the proportion of subjects who report full analgesia (FR). FR is operationally defined as a
patient with a PID ≥ 30% from visit 6 and visit 1 (NRS 0 to 10)
Other outcome measures:
- The opioid escalation index (time frame: 28 days)
- The proportion of subjects with an increase of opioid daily dose > 5% compared with the basal dosage
(OEI%)
Starting date April 2011
Contact information Location: Italy
Sponsors, collaborators: Mario Negri Institute for Pharmacological Research
Principal investigator: Oscar Corli, MD. Mario Negri Institute of Pharmacological Research - IRCCS
Contact: oscar.corli@marionegri.it; anna.roberto@email.it
Notes Target enrolment: N = 600
Study completion date: April 2014
Other study ID numbers: None reported
NCT02084355
Trial name or title Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate
to Severe Cancer Pain - Open Label, Randomized, Prospective Study
Methods Open-label, randomised, prospective study
Participants Inclusion criteria:
- age > 18 years
- patients who are being treated with one of strong opioids including oral oxycodone, oral hydromorphone,
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or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose (MEDD)
- moderate to severe cancer pain (numeric rating scale more than 3) at screening
- patients without uncontrolled adverse effects associated with currently applied opioid
Exclusion criteria:
- previous opioid rotation
- unable to take oral medication
- life expectancy less than a month
- newly started chemotherapy or radiotherapy within past 2 weeks of screening
- serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase > 2.5 times upper
normal limit
- serum total bilirubin or creatinine > 1.5 times of upper normal limit
Interventions Opioid rotation:
Patients who are randomised to opioid rotation are treated with strong opioid other than currently used strong
opioid (reduce the dose by 25% to 50% to allow for incomplete cross-tolerance between different opioids):
Oral oxycodone: convert to oral hydromorphone or fentanyl patch
Oral hydromorphone: convert to oral oxycodone or fentanyl patch
Fentanyl patch: convert to oral oxycodone or oral hydromorphone versus
opioid dose escalation:
Patients who are randomised to opioid dose escalation will be treated cancer pain by escalation dose of same
strong opioid:
Oral oxycodone: maintain oral oxycodone and titrate the dose
Oral hydromorphone: maintain oral hydromorphone and titrate the dose
Fentanyl patch: maintain fentanyl patch and titrate the dose
Outcomes Primary outcome measures:
The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale (time
frame: 18 months). (Designated as safety issue: Yes)
Starting date April 2014
Contact information Location: Republic of Korea
Sponsors, collaborators: Gyeongsang National University Hospital
Principal investigator/contact: Se-Il Go, M.D., tel@ +82 55 750 9454 ext 9454, e-mail: gose1@hanmail.net
Notes Target enrolment: N = 136
Study completion date: January 2016
Other study ID numbers: GNUH-2013-07-014
UMIN000011756
Trial name or title Randomized study of fentanyl citrate versus Oxycodone Hydrochloride Hydrate in patients with unresectable
advanced pancreatic cancer (FRONTIER)
Methods Randomised, single arm (?), phase III, open trial
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Participants Inclusion criteria:
- Aged 20 to < 100 years
- unresectable advanced pancreatic cancer
- ≥ 15 to 25 mg oxycodone hydrochloride hydrate per day required for cancer pain
Exclusion criteria:
- Serious liver, kidney, cardiac disorders
- pulmonary impairment
- nervous system and psychic disorders
Interventions Oxycodone hydrochloride hydrate: 10 mg every 12 hours, versus
Transdermal fentanyl citrate: 1 mg once a day
Outcomes Primary outcome measures:
The rates of gastrointestinal disorders events in four weeks
Secondary outcome measures:
Quality of life, rates of opioid rotation, pain score, time until stable pain control, overall survival time, adverse
events
Starting date 27 March 2014
Contact information Location: Japan
Sponsors, collaborators: National Cancer Center Hospital East; Welfare labor science research cost (MHLW
(Japan))
Principal investigator/contact: Minori Odanaka, Clinical Trial Support Office, National Cancer Center Hos-
pital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan Tel: +81-3-3547-5201, e-mails: minochant23@yahoo.
co.jp; modanaka@ncc.go.jp
Notes Target enrolment: N = 80
Study completion date: Not reported
Other study ID numbers: None reported
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D A T A A N D A N A L Y S E S
Comparison 1. Pain




participants Statistical method Effect size
1 Pain intensity 12 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 CR oxycodone v IR
oxycodone
3 578 Std. Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.06, 0.26]
1.2 CR oxycodone v CR
morphine
5 462 Std. Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.04, 0.32]
1.3 CR Oxycodone v CR
hydromorphone
1 62 Std. Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.63, 0.37]
1.4 CR oxycodone v ER
oxymorphone
1 74 Std. Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.23, 0.69]
1.5 CR oxycodone v ER
tapentadol
1 265 Std. Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.30, 0.18]
1.6 IR oxycodone v IR
morphine
1 38 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.79, 0.49]
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Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain intensity.
Review: Oxycodone for cancer-related pain
Comparison: 1 Pain
Outcome: 1 Pain intensity







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CR oxycodone v IR oxycodone
Kaplan 1998 (1) 156 1.3 (1.25) 156 1.3 (1.25) 54.2 % 0.0 [ -0.22, 0.22 ]
Parris 1998 (2) 103 1.4 (1.01) 103 1.1 (1.01) 35.4 % 0.30 [ 0.02, 0.57 ]
Stambaugh 2001 (3) 30 2.7 (1.9) 30 2.8 (1.9) 10.4 % -0.05 [ -0.56, 0.45 ]
Subtotal (95% CI) 289 289 100.0 % 0.10 [ -0.06, 0.26 ]
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.19 (P = 0.23)
2 CR oxycodone v CR morphine
Bruera 1998 23 24.3 (20) 23 22.9 (21) 10.1 % 0.07 [ -0.51, 0.65 ]
Heiskanen 1997 27 0.99 (0.62) 27 0.77 (0.36) 11.5 % 0.43 [ -0.11, 0.97 ]
Mercadante 2010 (4) 19 3.15 (3) 20 2.35 (2.36) 8.4 % 0.29 [ -0.34, 0.92 ]
Mucci-LoRusso 1998 79 1.3 (0.89) 79 1 (0.89) 34.1 % 0.34 [ 0.02, 0.65 ]
Riley 2014 80 2.05 (1.71) 85 2.36 (2.18) 35.9 % -0.16 [ -0.46, 0.15 ]
Subtotal (95% CI) 228 234 100.0 % 0.14 [ -0.04, 0.32 ]
Heterogeneity: Chi2 = 6.48, df = 4 (P = 0.17); I2 =38%
Test for overall effect: Z = 1.48 (P = 0.14)
3 CR Oxycodone v CR hydromorphone
Hagen 1997 31 28 (22.27) 31 31 (22.27) 100.0 % -0.13 [ -0.63, 0.37 ]
Subtotal (95% CI) 31 31 100.0 % -0.13 [ -0.63, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 CR oxycodone v ER oxymorphone
Gabrail 2004 37 2.8 (1.3) 37 2.5 (1.3) 100.0 % 0.23 [ -0.23, 0.69 ]
Subtotal (95% CI) 37 37 100.0 % 0.23 [ -0.23, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
5 CR oxycodone v ER tapentadol
Imanaka 2013 139 2.57 (2.027) 126 2.69 (2.223) 100.0 % -0.06 [ -0.30, 0.18 ]
Subtotal (95% CI) 139 126 100.0 % -0.06 [ -0.30, 0.18 ]
Heterogeneity: not applicable
-4 -2 0 2 4
Favours oxycodone Favours comparison
(Continued . . . )
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.46 (P = 0.65)
6 IR oxycodone v IR morphine
Kalso 1990 19 1.3 (1.2) 19 1.5 (1.4) 100.0 % -0.15 [ -0.79, 0.49 ]
Subtotal (95% CI) 19 19 100.0 % -0.15 [ -0.79, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 3.27, df = 5 (P = 0.66), I2 =0.0%
-4 -2 0 2 4
Favours oxycodone Favours comparison
(1) Please note that in comparison 1.1.1, CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(2) Please note that in comparison 1.1.1, CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(3) Please note that in comparison 1.1.1, CR oxycodone is input as the ’oxycodone’ group and IR oxycodone is input as the ’comparison’ group.
(4) Week 4 data
A D D I T I O N A L T A B L E S
Table 1. Summary of findings table
Quality assessment Summary of findings
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CR oxycodone versus CR hydromorphone: pain intensity
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CR oxycodone versus ER oxymorphone: treatment acceptability
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Table 1. Summary of findings table (Continued)
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Please note: CR = controlled release, IR = immediate release, ER = extended release, IV = intravenous, IM = intramuscular.
1 The quality of the evidence provided by the included studies was compromised by under-reporting, lack of blinding and/or missing
data.
2 One of the included studies was a cross-over trial with 30 patients. These 30 patients are included in the totals for both CR oxycodone
and IR oxycodone.
3 Two of the included studies were cross-over trials with a total of 50 patients. These 50 patients are included in the totals for both CR
oxycodone and CR morphine.
4 Low numbers of patients.
5 The included study was a cross-over trial. The total number of patients are listed in the totals for both CR oxycodone and CR
hydromorphone.
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Table 2. Controlled-release (CR) oxycodone versus immediate-release (IR) oxycodone: adverse events
Comparison CR oxycodone versus IR oxycodone
Study Kaplan 1998 Parris 1998* Salzman 1999 Stambaugh 2001
CR IR CR IR CR IR CR IR
Any adverse
events
38/54-55 38/54-55 10/30 10/30
Total ad-
verse events





Asthenia 3/78 8/82 2/24 1/24 2/30 2/30
Confusion 0/54-55 2/54-55 3/24 2/24
Constipa-
tion




5/78 11/82 8/54-55 10/54-55 2/24 0/24 3/30 3/30
Drowsiness,
somnolence
14/78 17/82 13/54-55 12/54-55 9/24 7/24 3/30 2/30
Dry mouth 3/78 5/82 4/54-55 3/54-55 3/24 1/24 1/30 1/30
Headache 0/78 6/82 7/54-55 3/54-55 1/24 1/24
Insomnia 2/78 4/82 3/54-55 1/54-55
Nausea 14/78 21/82 11/54-55 13/54-55 7/24 5/24 4/30 3/30
Nervouse-
ness




Pruritus 2/78 4/82 7/54-55 5/54-55 4/24 0/24 1/30 2/30
Sweating 4/78 3/82 1/54-55 5/54-55 2/30 1/30
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Table 2. Controlled-release (CR) oxycodone versus immediate-release (IR) oxycodone: adverse events (Continued)




6/78 10/82 4/54-55 7/54-55 1/24 2/24
*Total number of patients for safety evaluation = 109. Not clear which group had 55 and 54 patients, respectively.
Table 3. Controlled-release (CR) oxycodone versus CR morphine: adverse events
Com-
parison
CR oxycodone versus CR morphine
Study Bruera 1998 Heiskanen 1997 Lauretti 2003 Mercadante 2010* Mucci-LoRusso
1998
Riley 2014
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1/48 7/52 3/81 2/72
Dysp-
noea
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10/27 7/27 1/22 1/22 4/48 5/52 3/81 2/72
Seda-
tion
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*Mean (SD) ratings (out of 3) experienced during week 4.















IV oxycodone followed by IR oxy-
codone versus IVmorphine followed by
IR morphine
Study Hagen 1997 Gabrail 2004 Imanaka 2013 Leow 1995** Kalso 1990***
Oxy Hyd Oxyco Oxymo Oxy Tap IV Rectal IV oxy IR oxy IV mor IR mor
109Oxycodone for cancer-related pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



















0/19 1/19 0/19 1/19
Consti-
pation




































7/19 7/19 7/19 12/19
Pruri-
tus




3/19 1/19 3/19 2/19
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Table 4. Single-study comparisons: adverse events (Continued)
Seda-
tion
24 (4)* 18 (3)* 13/41 18/43 12/19 13/19 12/19 14/19
Sweat-
ing








1/19 1/19 2/19 0/19
Vomit-
ing









*Mean (SE) VAS across all days.
**Mean (SD) ratings (out of 3) experienced during the 24 hours of drug administration, apart from the total number of adverse events
which is read from the authors’ Figure 3.
**The measure is the sum of positive responses after each study period: moderate = 1, severe = 2.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
CENTRAL (Cochrane Library)
#1 MeSH descriptor: [Oxycodone] explode all trees
#2 (ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid):ti,ab,kw (Word variations have been searched)
#3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon):ti,ab,kw (Word variations have been searched)
#4 (endocet or endocodone or endone or eu?odal or eubine):ti,ab,kw (Word variations have been searched)
#5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone):ti,ab,kw (Word
variations have been searched)
#6 (remoxy or roxicet or rox?codone or roxilox):ti,ab,kw (Word variations have been searched)
#7 (supeudol or thecodinum or theocodin or tylox):ti,ab,kw (Word variations have been searched)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Neoplasms] explode all trees
#10 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*):ti,ab,kw (Word variations have been searched)
#11 #9 or #10
#12 #8 and #11
MEDLINE and MEDLINE In-Process (Ovid)
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1 Oxycodone/
2 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4 (endocet or endocodone or endone or eu?odal or eubine).tw.
5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6 (remoxy or roxicet or rox?codone or roxilox).tw.
7 (supeudol or thecodinum or theocodin or tylox).tw.
8 or/1-7
9 exp Neoplasms/
10 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11 or/9-10
12 8 and 11
13 randomized controlled trial.pt.







21 exp animals/ not humans.sh.
22 20 not 21
23 12 and 22
EMBASE (Ovid)
1 Oxycodone/
2 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
3 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
4 (endocet or endocodone or endone or eu?odal or eubine).tw.
5 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
6 (remoxy or roxicet or rox?codone or roxilox).tw.
7 (supeudol or thecodinum or theocodin or tylox).tw.
8 or/1-7
9 exp Neoplasms/
10 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
11 or/9-10







19 (doubl$ adj blind$).tw.
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26 Randomized Controlled Trial/
27 Single Blind Procedure/
28 or/13-27
29 (animal/ or nonhuman/) not human/
30 28 not 29
31 12 and 30
Web of Science (ISI) SSCI and SCI
#22 #21 AND #9
#21 #20 OR #17 OR #16 OR #15 OR #14 OR #11 OR #10
#20 #19 AND #18
#19 TS=random* OR TI=random*
#18 TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#17 TS=crossover* OR TI=crossover*
#16 TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#15 TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR Tripl* OR Trebl*)
#14 #13 AND #12
#13 TS=trial* OR TI=trial*
#12 TI=clin* OR TS=clin*
#11 TI=randomi* OR TS=randomi*
#10 TS=Randomized clinical trial* OR TI=Randomized clinical trial*
#9 #8 AND #7
#8 Topic=((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*))
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
#6 Topic=((supeudol or thecodinum or theocodin or tylox))
#5 Topic=((remoxy or roxicet or rox?codone or roxilox))
#4 Topic=((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone))
#3 Topic=((endocet or endocodone or endone or eu?odal or eubine))
#2 Topic=((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon))
#1 Topic=((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid))
BIOSIS (ISI)
#21 #20 AND #19 AND #12
#20 Topic=(((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta*
or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*)))
#19 #18 OR #17 OR #16 OR #15 OR #14 OR #13
#18 Topic=(((supeudol or thecodinum or theocodin or tylox)))
#17 Topic=(((remoxy or roxicet or rox?codone or roxilox)))
#16 Topic=(((“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone)))
#15 Topic=(((endocet or endocodone or endone or eu?odal or eubine)))
#14 Topic=(((dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon)))
#13 Topic=(((ox?codon* or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm
or oxynormoro or oxyrapid)))
#12 #11 OR #8 OR #7 OR #6 OR #5 OR #2 OR #1
#11 #10 AND #9
#10 DS=random* OR TS=random* OR TI=random*
#9 DS=(allocate* OR assign*) OR TS=(allocate* OR assign*) OR TI=(allocate* OR assign*)
#8 DS=crossover* OR TS=crossover* OR TI=crossover*
#7 DS=(mask* OR blind*) OR TS=(mask* OR blind*) OR TI=(mask* OR blind*)
#6 DS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TS=(singl* OR Doubl* OR Tripl* OR Trebl*) OR TI=(singl* OR Doubl* OR
Tripl* OR Trebl*)
#5 #4 AND #3
#4 DS=trial* OR TS=trial* OR TI=trial*
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#3 DS=clin* OR TI=clin* OR TS=clin*
#2 DS=randomi* OR TI=randomi* OR TS=randomi*
#1MQ=Randomized clinical trial* ORDS=Randomized clinical trial* ORTS=Randomized clinical trial* ORTI=Randomized clinical
trial*
PsycINFO (Ovid)
1 (ox?codon$ or oxycontin or oxycodeinon or oxycone or oxycdn or ox?conum or oxydose or oxyfast or oxygesic or oxynorm or
oxynormoro or oxyrapid).tw.
2 (dazidox or dihydrohydroxycodeinone or dihydrone or dinarkon).tw.
3 (endocet or endocodone or endone or eu?odal or eubine).tw.
4 (“m oxy” or oxecta or oxydihydrocodeinonum or pancodine or pavinal or percocet or percolone or proladone).tw.
5 (remoxy or roxicet or rox?codone or roxilox).tw.
6 (supeudol or thecodinum or theocodin or tylox).tw.
7 exp Neoplasms/
8 (cancer$ or neoplas$ or tumo$ or carcinoma$ or hodgkin$ or nonhodgkin$ or adenocarcinoma$ or leuk?emia$1 or metasta$ or
malignan$ or lymphoma$ or sarcoma$ or melanoma$ or myeloma$ or oncolog$).tw.
9 or/7-8
10 or/1-6
11 9 and 10
12 clinical trials/
13 (randomis* or randomiz*).tw.
14 (random$ adj3 (allocat$ or assign$)).tw.
15 ((clinic$ or control$) adj trial$).tw.
16 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.





22 exp program evaluation/
23 treatment effectiveness evaluation/
24 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
25 or/12-24
26 11 and 25
PubMed
(((Oxycodone[MeSH Terms]) OR ((ox?codon* OR oxycontin OR oxycodeinon OR oxycone OR oxycdn OR ox?conum OR oxydose
ORoxyfastORoxygesicORoxynormORoxynormoroORoxyrapid))OR ((dazidoxORdihydrohydroxycodeinoneORdihydroneOR
dinarkon)) OR ((endocet OR endocodone OR endone OR eu?odal OR eubine)) OR ((“m oxy” OR oxecta OR oxydihydrocodeinonum
OR pancodine OR pavinal OR percocet OR percolone OR proladone)) OR ((remoxy OR roxicet OR rox?codone OR roxilox)) OR
((supeudol OR thecodinum OR theocodin OR tylox))) AND and AND ((Neoplasms[MeSH Terms]) OR ((cancer* OR neoplas*
OR tumo* OR carcinoma* OR hodgkin* OR nonhodgkin* OR adenocarcinoma* OR leuk?emia*1 OR metasta* OR malignan* OR
lymphoma* OR sarcoma* ORmelanoma* ORmyeloma* OR oncolog*)))) AND and AND (((randomized controlled trial[Publication
Type]) OR (controlled clinical trial[Publication Type]) OR (randomized[Title/Abstract]) OR (placebo[Title/Abstract]) OR (drug ther-
apy[Title/Abstract]) OR (randomly[Title/Abstract]) OR (trial[Title/Abstract]) OR (groups[Title/Abstract])) NOT ((animals[MeSH
Terms]) NOT humans[MeSH Terms]))
114Oxycodone for cancer-related pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 2, 2015
Date Event Description
22 February 2013 New citation required and major changes This protocol has been significantly updated by new authors. See
Published notes.
11 February 2010 New citation required and major changes This protocol was originally published in Issue 4, 2002. As the
authors were unable to commit time to the completion of the
full review it was then withdrawn in January 2009. The original
authors are now able to work on completing the full review and
plan to do so by the end of 2010
13 January 2009 New citation required and major changes Withdrawn: the review groupwas unable tomaintain contact with
the contact author. New authors are being sought to take over
this protocol, please contact the PaPaS Review Group if you are
interested in working on this review title
22 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
MSH and MIB conceived and designed the review and wrote the protocol. SA devised and undertook the search strategy. MSH, NB,
and JSH screened the search results and performed the data extraction and ’risk of bias’ assessment of the included studies. MSH devised
and performed the analysis strategy, and wrote the first draft of the full review. MIB interpreted the results and wrote the ’Authors
conclusions’ section. All the authors approved the final version of the review.
D E C L A R A T I O N S O F I N T E R E S T
MSH: none known; MIB: none known; SA: none known; NB: none known; JSH: none known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the risk of bias assessments, we also included an item that captured whether data were available for both time periods in cross-over
trials, in order to make explicit this potential source of bias.
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N O T E S
This protocol was originally published in Issue 4, 2002. As the authors were unable to commit time to the completion of the full review
it was then withdrawn in January 2009. The original authors intended to publish in 2010 (Reid 2010) but experienced further delays.
The current author team has completed the full review.
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